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Abstract
Preeclampsia and fetal growth restriction (FGR) are common and costly obstetric
complications. Both conditions are associated with immediate and remote
mortality and morbidity for the mother and the offspring. Impaired placentation
and aberrant maternal systemic responses are implicated as pathophysiological
mechanisms in preeclampsia and FGR. Both preeclampsia and FGR are known
to have a clear genetic basis. This study has investigated the roles of several
candidate genes including those previously associated with diabetes (TCF7L2,
FTO, PPAR-g, CDKN2B-AS 1 and KCNJ11), and epidermal growth factor
(EGF). Functional consequences of variants within the EGF gene were also
investigated.
A bidirectional association between type 2 diabetes (T2D) and preeclampsia is
consistently reported, whereby each condition is associated with an increased
risk of the other. Furthermore, fetal growth restriction, which complicates 30%
of preeclamptic pregnancies, predisposes the offspring to an increased risk of
type 2 diabetes and coronary artery disease (CAD) later in life. 11 single
nucleotide polymorphisms (SNPs) reproducibly associated with T2D in the
TCF7L2, FTO, PPAR-y, CDKN2B-AS 1 and KCNJ11 genes were investigated as
susceptibility loci for preeclampsia and fetal growth restriction in a maternal case
control study. The study group consisted of 448 white western European women
with preeclampsia, 673 controls with no evidence of preeclampsia, 243 women
with pregnancies complicated by FGR, and 570 controls with no evidence of
growth restriction. A maternal haplotype on the T2D region of the CDKN2B-
AS I gene on chromosome 9p21 was found to be a risk variant for fetal growth
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restriction (P=O.005).The other 9 investigated SNPs in TCF7L2, FTO, PPAR-y,
and KCNJlI showed no association with growth restricted pregnancies. None of
the SNPs investigated showed an association with preeclampsia. These findings
suggest that some maternal diabetogenic risk variants are associated with an
altered risk of FOR pregnancy but not preeclampsia. The results require
replication in a larger sample and fetal-maternal gene interactions merit
investigation.
Epidermal growth factor (EOF) is described as a major regulator of the
placentation process. It also helps to maintain an adequate blood supply to the
growing fetus through its effects on umbilical vessel tone. Investigating the role
of two genetic variants of the EOF gene in susceptibility to preeclampsia and
FOR showed that the maternal variants, rs4444903 in the 5'UTR and rs2237051
in exon 14 of the EOF gene has no effect on the risk of preeclampsia or FOR
pregnancy. The 0 allele of the SNP rs4444903 was associated with higher
systolic blood pressure measures in the control group.
The 0 allele of the rs4444903 and the A allele of rs2237051 have been
associated with increased risk for FGR and lower birth weight in a previous
study from our laboratory. This led to investigations to characterize the
functional consequences of the two SNPs in the EOF gene on transcription,
translation and ribonucleic acid (RNA) splicing using a variety of methods.
These experiments have shown that the G allele of rs4444903 was
transcriptionally more active than the A allele in hepatocellular carcinoma
(Hep02) and more active than EGFP on its own in choriocarcinoma (Jeg-3) cell
lines using a luciferase reporter gene assay. There was no effect of this variant on
3
translational efficiency in the cell lines investigated using reporter gene assays,
or in a cell free environment using an in vitro translation assay. DNA-protein
interaction was investigated using nuclear extract from HepG2 cells to further
define the mechanism by which the G allele exerts its higher transcriptional
activity. Initial experiments suggest that the Sp1 transcription factor interacts
with and represses the A allele of the rs4444903 SNP. The study also
demonstrated no evidence of higher activity of the G allele on EGF expression in
vivo using term placental tissues. It was expected that higher EGF expression as
a function of genotype at rs4444903 SNP may lead to down regulation of the
EGFR in the placenta, which was not confirmed in this study. SNP rs2237051 in
exon 14 of the EGF gene is in strong linkage disequilibrium with rs4444903, and
disrupts a predicted exon splicing enhancer region. This polymorphism was
investigated using a minigene assay, but there was no evidence that it affected
splicing of exon 14. Taken together, these findings provide no evidence that
EGF genetic variants alter the risk of preeclampsia or FGR though functioning.
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Preface
This thesis describes some genetic and molecular genetic aspects of
preeclampsia and fetal growth restriction in a UK population.
The introductory chapter is presented in 2 sections. The first is related to
preeclampsia and the second to fetal growth restriction. In each of these sections,
the magnitude of the disease and its impact on public health and the development
of future cardio-metabolic disorders including type 2 diabetes (T2D), and
coronary artery disease (CAD) is highlighted. Definitions and diagnosis, risk
factors, and pathological features involving the placenta and the maternal
systemic disturbances are also described. Special attention is drawn to the
genetics of preeclampsia and fetal growth restriction, presenting evidence for a
genetic basis and the approaches and the future directions genetic investigations
may take. This chapter concludes with a statement of the hypothesis and the
objectives of the study.
The second chapter of this thesis describes the genetic case control association
study, investigating diabetes susceptibility genes and their role in preeclampsia
and fetal growth restriction. This chapter comes in 4 main sections. The first
section gives an overview of the 5 candidate genes to be investigated (TCF7L2,
FTO, ppARG, CDKN2B-ASI and KCNJ11. The second section of chapter 2
describes patient recruitment, genotyping and data analysis. The third and fourth
sections present the results and discussion of this investigation.
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The third chapter is devoted to epidermal growth factor (EGF). This chapter
comprises 4 sections each with its own introduction, methods, results and
discussion. The first section describes the EGF case control association study.
The second and third sections describe the functional impact of rs2237051 and
rs4444903 SNPs on mRNA splicing, transcription and translation of the EGF
gene respectively. The fourth section shows how the expression of the EGF and
EGFR in the placental tissues may vary as a function of genotype at rs4444903
SNP.
Chapter 4 provides a summary of all the experimental work, a discussion of the
strengths and limitations of the study and the prospects for future work.
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1 Introduction
Preeclampsia and fetal growth restriction (FGR) are two related pregnancy
disorders, in which fetal growth restriction complicates up to 30% of
preeclampsia cases. Both conditions carry substantial maternal and perinatal
morbidity and mortality. Preeclampsia and FGR are characterized by familial
aggregation and high recurrence rates among relatives, with a clear genetic basis.
There is substantial evidence that both maternal and fetal genes are involved in
the risk for preeclampsia and FGR.
Reduced uteroplacental blood flow due to abnormalities in vascular remodelling
of the maternal blood vessels and shallow trophoblast invasion are the
pathological features that characterize the placentas from preeclampsia and fetal
growth restriction. Signs of placental ischaemia are also reported in isolated
cases of fetal growth restriction. However, preeclampsia is a syndrome that is not
confined to the placenta, but involves all the maternal organs and systems, and a
proportion of cases of preeclampsia are free from placental abnormalities. This
indicates that although related, both conditions still have distinct features. This
introductory chapter will deal with preeclampsia and fetal growth restriction
separately, highlighting their impact on maternal and fetal health, the diagnosis,
the pathology, and the genetics of both conditions, and will highlight the shared
and disparate feature between preeclampsia and FGR.
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1.1 Preeclampsia
Preeclampsia is a syndrome affecting 3-5% of pregnant women worldwide,
manifested by new onset hypertension and proteinuria at or after 20 weeks of
gestation (Redman and Sargent, 2005). In its most severe forms it is a life
threatening condition, and carries both immediate and long term adverse
consequences to the mother.
1.1.1 Epidemiology of preeclampsia
Preeclampsia is a leading cause (12%) of maternal death worldwide, and
contributes to around 16% of maternal deaths in the developed countries. In
developing countries, where 99% (35500) of global maternal deaths occur,
preeclampsia comes after birth related haemorrhage and sepsis as a cause of
maternal death (Khan et aI., 2006, Duley, 2009). Preeclampsia is also associated
with fetal and neonatal complications, including FGR in 30% of cases, and an
increased rate of prematurity as a result of expedited delivery as a treatment for
severe preeclampsia. Other neonatal complications include perinatal death, and
long-term cardiovascular morbidity associatedwith low birth weight (Sibai et aI.,
2005).
The spectrum of the problem extends beyond the index pregnancy. Women
affected by preeclampsia are at increased risk of developing preeclampsia in
subsequent pregnancies, which may influence maternal decisions about future
pregnancies. The recurrence risk for preeclampsia in a subsequent pregnancy
ranges from 7.5% to 65%, depending on sample size and inclusion criteria.
Trogstad et al (2004) reported that the risk of preeclampsia in a subsequent
pregnancy was 14% and 7% after singleton and twin pregnancies respectively
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(Trogstad et al., 2004). A wide time interval between pregnancies and a change
of partner are also associated with an increased recurrence risk of preeclampsia.
The odds ratios (OR) for recurrence of preeclampsia in subsequent pregnancy are
11.8 (95% confidence intervals (Cl) 11.1 - 12.6), and OR 8.2 (95% Cl 5.9 - 11.3)
with a different partner and the same partner respectively (Lie et al., 1998).
The clinical features of preeclampsia frequently resolve within days to a
maximum of 3 months postpartum. However, it has been shown that
preeclampsia is associated with long lasting morbidity for the mother, including
an increased risk of type 2 diabetes (T2D), hypertension (HT), and coronary
artery disease (CAD).
Libby et al (2007) examined the relationship between preeclampsia and the
future development of T2D in their intergenerational cohort study composed of
7,187 mothers who give birth in Scotland between 1952 and 1958. They found
that women with a history of preeclampsia were at increased risk of T2D in later
life (OR 1.4, 95% Cl 1.12-1.75, P= 0.003). This OR was adjusted for baby's
birth weight and for social class (Libby, 2007) . .This was evident in a more recent
study by Lykke et al (2009) who showed an increased risk for T2D in relation to
hypertension in pregnancy. In this study, severe, recurrent, and early onset
preeclampsia were associated with greater risk, after an average of 14 years
follow up from the index pregnancy (Lykke et al., 2009). In agreement with this,
in a study by Carr et al (2009) with a median follow-up of 8.2 years, the OR for
diabetes in women with a history of preeclampsia was 1.82 (95% Cl 1.26 -2.62)
compared to women without preeclampsia after adjusting for age, parity, and
gestational diabetes (Carr et al., 2009).
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Persistence of metabolic syndrome and insulin resistance (lR) has been reported
both in the early post-natal period after pregnancies complicated by preeclampsia
and up to decades later in life. Sowers et al (1993) found altered plasma glucose
and insulin responses to an oral glucose load in women 40 weeks after
pregnancies complicated by preeclampsia, suggesting that an abnormality of
carbohydrate metabolism persisted in those subjects (Sowers et al., 1993).
Higher waist circumference, waistlhip ratio, body mass index, as well as
increased serum insulin levels and lower glucose/insulin ratios have been
reported in women with a history of preeclampsia compared to women with
normal pregnancies (Pouta, 2004 ). Higher values of IR were reported in
preeclamptic women one year after pregnancy compared to controls (Wolf et al.,
2004). Higher levels of fasting insulin, lipids, coagulation factors, and adhesion
molecules after pregnancies complicated by preeclampsia compared to controls
have also been reported (He et al., 1999, Sattar et al., 2003). Girouard et al
(2007) found significantly reduced levels of high-density lipoprotein (HDL)
cholesterol and adiponectin, and elevated apolipoprotein B/apolipoprotein Al
ratio, homocysteine, leptin, and insulin levels among preeclampsia subjects
compared with control subjects seven years after delivery (Girouard et al., 2007).
In relation to cardiovascular diseases, Ray et al (2005) analysed follow-up data
from 1million Caucasian women. They defined maternal placental syndrome as
a composite of gestational hypertension, preeclampsia, placental abruption, and
placental infarction, affecting 7.5% of the study population. They reported
doubling of the risk of premature (before 38 years) cardiovascular disease in
women who had had maternal placental syndrome compared to controls. The
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risk was tripled in the presence of fetal complications, or pre-existing risk factors
for cardiovascular disease, including features of the metabolic syndrome and
tobacco use. The association was evident when every component of the maternal
placental syndrome was tested separately. The risk conferred by preeclampsia,
which complicated 3.7% of cases, was comparable to that associated with the
traditional risk factors for cardiovascular disease such as metabolic syndrome
and tobacco use (Ray et al., 2005). This is in agreement with a more recent study
carried out by Lykke et al (2009) of nearly the same size who reported that the
risk for ischaemic heart disease was increased 1.48 fold (95% Cl 1.25-1.76) after
gestational hypertension, 1.57 fold (95% Cl 1.44-1.72) after mild preeclampsia
and 1.61 fold (95% Cl 1.34-1.94) after severe preeclampsia following adjustment
for maternal age, fetal birth weight, preterm delivery and T2D after 14 years
follow up (Lykke et al., 2009). The increased effect associated with severe
preeclampsia was confirmed in a study by Wikstrom et al (2005) in which the
risk for ischaemic heart disease following mild preeclampsia was 1.9 (95% Cl
1.6-2.2), compared with 2.8 (95% Cl 2.2-3.7) following severe preeclampsia
(Wikstrom et aI., 2005). In a meta-analysis carried out by Bellamy et al (2007),
the relative risk for hypertension was 3.70 (95% Cl 2.70 to 5.05) after 14 years'
follow-up, and 2.16 (95% Cl 1.86 to 2.52) for ischaemic heart disease after 11.7
years (Bellamy et al., 2007). Levels of C reactive protein (CRP), an
inflammatory marker of ischaemic heart disease, were found to be higher
together with high blood pressure, an atherogenic lipid profile, higher fasting
insulin and homeostasis model of insulin resistance in women 30 years after a
diagnosis of eclampsia (Hubel et aI., 2008). Although the studies described here
were retrospective in nature with the possibility of recall bias for the study
parameter, and the potential of unidentified confounders, the agreement among
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studies on the effect of preeclampsia on future risk of maternal metabolic and
vascular diseases, and the biological plausibility of the findings, are persuasive.
Pregnancy acts as a life long stress test for the mother. During pregnancy all
maternal systems and organs must adjust to the increased demand of the growing
fetus. Gestational diseases like preeclampsia develop when the mother is unable
to cope with the increased metabolic and vascular load. Delivery is associated
with remission, but there is evidence of residual cardiovascular compromise.
This may indicate that preeclampsia induces irreversible metabolic and vascular
changes in the mother rendering her susceptible to metabolic syndrome, T2D and
CAD (Ramsay et aI., 2003, Sattar and Greer, 2002), (Figure 1-1). An alternative
explanation is that women with a predisposition to cardio-metabolic disorders
are at increased risk of preeclampsia. Genetic risk factors may represent the link
between preeclampsia and the cardio-metabolic disorders. A mother with
cardiovascular risk factors including diabetes and chronic hypertension is
currently considered as a high risk during pregnancy, and closely monitored
accordingly. Similarly, it has been argued that women with history of
preeclampsia would benefit from earlier screening for cardiovascular disease and
life style modification in order to lower their risk of metabolic and ischaemic
vascular disease.
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Figure 1-1: Preeclampsia as a life long risk for cardio-metabolic disorders
Preeclampsia is the metabolic syndrome of pregnancy. Preeclampsia is associated with
an increased risk of future cardiovascular and metabolic disorders (adapted from (Sattar
and Greer, 2002).
Healthy pregnancy
Preeclampsia
Threshold for Cardio-metabolic disease
1.1.2 Clinical manifestations of preeclampsia
The first criterion is a systolic blood pressure ~140 mm Hg or a diastolic level
~90 mm Hg on two or more occasions at least 4-6 h apart, at or after the 20th
week of gestation. Clinically an increase in blood pressure of 30 mm Hg
(systolic) or 15 mm Hg (diastolic) should prompt patient monitoring for
preeclampsia. An increase in blood pressure is expected towards the end of an
otherwise healthy pregnancy, so cannot be regarded as a pathognomonic sign of
preeclampsia. The second diagnostic criterion is proteinuria, defined as ~O.3 g
protein in a 24 hour urine sample (Leeman and Fontaine, 2008, National High
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Blood Pressure Education Program Working Group on High Blood Pressure in
Pregnancy, 2000). When a 24 hour urine collection is not feasible, two random
urine samples taken at least 4-6 hours apart can be used to measure
protein/creatinine ratios; 30 mg protein/mmol urinary creatinine is regarded as
the threshold for preeclampsia (Cote et al., 2008). The cheap, convenient urinary
dipstick testing is widely used and ~ +1 equivalent to ~ 0.3 g protein provides a
provisional diagnosis of proteinuria (Leeman and Fontaine, 2008). Results of
dipstick testing should be interpreted with caution, because urine dipsticks can
be affected by other maternal conditions e.g. dehydration (Sibai, 2003).
Furthermore a negative test should not be ignored in a woman with new
hypertension or symptoms or signs suggestive of preeclampsia; 12%of negative
results will be false negatives as assessed against 24-hour urine collections
(Magee et al., 2008).
The appearance of de novo proteinuric hypertension in pregnancy is diagnostic
of preeclampsia, but some atypical presentations of preeclampsia occur.
Hypertension after the 20th week of gestation without proteinuria can precede the
development of the full spectrum of preeclampsia in 50% of cases. Persistent
non-proteinuric hypertension is known as gestational hypertension; the severe
form is typically associated with adverse maternal outcomes comparedwith mild
preeclampsia (Buchbinder et aI., 2002).
Pre-existing high blood pressure before pregnancy or before the 20th week of
gestation is diagnosed as chronic hypertension, and up to 30% of women with
this condition develop preeclampsia (Chappell et aI., 2008). A sudden increase in
blood pressure, new proteinuria, or signs and symptoms of other organ
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involvement indicate superimposed preeclampsia. In the absence of pre-
pregnancy records chronic hypertension may be overlooked due to the
physiological fall in blood pressure during pregnancy. It is sometimes difficult to
differentiate chronic hypertension from preeclampsia during pregnancy.
Resolution of hypertension by 12 weeks postpartum suggests a retrospective
diagnosis of preeclampsia. Persistence of hypertension beyond 12 weeks
postpartum is often regarded as preeclampsia superimposed on chronic
hypertension, although the possibility that massive endothelial damage caused by
preeclampsia has resulted in chronic hypertension cannot be excluded. Similarly
pre-existing proteinuria due to renal disease should be detected at early antenatal
checks as this is associated with an increased risk of superimposedpreeclampsia.
The preeclampsia syndrome may affect many body systems due to systemic
endothelial activation and systemic inflammation, (e.g. impaired liver function,
impaired renal function, coagulopathy, pulmonary oedema, and brain oedema)
(Lowe et al., 2009). Consequently, women with new onset hypertension should
be investigated with a full blood count, urea, creatinine, electrolytes, and liver
function tests, and surveillance of fetal growth and amniotic fluid volume by
ultrasound, and uterine and umbilical artery volocimetry should be carried out
(Lowe et al., 2009).
Clinically preeclampsia is classified into mild and severe forms, depending on
the clinical features. Severe preeclampsia is characterized by one or more of the
following signs: systolic blood pressure more than 160 mm Hg and diastolic
blood pressure greater than 110 mm Hg; proteinuria >5g 124 hours; oliguria <
500 ml in 24 hours; liver involvement manifested by elevated liver enzymes;
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pulmonary oedema; thrombocytopenia; and involvement of the central nervous
system in the form of convulsions (Leeman and Fontaine, 2008, National High
Blood Pressure Education Program Working Group on High Blood Pressure in
Pregnancy, 2000). HELLP syndrome, a triad of Haemolysis, glevated Liver
enzymes and Low flatelet count is a severe form of preeclampsia that can
proceed to disseminated coagulopathy. Eclampsia, characterized by convulsions,
complicates 2% of preeclampsia cases. 12% of cases of HELLP syndrome and
20% of eclampsia cases occur in normotensive nonproteinuric subjects (Landon
et al., 2004, Magee et al., 2008, Steegers et al., 2010).
Preeclampsia is further classified into early onset and late onset depending on a
time of diagnosis before or after 34 weeks of gestation (von Dadelszen et al.,
2003). Early onset disease is less common (20%), more severe and usually
complicated by the fetal syndrome of FGR and often associated with abnormal
uterine and umbilical artery Doppler. Late onset preeclampsia is more common
(80%), usually mild, and without fetal complication (Sibai et al., 2005). The
differential diagnosis of hypertension in pregnancy is outlined in (Table 1-1).
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Table 1·1: Classification and Diagnostic Features of Hypertension in
Pregnancy
(Wagner et al., 2007). with permission.
Hypertensive disorders Definitions and clinical manifestations
of pregnancy
Preeclampsia/eclampsia Preeclampsia, a pregnancy-specific disorder that occurs in
30/0-5% of pregnancies, is a multisystem disease
characterized by hypertension and protein level ~300 mg in
a 24-hour urine collection. Eclampsia, the convulsive form
of preeclampsia, affects 0.1% of all pregnancies.
Gestational Hypertension that occurs for the first time during the second
hypertension half of pregnancy in the absence of proteinuria. It includes
both women with preeclampsia who have not yet developed
proteinuria and those with hypertension only; in a subset of
patients with gestational hypertension, blood pressure
remains elevated after delivery, leading to the diagnosis of
chronic hypertension. Transient hypertension is
characterized by blood pressure normalization by 12 weeks'
postpartum.
Chronic hypertension Blood pressure ~ 140/90 mm Hg before pregnancy or
before the 20th week of gestation. Most patients in this
category will have a benign course with normalization of
blood pressure midpregnancy.
Preeclampsia
superimposed on
chronic hypertension
Up to 30% of women with chronic hypertension develop
preeclampsia, indicated by proteinuria that occurs for the
first time in the third trimester, which is absent in
uncomplicated chronic hypertension.
1.1.3 Risk factors for preeclampsia
A previous history of preeclampsia as well as a history of preeclampsia in a first
degree relative (mother and sister) is reported to be associated with a doubling of
the risk of preeclampsia (Nilsson et al., 2004, Plunkett et al., 2008). The
partner's history is also important; being an offspring of a preeclamptic
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pregnancy or fathering a previous preeclamptic pregnancy is considered a risk
factor (Lie et al., 1998, Skjaerven et al., 2005). Based on these facts, a genetic
component of preeclampsia including a role for paternal genes has been
proposed. Preeclampsia is more common in nulliparous women (7.5%), and in
parous women if they have wide inter-pregnancy intervals (>10 years),
(Skjaerven et al., 2002) or have a new partner (Lie et al., 1998). Limited sperm
exposure in these women might explain this increased risk, as a previous
abortion or healthy pregnancy is associated with reduced preeclampsia risk
(Trogstad et al., 2008).
Multiple pregnancy and hydatidiform mole, both associated with an increase in
placental size, are also associated with increased risk for preeclampsia,
indicating the central role of the placenta in its pathogenesis. Extremes of
maternal age « 20 and >40 years) also carry an increased risk of preeclampsia
(Milne et al., 2005).
Pre-existing diabetes, high body mass index (BMI) before pregnancy,
hypertension, renal disease, and thrombophilia are independent risk factors for
preeclampsia. This is discussed in detail here because it is of particular interest in
this study.
In 2003, Dunne et al carried out a study in the West Midlands, UK to investigate
the effect of diabetes on pregnancy outcome and reported that the incidence of
preeclampsia (among other adverse fetal and maternal outcomes) in 182 diabetic
women was 20% compared with 10% in non-diabetic women in the local
population (Dunne et al., 2003). Moreover, a study carried out by Rosenberg et
31
al (2005) in the US, including approximately 300,000 singleton pregnancies,
reported that mothers with pre-gestational diabetes showed an increased risk for
preeclampsia (OR 2.77; 95% Cl 2.22-3.47). Gestational diabetes irrespective of
ethnicity (White, Black, Asian, and Hispanic) was also associated with an
increased risk of preeclampsia (Rosenberg et aI., 2005). Moreover, a history of
diabetes in a sibling was associated with an increased risk of preeclampsia in a
study which included 190 cases and 373 controls (OR 4.7; 95% CIl.l to 19.1)
(Qiu et aI., 2003).
Obesity is an independent risk factor for preeclampsia. It has been extensively
studied in relation to preeclampsia, in which the risk escalates with different
degrees of obesity. Compared with women with a BMI of 21, the adjusted risk of
preeclampsia doubled at a BMI of 26 (OR 2.1, 95% Cl 1.4 - 3.4) and nearly
tripled at a BMI of30 (OR 2.9, 95% Cl 1.6 - 5.3). This was adjusted for diabetes,
social status, smoking history and race and included 1179 nulliparous mothers
(Bodnar et aI., 2005). They showed also that women with a lower BMI (17 and
19) had a 57% and 33% reduction in preeclampsia risk respectively compared
with women with a BMI of 21. In 2005, a larger study including 300,000
singleton pregnancies replicated this effect of BMI on preeclampsia risk
(Rosenberg et aI., 2005). It has been suggested that obesity confers risk for
preeclampsia via increased insulin resistance as evidenced by higher leptin and
lower adiponectin and sex hormone binding globulin (SHBG) in obese
preeclamptic women compared to normotensive women (Catalano, 2010).
Hyperinsulinaemia early in pregnancy was able to predict the development of
preeclampsia latter in pregnancy. IR as indicated by higher fasting insulin and
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higher blood glucose and insulin levels after oral glucose measured in early
pregnancy have been reported in several studies as a predictor for the
development of hypertension in pregnancy (Solomon et al., 1999, Solomon et al.,
1994). Low measures of SHBG, which correlates with insulin resistance, higher
24h urinary insulin as well as high HOMA-IR (Homeostasis Model of
Assessment-Insulin Resistance) antedated the clinical diagnosis of preeclampsia
(Emery et al., 2005, Sierra-Laguado et al., 2007, Thadhani et al., 2004).
This increased risk of preeclampsia in obese women, prediabetic, and diabetic
mothers implies that these conditions might share the same pathological changes,
including endothelial dysfunction, oxidative stress, systemic inflammation and
coagulopathy. Conversely, as discussed earlier in this chapter, a history of
preeclampsia is associated with an increased risk of cardio-metabolic diseases
later in life. This indicates that certain shared risk factors may be present in early
adult life, during the child-bearing period, and extending into middle age,
making the affected mothers more vulnerable to both conditions (Figure 1-1).
Genetic risk factors are strong candidates for the shared predisposition to
preeclampsia and cardio-metabolic disorders in later life.
1.1.4 The role of the placenta
The aim of the placentation process is to anchor the fetus to the uterine wall,
establish a means of communication between maternal and fetal circulations, and
provide a barrier through which gas and nutrient exchange take place. This is
accomplished by establishment of the placental villous tree and spiral artery
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remodelling. Abnormalities involving these two processes are major
characteristics of the preeclamptic placenta.
The central role of the placenta in the pathophysiology of preeclampsia is clearly
evident, in that the presence of the placenta is essential for preeclampsia to occur
and its delivery is the only cure. Preeclampsia is a complication of hydatidiform
molar pregnancies which lack a fetus, and in women with postpartum
preeclampsia curettage of the uterus leads to subsidence of preeclampsia
symptoms (Young et al., 2010).
1.1.4.1 Insufficient spiral artery remodelling
Spiral artery remodelling is the transformation of the terminal branches of the
uterine artery, occupying the endometrium and the inner part of the myometrium,
from narrow coiled contractile high pressure vessels 200 urn in diameter into
thin-walled flaccid low pressure vessels 2 mm in diameter (Figure 1-2). This
ends with proper establishment of the feto-maternal circulation with an increase
in the umbilical artery end diastolic velocity and an increase in the 02 tension in
the placental bed from 20 mm Hg to about 60 mm Hg. This process starts
between the 8th and 10thweeks of gestation and becomes established around the
20th - 24thweeks of gestation during which there is an exponential increase in the
fetal nutrient and gas requirement (Whitley and Cartwright, 2010).
During the early weeks of gestation, the highly proliferative villous
cytotrophoblast (CT) cells stream out of the tips of villi and penetrate the
overlying syncytiotrophoblast (ST) to form CT columns that invade the decidua
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as extra-villous trophoblast (EVT). Two subtypes of the EVT are recognized, the
interstitial and the endovascular. Interstitial EVT accumulates around the
remodelling site where the decidual immune and stromal cells initiate the
remodelling process (Lunghi et al., 2007). Endovascular EVT migrates into, and
plugs, the terminal part of the vessel early in pregnancy to ensure the hypoxic
state required at this stage. Later it erodes and replaces the endothelial cell (EC)
lining of the vessel and the vascular smooth muscle cells (VSMC). Oxygen
pressure must be maintained at defined levels throughout gestation so that the
development of the early embryo during the first trimester of pregnancy takes
place in a low oxygen environment (Jauniaux et al., 2000). Low levels of oxygen
are important to ensure higher proliferative activity, lower invasive activity of
CT, and reduced levels of reactive oxygen species (ROS), thus less DNA
damage to the developing fetus (Huppertz et al., 2009).
The process of remodelling involves apoptosis of the VSMC and EC as well as
alteration in the extracellular matrix. A wide range of molecules is involved in
this process. Tumour necrosis factor-a (TNFa), TNF-related apoptosis inducing
ligand (TRAIL) and Fas ligand (FasL) are expressed by trophoblasts, and their
receptors are expressed on both VSMC and EC with a shift in the balance of
these molecules towards apoptosis (Harris et al., 2006, Ashton et al., 2005).
Disruption of the extracellular matrix is thought to take place even before being
in contact with the EVT as part of the decidualization process. Both trophoblast
and VSMC produce matrix metalloproteinase(s) MMPs 1, 2, 9, and 12 that
degrade the extracellular matrix with further disruption of the vessel wall (Harris
et al., 2010).
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In preeclampsia, invasion of the uterine spiral arteries is limited to the proximal
decidua (Naicker et aI., 2003). Both the invasive depth and numerical density of
interstitial trophoblast are significantly reduced (Kaufinann et aI., 2003), (Figure
1-2). This failure of trophoblast invasion in preeclampsia results in a reduction in
utero-placental perfusion, with the placenta becoming increasingly ischaemic as
gestation progresses. Reduced placental perfusion is evident as multiple central
or large peripheral placental infarcts affecting 5% of the placenta, atherosclerotic
changes in the placental vessels, endothelial damage, vascular thrombosis and
fibrin deposition (Roberts and Post, 2008) as well as abnormal umbilical and
uterine artery Doppler measurements (North et aI., 1994).
Abnormal spiral artery remodelling leads not only to a reduction in the absolute
amount of blood entering the placenta but also the manner by which the blood
enters the inter-villous space. The blood enters the inter-villous space in an
interrupted stream of jets of high velocity, as the vessel wall still retains its
muscular layer. This creates a state of hypoxia Ireperfusion that is deleterious to
villous membrane integrity and function, and leads to enhanced apoptosis and
necrosis. Furthermore, it will impose mechanical effects leading to excessive
shedding of syncytial knots into the maternal circulation. It also leads to the
formation of inter-villous lakes with the potential for thrombosis (James et aI.,
2010). The deformed chorionic plate and the increase in inter-villous space
pressure also interfere with transport across the syncytial membrane. These
changes in spiral artery remodelling occur primarily in early onset preeclampsia,
often with FGR. Interestingly they may occur with isolated cases of FGR,
indicating that such abnormalities may not be specific to preeclampsia
(Huppertz, 2008).
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Figure 1-2: Spiral artery remodelling in normal and hypertensive
pregnancy
Defective spiral artery remodelling leads to placental hypoxia with subsequent release of
soluble factors like sFlt-1 Into the maternal circulations leading to maternal systemic
dysfunction and vasoconstriction (Redman and Sargent, 2005), with permission.
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1.1.4.2 Abnormalities of the villous trophoblast
Under normal conditions, the villous tree starts to form upon implantation. It
passes through three stages: primary, secondary and tertiary villi. The tertiary
villi are formed of ST, a secretory multinucleated cell layer facing towards the
maternal side of the villi. The second layer, facing towards the fetal side, is the
CT. This layer is highly proliferative and responsible for continuously
replenishing the ST layer by membrane-membrane fusion. The villi have also a
connective tissue core that contains the newly formed fetal blood vessels. In the
terminal branches of the villi, capillaries dilate into sinusoids covered by a
vasculo-syncytial membrane (separating maternal and fetal circulations).
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The vasculo-syncytial membrane consists of the ST and the endothelium of the
capillary, separated by a joint basement membrane. The terminal villi are the
physiologically most important components of the villous tree of the human
placenta. The integrity of the ST is important because it carries a variety of
transporters, receptors and enzymes that regulates maternal-fetal exchange
(Jones et al., 2007).
Under normal conditions, ST is continuously replenished by fusion of CI' cells,
and the old and depleted ST undergoes apoptosis and shedding into maternal
circulation as syncytial knots. The syncytial knots are cleared by the
macrophages in the lung vasculature as they are too large to pass into the
peripheral maternal circulation.
A large number of growth factors, adhesion molecules, cytokines, and cell cycle
regulators have been implicated in the regulation of Cf trophoblast proliferation
and differentiation into syncytiotrophoblast, acting in autocrine and paracrine
fashions. Many excellent reviews are available to describe such factors in details
(James et al., 2010, Lunghi et al., 2007). Epidermal growth factor (EGF) and its
receptors are expressed at the fetomaternal interface very early in pregnancy.
EGF was found to regulate CI' proliferation, differentiation and invasion in a
gestational age dependent manner (Bass et al., 1994). It has been also implicated
in abrogating the effect of apoptotic stimuli on the trophoblast cell lineage (Moll
et al., 2007).
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Vascular endothelial growth (VEGF) is one of the growth factors that has been
extensively studied in relation to the placentation process; soluble receptors for
this factor have been implicated in the pathology of preeclampsia (discussed in
section 1.1.5). Both villous trophoblast and decidual immune cells are known to
express VEGF and placental growth factor (PGF). VEGF expression is
stimulated by hypoxia inducible factor-I (HIF-1), under the hypoxic conditions
encountered during early placentation. VEGF mediates its actions via 2 tyrosine
kinase receptor isoforms, VEGF-receptor 1, (VEGF-Rl or fit-I) and VEGF-R2.
VEGF-R2 binding by VEGF induces endothelial cell proliferation (associated
with branching angiogenesis), while binding to VEGF-Rl stimulates endothelial
tube formation. PGF is stimulatedby oxygen and binds exclusively to VEGF-Rl,
resulting in non branching angiogenesis that dominates in the second half of
pregnancy (Arroyo and Winn, 2008).
Placentas from early-onset preeclampsia exhibited a reduction in placental
weights, volume of the intervillous space, surface area and volumes of the
terminal villi. The picture was more extensive in the placentas from
preeclampsia complicated by FGR, or in cases of FGR in which the intermediate
and stem villi are also reduced in volume. The pathology involves reduction in
the surface area of the villous capillaries and the blood vessels (Egbor et al.,
2006a, Egbor et al., 2006b). Isolated cases of late onset preeclampsia are free of
these changes (Egbor et al., 2006b, Mayhew et al., 2004).
The preeclamptic placenta is characterized by enhanced apoptosis and formation
of more syncytial knots compared to normal placenta due to uncontrolled
extrusion of apoptotic materials. It has been suggested these apoptotic materials
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trigger systemic manifestations of preeclampsia (Gauster et al., 2009, Chen et al.,
2010, Crocker et al., 2003). Syncytial knots are more common in placentas from
preeclamptic pregnancies complicated by FOR compared to the normal villous
histology of control pregnancies (Ishihara et al., 2002, Guller et al., 2008).
Additionally, increased apoptosis may affect the transport function of the ST and
consequently may be associated with FOR.
Moreover it has been noted that it is not only the apoptosis pathway which is
enhanced; signs of aponecrosis and necrosis were reported in preeclampsia
placentas. These pathways create subcellular particles of 100-200 nm known as
the syncytio-trophoblast microparticles (STMPs) (Redman and Sargent, 2008).
The ST trophoblast also releases smaller particles of 20-40 nm, termed
nanoparticles or exosomes. Both STMPs and exosomes are rich in lipid and
cytoplasmic components of the cell as well as DNA and microRNA of fetal
origin. Consequently they are able to induce immune and inflammatory
responses in the mother (Vanwijk et al., 2002, Redman and Sargent, 2008).
These aponecrotic structures are released under normal conditions but in
preeclampsia they are released in large numbers. In contrast to inefficient spiral
artery remodelling and increased formation of syncytial knots, pathologies which
are shared between preeclampsia and FOR, STMPs are only detected in
preeclampsia (Goswami et al., 2006).
STMPs are placenta-derived micropartic1es, but other types of microparticles
(MP) derived from platelets, granulocytes, T- cells and endothelium are also
reported. These MP are suggested to be proinflammatory, procoagulant, and
induce endothelial dysfunction in a group of diseases like CAD, diabetes, and
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atherosclerosis (VanWijk et al., 2003). This suggests that MP might be a possible
link between the local changes occurring in the placenta and the aberrant
systemicmaternal responses in preeclampsia.
1.1.5 Maternal systemic changes during pregnancy and preeclampsia
Aberrant maternal systemic responses in preeclampsia are the extreme of the
adaptive mechanisms taking place during normal pregnancy (Roberts and Hubel,
2009).
Healthy pregnancy is associated with a state of insulin resistance, induced by
hormones released by the developing placenta - placental growth factor,
placental lactogen, progesterone and corticotrophin releasing hormone - to
ensure the glucose supply to the fetus (Butte, 2000). An atherogenic lipid profile
is created by mid-pregnancy (Hadden andMcLaughlin, 2009).
Pregnancy is also characterized by enhanced coagulation activity due to
elevations in plasma fibrinogen, von Willebrand factor, and other coagulation
factors as well as increased platelet aggregability (Bremme, 2003). Increased
inflammatory responses are also reported during normal pregnancy as indicated
by leukocytosis (Sacks et al., 1998) and raised CRP compared to non pregnant
states (Picklesimer et al., 2008).
Being responsible for a vast array of homeostatic functions such as blood
pressure, blood flow, angiogenesis, coagulation, fibrinolysis, and inflammation,
the endothelium is a major player in maternal adaptation for pregnancy.
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Endothelial dysfunction is characteristic of preeclampsia, with an altered balance
between vasodilator and vasoconstrictor mediators and an altered coagulation
cascade secondary to endothelial damage. The damage is widespread and
involves the placental vessels, renal, hepatic, cerebral and other systemic vessels.
Soluble factors released secondary to placental hypoxia-reperfusion and STMPs
are regarded as the link between abnormal placentation and widespread
dysfunction of the maternal vascular endothelium. On the other hand, evidence
that impaired endothelial functions precede preeclampsia suggests that
endothelial dysfunction might be a cause, not an outcome in the course of
preeclampsia (Granger et al., 2001).
The hypoxic placenta releases certain factors, many of which are known to
interfere with angiogenesis and the integrity of the endothelium. Soluble fins-like
tyrosine kinase-l (sFlt-l) is an alternative splice variant of Flt-l that lacks the
transmembrane and cytoplasmic domains of FIt-I, and is released in large
amounts into the blood of preeclamptic mothers compared to normotensive
controls (Shibata et al., 2005, Levine et al., 2004, Gu et al., 2008). The high
levels of sFlt-I sequester both local and circulating VEGF and PGP and
consequently interfere with their local and systemic effects. Locally it results in
impaired angiogenesis, trophoblast proliferation and invasion. This was
evidenced by an in vitro experiment showing defective human CI' invasive
capacity when sFltl-Fc fusion protein was added to the culture medium. VEGF
is important for integrity of the endothelium as well as the production of nitric
oxide NO and prostacyclins, thus VEGP deficiency due to excess sFlt-I results
in systemic endothelial damage. Supporting evidence comes from experiments in
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rats which manifested systemic vasoconstriction and proteinuria after
administration of sFlt-l (Maynard et al., 2003).
Endoglin is a co-receptor for transforming growth factor B (TGF-B) 1 and 3. The
extracellular domain of endoglin can be shed as soluble endoglin (sEng), which
is thought to impair TGF-Bl binding to cell surface receptors and decrease
endothelial nitric oxide signalling, thus inhibiting angiogenesis and promoting
vascular dysfunction (Venkatesha et al., 2006) sFlt-l and sEng are significantly
increased in maternal serum prior to the onset of preeclampsia (Erez et al., 2008,
Romero et al., 2008).
NO is also involved in impaired endothelial function in preeclampsia. NO
enhances trophoblast functions (Dash et al., 2005). It is also responsible for
systemic vascular dilatation occurring during pregnancy, and is thought to be a
downstream mediator of VEGF; relative deficiency of this factor is associated
with altered function of NO with subsequent loss of its vasodilator and
antioxidant effects. Sandrim et al (2008) found that the level of nitrite, a
metabolite of NO, is reduced in serum of preeclamptic women, correlating with
higher levels of sFlt-l and s-Eng (Sandrim et al., 2008).
The whole balance of ROS and antioxidant levels is challenged in preeclampsia.
Many studies have reported an increase in maternal and placental production of
ROS with subsequent lipid and protein oxidation (Serdar et al., 2003).
Furthermore there is reduction in maternal antioxidant defence mechanisms as
evidenced by reduced activity of superoxide dismutase and glutathione
peroxidase, and reduced tissue and serum concentrations of antioxidant vitamins
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(Aydin et aI., 2004, Atamer et aI., 2005). In spite of these suggestive
observations, supplementation with vitamin C and E during pregnancy showed
no effect on risk of preeclampsia (Rumbold et aI., 2006, Poston et aI., 2006).
An imbalance of anticoagulant and procoagulant processes is found in
preeclampsia, as increased levels of proteins of the coagulation cascade have
been reported in these women. Circulating levels of fibronectin are significantly
increased as early as 20 weeks of pregnancy in women who subsequently
develop preeclampsia, as well as other procoagulant proteins such as tissue
plasminogen activator, plasminogen activator inhibitor-I, and fibronectin
(Shaarawy and Didy, 1996). Von Willebrand factor and homocycsteine are
elevated in preeclampsia while the levels of anticoagulant proteins like
antithrombin III, protein C and Protein S are reduced (Kupferminc, 2003).
Dyslipidaemia is also a manifestation of preeclampsia, especially the early onset
form (Clausen et aI., 2001). It is characterized by increased low density
lipoprotein (LDL), triglycerides, and free fatty acids and low high density
lipoprotein (HOL) (Sattar et aI., 1997,Kaaja et aI., 1995). This is reflected in the
placenta by a picture of acute atherosis due to uptake of the oxidized LOL by
macrophages to form foam cells.
Oxidative stress, inflammation, dyslipidaemia, hypercoagulabilty and endothelial
dysfunction are in a state of interaction and potentiate each other resulting in
cumulative vascular and endothelial damage.
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1.1.6 The relation between abnormal placentation and systemic
maternal manifestations
It has been suggested that preeclampsia is a two stage disease, in which placental
ischaemia induces and is followed by endothelial damage (Roberts and Hubel,
2009). The issue of a two stage disorder is questionable firstly because many
cases, especially those which present with late onset preeclampsia, show no
pathological features in the placenta. Secondly, the placental pathology appears
in other pregnancy-related disorders such as preterm birth and isolated cases of
FGR unrelated to preeclampsia. Lastly, markers of endothelial dysfunction
(fibronectin, von Willebrand factor, adhesion molecules, reduced nitric oxide,
and endothelin-l) have been reported in preeclamptic women weeks before the
clinical presentation, indicating that endothelial dysfunction might not be a
sequel of placental ischaemia but rather an independent contributor to the
development of preeclampsia (Granger et al., 2001).
An oversimplified classification is: 1-) abnormal placentation combined with
endothelial dysfunction leads to the early onset form of preeclampsia with FGR;
2-) abnormal placentation with normal maternal endothelium leads to isolated
cases of FGR; 3) normal placentation with endothelial dysfunction leads to late
onset preeclampsia. There is a possibility that both abnormal placentation and
endothelial dysfunction share the same risk factors (Craici et al., 2008), which
may be genetic in nature.
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1.1.7 Genes and preeclampsia
1.1.7.1 Heritability of preeclampsia
A large body of evidence indicates that genes are risk factors for preeclampsia.
There is a high recurrence rate of preeclampsia across generations (Amgrimsson
et aI., 1990) as well as an increase in the incidence of preeclampsia in first
degree relatives of affected women. Daughters of mothers with a history of
preeclampsia showed a 1.7 fold increase in the risk of preeclampsia; this risk was
uniformly spread over first and second pregnancies, and was similar in daughters
whether they were offspring of the preeclampsia pregnancy or not (Mogren et
aI., 1999). This implies that the risk is not related directly to the intrauterine
environment but to inherited genetic factors. This was replicated in two other
large studies from Sweden and Norway in which the mother to daughter risk
ratio was estimated to be 2.6 and 2.2 respectively (Nielsen et aI., 2003, Skjaerven
et aI., 2005). There is also an increased risk of preeclampsia among sibs as
reported in different populations. Nilsson et al (2004) reported an OR of 3.3
(95% Cl 3-3.6) for sibs of affected Swedish women. Similarly, a US study
reported a sib OR of 4.52 (95% Cl 4.21-4.83) and 4.11 (95% Cl 3.59-4.63) in
white and black women respectively (Plunkett et aI., 2008).
The heritability of preeclampsia was estimated to be around 50%. Salonen Ros
et al used the Swedish twin register to determine the role of genetic and
environmental factors in the liability for preeclampsia and reported that
monozygotic twins showed 57% concordance for preeclampsia compared to 18%
in dizygotic twins, and estimated the heritability to be 54% (0-71%); the wide
confidence interval was related to the small sample size (Salonen Ros et aI.,
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2000). Lower estimates of preeclampsia heritability of 30% were reported in
more recent studies (Cnattingius et al., 2004, Nilsson et al., 2004). Cnattingius et
al provided a detailed dissection of the genetic component of preeclampsia using
the Swedish Birth and MultiGeneration Registries (Cnattingius et al., 2004). In
his study, sister pairs, brother pairs and sister-brother pairs were used to
differentiate between genetic and environmental components of preeclampsia
and also to estimate the effect of maternal and fetal genes. The authors reported
that 35% and 20% of the variance in liability of preeclampsia was attributable to
maternal and fetal genetic effects respectively.
50% of fetal genes are maternally derived and 50% are paternally derived.
Evidence for the involvement of paternal genes comes from the observation that
the risk of fathering a preeclamptic pregnancy is increased among males who
fathered a preeclamptic pregnancy with a different partner (Skjaerven et al.,
2005, Lie et al., 1998) and among males who were themselves born from a
pregnancy complicated by preeclampsia (Esplin et al., 2001, Sibai et al., 2005).
Fetal genes are predicted to raise maternal blood pressure in order to enhance the
utero-placental blood flow whereas maternal genes will act the opposite way.
Endothelial dysfunction in preeclamptic mothers could, therefore, be interpreted
as a fetal attempt to compensate for an inadequate utero-placental nutrient supply
(Sibai et al., 2005).
Segregation analysis of preeclampsia pedigrees showed no clear pattern of
inheritance. Early reports referred to a maternal recessive mode of inheritance as
the incidence of preeclampsia is more common in mothers and sisters of the
affected cases than in the general population, but is less than 50 % which is
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expected in a dominant mode of inheritance, unless the genes were affected by
low penetrance. However, recessive fetal inheritance was also proposed as the
incidence in sisters-in-law is higher than expected in the general population
(Cooper and Liston, 1979). Mitochondrial inheritance was suggested based on
the finding that a mitochondrial gene defect Was detected in preeclampsia
(Folgero et al., 1996) but did not receive much support, partially because of the
finding of a paternal contribution to the genetic risk of preeclampsia.
The nature of preeclampsia, being sex-limited and occurring only during
pregnancy with the absence of known genetic carriers and the inconsistency of
reports on consanguinity does not give solid support for the recessive mode of
inheritance. In addition susceptibility to preeclampsia can be affected by
maternal genotype, fetal genotype, or by an interaction of the two genotypes.
Moreover, the contribution of the placenta, a major site for genomic imprinting,
makes it difficult to assign a specific mode of inheritance for preeclampsia
(Amgrimsson, 2005).
Currently preeclampsia is regarded as a complex genetic disorder in which many
genes each contribute a modest effect to the phenotype. Susceptibility to
preeclampsia is thought to result from complex interactions between maternal
and fetal/paternal genotypes and environmental factors.
1.1.7.2 Genetic studies in preeclampsia
There are two main approaches to the identification of susceptibility genes:
linkage and association studies. Each of these has 2 main components, either
testing a candidate gene or chromosomal locus based on biological
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understanding of the disease or searching the whole genome for loci that might
affect the disease risk. In the following paragraphs the basic characteristics of
each type of study and recent advances in relation to the genetics of preeclampsia
will be discussed.
1.1.7.3 Genetic linkage studies
Linkage studies are based on the co-segregation of chromosomal loci with the
disease in affected families. These chromosomal loci are identified by
genotyping genetic markers assuming that these markers are co-inherited with
the disease causing loci (individuals with similar phenotype share the same
genetic markers). Linkage studies are effective in detecting risk variants that
confer moderate to high disease risk. The markers used in linkage studies are
usually microsatellite markers (polymorphic markers) so that segregation with
the disease can be easily traced in families (Dawn Teare and Barrett, 2005).
Early studies of preeclampsia using the linkage approach focused on segregation
of candidate loci in the affected family members. Linkage to the angiotensinogen
gene on chromosome lq42-43 (Arngrimsson et aI., 1993) and to the endothelial
nitric oxide synthase (eNOS) gene on chromosome 7q36 (Arngrimsson et aI.,
1997, DeFronzo et aI., 1992) have been reported in Icelandic and Scottish
families.
Later linkage studies did not focus on candidate loci but used a whole genome
approach by genotyping evenly distributed markers along the whole genome in
affected families. A number of chromosomal loci have been implicated in the
risk of preeclampsia including 2p, 2q, 4p, 9q and 10q (summarized in
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(Nejatizadeh et aI., 2008). The chromosome 2p13 locus was first proposed by
Amgrimsson et al (1999) in Icelandic families; linkage was related mainly to 2
multicase families. When these families were excluded from the analysis
suggestive linkage appeared for a different locus on chromosome 2q23
(Amgrimsson et al., 1999). A subsequent genome-wide scan in families from
Australia and New Zealand confirmed the presence of a susceptibility region on
chromosome 2q22 located close to the loci identified in the former Icelandic
study (Moses et aI., 2000). Interestingly this chromosomal region was linked to
essential hypertension in a UK family study (Padmanabhan et al., 2006). A case
control study from Norway reported that an activin receptor gene is located in
this region and 4 SNPs within this gene were associated with preeclampsia
(Roten et aI., 2009). Although these findings were not replicated in another study
of Australian families (Fitzpatrick et aI., 2009), a role for the activin receptor
gene in preeclampsia can not be ruled out based on the potential biological
effects of the gene in regulating decidualization and placentation.
A susceptibility locus on chromosome 9p13 was revealed by a genome-wide
scan in 15 multiplex Finnish families (Laivuori et al., 2003). With respect to the
association of preeclampsia with diabetes and cardiovascular disease mentioned
earlier, it is of particular interest that the 9p13-p21 locus was shown to be a
candidate region for type 2 diabetesmellitus in studies from Finland (Lindgren et
aI., 2002) and China (Luo et al., 2001). Recent genome wide association studies
also demonstrated SNPs on chromosome 9p21 to be associated with T2D and
CAD as will be discussed in the next chapter, making this region interesting for
investigation. Harrison et al. (1997) found evidence of linkage to chromosome
4q. This region is close to the EGF gene region (Harrison et aI., 1997), an
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important regulator of trophoblast function and a candidate gene for FGR and
preeclampsia.
The overall impact of the linkage studies is limited in defining the disease risk
loci. Different study groups had their own inclusion and exclusion criteria, and
identified different genetic risk loci. Ethnic heterogeneity (the disease co-
segregates with different loci in different population) and phenotypic differences
may have contributed to the lack of reproducibility of results. Linkage studies
also have the inherent limitation of identifying only large chromosomal loci of
around 30-50 cM that require fine mapping to locate the exact susceptibility
region.
1.1.7.4 Candidate gene studies
Candidate gene association studies have been very widely used in the search for
genetic variants which predispose to complex disorders. They test the prior
hypothesis that biologically plausible genes or groups of genes in metabolic
pathways are associated with disease risk by comparing the frequency of genetic
markers, usually SNPs, in affected and unaffected individuals. The tested
markers are mapped to the candidate genes and may purposely target putative
functional SNPs. Compared to linkage studies association studies have more
precision in identifying susceptibility markers that are relatively common in the
population and confer a moderate to low risk of disease. Although this would
improve understanding of the pathophysiological process of the disease, this
approach is limited by the biological candidacy of the gene to previously
suspectedmechanisms.
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Case control studies are the most common method used for genetic association
studies. Cases and controls are easy to enrol compared to family-based studies so
that large samples can be collected. Statistical analysis in the case of a
dichotomous disease is easy to perform using Chi square testing and binary
logistic regression to calculate the OR. Well defined phenotypes of cases and
controls and adequate sample size are crucial to avoid spurious association.
Careful selection of markers/SNPs is required to detect true association.
1.1.7.4.1 Selection of cases and controls and phenotype definition
Currently, the preeclampsia syndrome is viewed as an early-onset placental form
(before 34 weeks of gestation), and a late-onset maternal form, mainly with
endothelial dysfunction (after 34 weeks of gestation) (Redman and Sargent,
2005). These forms might be divergent in genetic risk and inheritance (Duckitt
and Harrington, 2005). Late-onset, maternal preeclampsia arises from the
interaction between a normal placenta and a constitutionally predisposed mother
as occurs with pre-existing hypertension, diabetes or other states of metabolic
imbalance associated with endothelial dysfunction. In contrast, early-onset
placental preeclampsia starts with abnormal placentation, has a high recurrence
risk, runs in families with a clear genetic component and is often associatedwith
intrauterine growth restriction (Redman and Sargent, 2005). However recent
studies have noted that endothelial dysfunction might cause abnormal
placentation in early onset preeclampsia. This indicates that, although early and
late onset preeclampsia may have different presentation, they share fixed risk
factors, probably genetic in nature. This suggests that late onset-mild and early
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onset-severe preeclampsia are parts of a continuum, and can be treated as one
group for the purpose of genetic studies.
Any definition of preeclampsia will inevitably lead to the exclusion of some
affected subjects with atypical presentations, for example those who develop
gestational hypertension before developing proteinuria, women with chronic
hypertension, T2D, obese women or multiparous. These criteria may actually
select against those with the strongest genetic risk factors.
1.1.7.4.2 Selection of genetic markers for association study
Currently the most widely used markers for association studies are SNPs. This is
because they are widely distributed across the genome (around one SNP in every
100-300 base pair (bp) and they are technically easy to genotype.
Currently around 11 million SNPs of minor allele frequency (MAF) > 1% are
estimated to be present in the human genome. The selection of which SNPs to
test depends on many factors. Restricting analysis to SNPs with a MAF of~ 5%
would be reasonable, as most sample sizes are inadequately powered to detect
risk alleles with lower frequencies. Non synonymous SNPs, or SNPs mapped to
regulatory regions (5'and 3' untranslated regions (UTR), promoter regions, or
those in the putative splicing sites) are potentially functional and expected to be
deleterious or beneficial in term of disease risk (Newton-Cheh and Hirschhorn,
2005). Recently data generated by the International HapMap project and the
availability of high throughput low cost genotyping have facilitated
comprehensive coverage of a whole gene or group of genes. This is
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accomplished by selecting a group of tagging SNPs which provide a complete
coverage of variation within the gene (s) of interest based on the presence of
linkage disequilibrium (LD), (Gabriel et aI., 2002). A pairwise linkage
correlation coefficient (~) between two SNPs of 1 indicates that the markers are
perfectly correlated, and can act as proxies for one another. This occurs when
both markers are located within the same haplotype block, and greatly reduces
the number of SNPs which must be genotyped to capture the underlying genetic
variation.
As a result of LD, a genotyped marker which is associated with disease may be
either the causal allele (direct association), or be in LD with the causal allele
(indirect association). Association attributable to chance, selection bias, or other
confounding factors may also occur (Cordell and Clayton, 2005).
When testing more than one SNP it becomes possible to test for the haplotype
effect. Sometimes SNPs have small or no detectable effect on the disease risk
when tested individually. When tested in cis they may show an effect, or a larger
effect size, indicating either that there is an interaction between the tested SNPs
or sometimes that the haplotype is acting as a proxy for non genotyped causal
variants (Chapman et aI., 2003, Palmer and Cardon, 2005).
1.1.7.4.3 Limitations of candidate gene association studies
Though association studies are a popular approach in mapping genetic variants
for complex disease, they face the problem of lack of reproducibility.
Association studies of preeclampsia reflect the situation in other complex
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diseases. Goddard et al (2007) reported that of 127 polymorphisms in 61 genes
tested for association with preeclampsia, 17 polymorphisms were significantly
associated according to the authors of the studies. The association has been
replicated for only nine polymorphisms in two or more studies (Goddard et al.,
2007). The reason for this can be summarized into 3 major categories. Firstly a
false positive association is correctly not replicated; secondly a true association
fails to be replicated in an underpowered study, and lastly a true association in
one population is not present in another due to variation in genetic and/or
environmental background (Newton-Cheh and Hirschhorn, 2005).
Population stratification (admixture) is one reason for lack of replication.
Population stratification occurs when populations with different ethnic origins
and different rates of disease are mixed in a single study. If the genotyped
marker is more common in one of these populations, a spurious association will
result. So it is important in the design of any association study to match the
cases and control with regard to ethnic background. Most studies depend on self-
reported ethnic background (Freedman et al., 2004), but other strategies can be
applied to avoid the effects of population stratification. The use of family-based
association studies is one widely used solution. Transmission-disequilibrium
testing (TDT) is the most popular method. The TDT design requires trios
comprising an affected offspring and both parents. TDT depends on the biased
transmission of the disease causing allele from heterozygous parents to affected
offspring. The untransmitted allele acts as a control, so that any population-level
allele frequency differences become irrelevant (Schaid, 1998). The disadvantage
of TDT is the loss of statistical power because it relies on heterozygous parents
only, which occur at a maximum of 50% for any given biallelic marker. It is
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more laborious in terms of recruiting and genotyping trios, rather than individual
cases and controls. It is also more sensitive to genotyping errors and missing
data. Genome-based methods to correct for population stratification by
genotyping random unlinked markers are also available. If true population
stratification is present a disease-marker association test can be done in each
matched subgroup; the total test for disease association is then a statistical
combination of results from each component subgroup (Freedman et aI., 2004).
Inadequate sample size has a major impact on the ability to detect true
association and on successful replication of association reported in previous
studies. The threshold P value at which investigators report association is
critical, especially when testing multiple markers and many phenotypes, when
correction for multiple testing should be carried out (Newton-Cheh and
Hirschhorn, 2005). A sample of several hundreds to several thousands
(depending on the MAF) is needed to achieve a false positive rate of < 0.05. It is
recommended that the power of the study should always be reported, and that the
magnitude of the genetic effect which can be excluded is reported as the 95%
confidence interval around the OR (Ioannidis et aI., 2001). Genotyping errors,
missing data, genotyping cases and control separately with variation in genotype
call rate sometimes results in spurious association.
Additional factors which affect any genetic study include population and genetic
heterogeneity, reduced penetrance, and phenocopies. Population heterogeneity is
a condition in which the causative genetic variants are different among
populations of different genetic and environmental backgrounds. Genetic
heterogeneity refers to the condition in which different genetic variants lead to
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the same phenotype. It includes locus heterogeneity, when various different
genes lead to the same phenotypic expression and allelic heterogeneity, when
more than one allele in a given gene is causative. Efforts to reduce genetic
heterogeneity by using stringent definitions of phenotype or by testing subtypes
of a disease can be considered. Reduced penetrance refers to the situation in
which individuals carry the causative genetic variant without expressing the
phenotype, and is the norm in genetically complex disorders. Conversely, a
phenocopy is the situation in which an individual expresses the disease in the
absence of any predisposing genotype. In complex disorders, reduced penetrance
and phenocopies are frequently encountered, which may lead to misclassification
of cases and controls, weakening the power of the study.
More than 60 genes have been studied in relation to preeclampsia. Candidate
genes were chosen based on the pathways known to be involved in the
pathophysiology of preeclampsia. They include genes related to vasoactive
proteins/vascular remodelling, thrombophilia and hypofibrinolysis, oxidative
stress, lipid metabolism, endothelial injury, placentation/imprinting and growth
factors. Figure 1-3 highlights some of these genes (Mutze et al., 2008). There is
lack of replication in most of the studies due to the aforementioned factors and.
no single gene has been unequivocally established as a susceptibility gene for
preeclampsia (Chappell and Morgan, 2006).
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Figure 1-3: Some of the candidate gene studied in preeclampsia
Endothelial
dysfunction
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ILI,ILlO
Abnormal vascular
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angiogenesis, cg AGT,
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Genomic imprinting,
STOXI
Oxidative stress, cg NOS,
SOO,GST
Lipid metabolism disorder,
eg LPL,ApoE
Two impressively large association studies in preeclampsia are worth noting
because both of them addressed many of the potential limitations mentioned
earlier, and they reflect the current situation of the genetics of preeclampsia. In
addition, both of these studies investigated the role of maternal and fetal genes
on the risk of preeclampsia. The first was carried out in the UK as a British
multicentre candidate gene study, by the GOPEe consortium. In this study 28
SNPs in 7 genes (angiotensinogen, (AGT), angiotensin receptor type 1 (AGTRl)
and 2 (AGTR2), TNF-a, endothelial nitric oxide synthase (NOS3), factor- V
Leiden, and methylene tetrahydrofolate reductase (MTHFR)), commonly
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reported to confer susceptibility for preeclampsia, were investigated. TDT was
applied to 398 preeclampsia maternal (mother and her parents), and 536 fetal
(preeclampsia mother, her partner and the offspring) trios. Besides avoiding
population stratification by using TDT test, the study also applied a stringent
level of significance by testing the association in the context of prior probability
of gene candidacy and reported an 85% power to detect modest genetic risk. Of
the 28 SNPs that had been investigated only 2 markers in AGTR2 (fetal and
maternal) one marker in AGT and TNF-a for fetal genes showed a marginal
protective effect (genotype relative risk range from 0.48-1.0), excluding a major
risk conferred by these genes (The GOPEC Consortium, 2005).
The second study was conducted by Goddard et al (2007) who investigated 775
SNPs in 190 candidate genes in 394 preeclamptic women and their 342 offspring
in comparison to 602 healthy pregnant control women and their 631 offspring.
Again the common candidate genes MTHFR and NOS3 were not significantly
associated with preeclampsia. Maternal collagen type I alpha 1 (COLlAl) and
interleukin Ialpha (ILl A) genotype, fetal plasminogen activator, and urokinase
receptor genotype, and fetal and maternal insulin like growth factor 1 (IGFl) and
interleukin 4 receptor (IL4R) gave promising results. The study had some
limitations; including the sample size in relation to the number of SNPs
investigated which is reflected in the lack of significance for all variants after
correcting for multiple testing. They also used whole genome amplified DNA
rather than genomic DNA with the possibility of sequence errors. The authors
reported the study had 80% power to detect a genotype relative risk of between
1.6and 1.8, so smaller effects might remain undetected (Goddard et aI., 2007).
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1.1.7.4.4 Awaited genome wide association studies (GWAS)
The completion of the Human Genome Project and of the International HapMap
project has increased knowledge of the structure of the genome. Massive
advances in high throughput genotyping technology have enabled the genotyping
of up to 1 million genetic variations, (mainly SNPs) in a single experiment using
SNP chips. The advances have made GWAS possible. OWAS is an unbiased
approach with the potential to detect new causative variants and shed light on
novel biological mechanisms that may help in understanding and managing the
disease under investigation. For such studies to achieve statistical power
thousands of cases and controls are required and replication of significant results
in an independent sample set is essential. The first OWAS for preeclampsia is
underway now, as a part of the Wellcome Trust Case Control Consortium 3
(WTCCC3).
1.2 Fetal growth restriction
Fetal growth restriction (FOR) is a condition in which a fetus fails to achieve its
full growth potential due to reduced tissue deposition and/or reduced nutritional
supply from the utero-placental circulation (Cetin et al., 2004). FOR is a
complex disorder affecting up to 10% of neonates.
Normal fetal growth passes through different stages. The early stage involves the
proliferation, organization, and differentiation of the embryo (embryonic life).
The later stage comprises continuous growth and functional maturation of the
different tissues and organs of the fetus (fetal life). The acquisition of fetal
weight progressively increases with advancement of gestation from 5 g/day
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during the 1st trimester and reaches around 30-35 g/day at 34 weeks. Therefore,
most fetal weight gain occurs in the last 20 weeks of gestation (Monk and
Moore,2004).
By mid-gestation two significant events have occurred: establishment of the
fetomaternal circulation, and secretion of measurable quantities of insulin by the
fetal pancreas. This ensures patent maternal supply lines to, and resource
utilization by, the growing fetus. Glucose is the principle source of energy for the
fetus. Its constant availability and supply by the mother, placental transport by
specialized adaptive mechanisms, along with fetal insulin secretion facilitate
glucose utilisation by the fetus (Hay, 2006).
Securing adequate nutrient and oxygen supply to the developing fetus depends
on the genetic profile of the embryo (maternal and paternal genes), the maternal-
placental-fetal unit, and environmental factors (hormones, nutrition, infection,
smoking) in the maternal milieu (Murphy et al., 2006).
1.2.1 Definition of FGR
Classification of birth weight has been based on population growth curves after
correcting for gestational age. Babies were classified according to their birth
weight centile (BWC) into 3 categories: infants with birth weights<10th centile,
called small for gestational age (SGA); infants with birth weights between 10th
and 90th centile, called appropriate for gestational age (AGA); and infants with
birth weights >90th centile, called large for gestational age (LGA) (Reeves and
Bernstein, 2008b).
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The problem with this classification is that a subset of SGA and LGA babies are
simply constitutionally small or large due to, for example, a small or large sized
mother, or representing the tail of the normal distribution. On the other hand
some babies with a BWC > 10 manifest some features of growth restriction,
because the definition of SGA does not address true intrauterine growth but
rather size at birth (Gardosi, 2004). So, SGA is an inadequate proxy for fetal
growth restriction (FGR). The most commonly used definition of FGR is a
sonographically estimated fetal weight (EFW) that falls below the 10th centile for
gestational age (American College of Obstetricians and Gynecologists. 2000).
Ideally, SGA definitions based on population derived birth weight curves would
utilize data from healthy pregnancies only (Reeves and Bernstein, 2008b,
Goldenberg and Cliver, 1997). Birth weight curves adjusted for gestational age
alone ignore some of the biological factors that might affect fetal or birth weight
variations, including fetal sex (girls are lighter than boys), ethnicity (European
are heavier than East Asian populations), parity (which is positively correlated
with birth weight), and maternal height and weight. These factors were
incorporated into customized antenatal charts (Gabriel et al., 2002). With the use
of the customized charts, 28% and 22% of SGA and LGA babies from
conventional charts were recategorised as AGA.
Important criteria are required for reliable estimation of the fetal weight centile,
including: 1. an accurate gestational age estimation, using ultrasonic
measurement of the crown rump length in the first trimester pregnancy, the head
circumference in second trimester, or the date of the last menstrual period; and 2.
an estimated fetal weight using at least 3 variables: biparietal diameter,
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abdominal circumference and femur length. A weight percentile can then be
calculated from the estimated weight and gestational age using available curves
(Platz and Newman, 2008).
The estimation of fetal weight centile has some limitations. Ultrasonic
measurements are technically difficult and subject to inaccuracy due to inter and
intra observer variability. Population data derived from a large number of
pregnancies are essential for reliable estimates of fetal weight centile. Around
25% error between the actual and predicted weights can occur, particularly in the
estimation of macrosomia or FOR, most probably due to limitations in
estimating soft tissue mass. Incorporation of other indices like amniotic fluid
volumes and umbilical artery Doppler velocimetry has been shown to improve
the diagnosis of FOR (Platz and Newman, 2008, Gardosi, 2004).
Gardosi et al (1995) incorporated the factors shown to affect variation in birth
weight (gestational age, fetal sex, ethnicity, maternal weight, height, and parity)
into a computer software package from which the expected term birth weight can
be calculated as the customised birth weight centile or term optimal weight
(TOW). To further adjust for intrauterine growth, estimated fetal weight based
on ultrasonic measurement between 24 and 42 weeks of gestation expressed as
proportion of the term birth weight was incorporated in this software, termed
gestation related optimal weight (OROW). From this software the birth weight
can give insight into fetal growth (Gardosi et al., 1995). These customized curves
are more accurate in predicting the neonatal outcome, low Apgar score, neonatal
intensive care admission and neonatal death (Gardosi, 2004, Gardosi et aI.,
2009). When applied retrospectively to mothers who had induction of labour due
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to FOR based on population curves, the customized curves suggested that 60%
of these pregnancies were free of FOR (Avery et al., 2006). They were also more
successful in identifying SOA babies who were truly growth restricted and more
prone to later metabolic disturbances (Verkauskiene et al., 2008). The
customized curves are valuable in identifying growth restriction in preterm
babies, who form a large proportion of the SOA babies (Ananth and Vintzileos,
2009). It cannot be applied to twin pregnancies.
It is clear that not all FOR babies are SOA and vice versa. Nevertheless, SOA is
still used as a surrogate for FOR especially in the research environment. Some
variation exists in the cut-off values at which the diagnosis of FOR is made. This
ranges between <3rd up to 15th centile. The use of the 3rd centile was associated
with a higher OR for adverse neonatal outcomes (lOO-fold increase), but it also
missed many FOR cases. On the other hand, although a large proportion of the
<10th centile group turn to be constitutionally small, the use of this cut off
threshold can still detect up to a 30-fold increase in adverse neonatal outcomes
and was found to be highly correlated with still birth related to SGA (Platz and
Newman, 2008).
1.2.2 Implication of FGR
FOR complicates up to 10% of all pregnancies. It is therefore a common
obstetrical condition, but hard to manage due to its high rate of complications
,
and adverse consequences. A history of SGA in a previous pregnancy was found
to increase the risk of SGA in a subsequent pregnancy (OR 2.5; 95% Cll.7-3.3);
the risk was greater when combined with smoking and low maternal BMI
(Bakketeig et al., 1993). FOR complicates about 30% of preeclamptic
64
pregnancies and is regarded by some as a sign of severe preeclampsia. It also
represents an increased risk for preeclampsia in a subsequent pregnancy (Lie et
al., 1998).
The complications of FGR are either immediate in the perinatal period or occur
later In adult life. Immediate complications include hypothermia,
hypoglycaemia, pulmonary haemorrhage, encephalopathy, necrotizing
enterocolitis, and retinopathy, (McIntire et al., 1999, Benedict et al., 2001).
Neonatal mortality is high in the SGA babies especially in those who are
preterm, who have a 33% mortality compared to 17% in AGA preterm babies
(Giapros et al., 2011).
A large body of epidemiological data has accumulated suggesting that being
small sized at birth is associated with a substantial risk of developing adult
diabetes, hypertension, and coronary heart disease especially when combined
with catch-up growth during childhood (Barker et al., 1989a, Barker et al., 2002,
Osmond and Barker, 2000).
A study including around 15000 subjects born from 1911 to 1930 in
Hertfordshire, UK, showed that death rates from CAD increase in relation to low
birth weight and are also independently affected by lower weight estimates at the
age of 1 year (Barker et al., 1989b). These data have been confirmed in different
populations including the Finnish population, using the Helsinki birth cohort
study of nearly the same sample size as the Hertfordshire study (Eriksson, 2007)
and a study including 70000 women from the US (Rich-Edwards et al., 1997).A
combination of low birth weight and high BM! at the age of 19 was associated
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with an increased risk of CAD in Danish subjects after adjustment for social and
educational class (Osler et aI., 2009).
Barker et al (1993) showed that individuals with low birth weight have a 10-fold
increased risk of developing metabolic syndrome at the age of 64 compared to
those who have a higher birth weight, and that this was independent of
prematurity or smoking habits (Barker et aI., 1993). T2D was also associated
with low birth weight in the Hertfordshire collection. The OR was 1.3 with low
birth weight and low BMI and increased to 2.5 when the BMI was higher at the
age of 11 years (Barker, 2002). This was replicated in Swedish (Lithell et aI.,
1996) and Taiwanese populations (Wei et aI., 2003). Thinness at birth was also
associated with insulin resistance (Jensen et aI., 2002), and markers of
endothelial dysfunction (Pellanda et aI., 2009). Moreover parents of SOA infant
are at increased risk of T2D and insulin resistance (Lindsay et aI., 2000, Lawlor
et aI.,2002).
1.2.3 Aetiologyand risk factors for FGR
It has long been appreciated that FOR is not a single disorder, but instead has
various causes. A list of factors associated with increased risk for FOR is
presented in Table 1-2 (reviewed in (Hendrix and Berghella, 2008, Murphyet
aI.,2006».
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Table 1·2: Fetal and maternal risk factors for FGR pregnancy
{adapted from (Hendrix and Berghella, 2008).
Fetal
• Genetic diseases(5% to 20%) (chromosomal abnormalities, single gene defect, and
polygenic disorders)
• Infection (5% to 10%) (toxoplasmosis in developed and malaria in developing
countries)
• Malformations (1%to 2%)
• Multiple gestation (3%)
• Placental/cord abnormalities (3%) (abruption, mosaicism, 2 vessel cord, placenta
praevia, abnormal umbilical artery insertion, etc.)
Maternal
• Hypertensive disorders (20% to 30%)
• Pregestational diabetes
• Autoimmune disease (systemic lupus erythematosus)
• Cardiac disease (eg, complex cyanotic congenital heart diseases)
• Toxin exposure (smoking, alcohol, cocaine)
• Malnutrition
• Living at high altitudes
• Living in developing country
• Low socio-economic status
• Race (eg, African-American)
• Family or prior history ofFGR
• Extremes of maternal age
• Infertility/assisted reproduction technology
• Short inter-pregnancy interval
Genetic factors, notably chromosomal aberrations like trisomy 21 (Downs
syndrome), trisomy 13, and trisomy 18 are known to exhibit FGR mainly due to
abnormal development of the placental vessels. Deletion of part of a
chromosome can also lead to FGR as is the case with chromosome 4q known as
Wolf-Hirschhorn syndrome. Confined placental mosaicism and uniparental
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disomy (e.g. UDP7) can also lead to FGR (reviewed in «Hendrix and Berghella,
2008).
Toxoplasmosis and cytomegalovirus in developed countries and malaria in
developing countries are maternally transmitted infections that affect growth and
development of the fetus by affecting the vascular system and by causing
congenital malformations. It has recently been suggested that H. pylori infection
in pregnant women may affect fetal intrauterine growth (Eslick et al., 2002).
Preeclampsia is a major risk factor for FGR, as around 30% of preeclampsia is
associated with FGR. Both conditions have shared pathology in the form of
impaired trophoblast invasion and apoptosis and limited villous development.
Underlying maternal medical conditions which lead to reduced oxygen carrying
capacity (anaemia, high altitude) or affect the maternal vascular system (sickle
cell anaemia, systemic lupus erythematosis, anti-phospholipid syndrome, and
thrombophilias) are also associated with FGR pregnancies (Chakravarty et al.,
2008).
Maternal diabetes, hyperglycaemia, or insulin resistance have long been known
to affect birth weight in the direction of macrosomia, resulting in LGA babies
(Ong et al., 2008). This is due to increased fetoplacental availability of nutrients
in late gestation due to maternal hyperglycaemia (Hay, 2006). Diabetes also is
reported to cause SGA especially if it is long-standing diabetes associated with
vascular injury (Haeri et al., 2008, Howarth et al., 2007). AU-shaped
relationship between maternal diabetes and birth weight was described. In fact
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both SOA and LOA in diabetic pregnancy are subject to adverse fetal and long
lasting outcomes.
Low maternal BMI (BMI <20) is associated with an increased risk of having a
low birth weight baby, whilst maternal BMI > 25 is associated with high birth
weight (Baeten et al., 2001, Bhattacharya et al., 2007).
Smoking is a major (avoidable) risk factor for FOR. Mothers who smoke 4-5
cigarettes per day have a 2-3 fold increased risk for SOA, with a reduction of
150-300g in birth weight (Wang et al., 2002, Aagaard-Tillery et al., 2008,
Dejmek et al., 2002). Smoking increases carbon monoxide, reduces NO and
causes vasoconstriction, limiting the oxygen supply to the fetus (Reeves and
Bernstein, 2008a). It is also suggested that smoking reduces mitochondrial
respiratory function in the placenta and consequently reduces energy availability
(Bouhours-Nouet et al., 2005). Smoking is associated with a reduced risk for
preeclampsia (England et al., 2002, Mortensen et al., 200I, Broughton-Pipkin,
2008) although smoking causes endothelial dysfunction.
1.2.4 The role of the placenta in FGR
The main determinants of fetal growth can be categorized into 3 major
components: fetal, placental, and maternal. These factors control the genetic
profile of the embryo, proper placentation, the integrity of the materno-placento-
fetal unit, adequate nutrient and oxygen supply to the developing fetus, and the
hormonal milieu. These factors typically interact with each other to optimize the
outcome for the baby and the mother.
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Shallow trophoblast invasion and abnormal spiral artery remodelling, increased
apoptosis of the villous trophoblast, and reduced vascular development, are
shared pathological features between preeclampsia and FGR as described earlier
(Section 1.1.4). A state of hypoxia develops secondary to impaired development
of the placenta.
However specific changes in placental transport properties are described in the
FOR placenta. Hypoglycaemia and reduced essential amino acid concentrations
were reported in SOA babies. In vitro studies using isolated microvillous
membrane suggested that FGR is associated with a number of changes in the
activity and/or expression of placental nutrient and ion transporters. For example
Cetin et al (2002) reported that system A (for essential amino acids, (AA» and
system L (for arginine amino acid) transporters were reduced in placenta from
FGR fetuses, whilst they maintain glucose transporters. Transfer of
polyunsaturated fatty acids from the maternal circulation across the placenta was
found to be disturbed in FGR as reflected by lower fetal/maternal ratio for these
fatty acids in FGR compared to control babies during the second half of
pregnancy (Cetin et al., 2002). Modifying the placental delivery of fatty acids to
the fetus in a crucial period when fat deposition increases exponentially and is
required for neural development may explain neural defects in FGR babies
(Cetin et aI., 2002).
The placenta also has an important endocrine function. It is responsible for the
release of many hormones including estrogens, progesterone, human placental
lactogen (hPL) and human growth hormone splice variants (hGHV). These
hormones create a state of insulin resistance in the mother and ensure adequate
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glucose and amino acid supply to the growing fetus. The level of hPL in the
mother was found to be correlated with fetal growth velocity (Sorensen et al.,
2000). Lower maternal levels of hPL were reported with FGR (Bersinger and
Odegard, 2004).
1.2.5 Genetics of FGR
The influence of genes on birth weight is reflected in lower birth weight in
relation to female sex. The heritability of birth weight has been estimated as
between 30% and 90%. In a study of mother-father-baby trios from Norway.
maternal and paternal birth weight were independent predictors of offspring birth
weight, with the coefficient of correlation between baby's birth weight and
maternal and paternal birth weight calculated as 0.22 and 0.13 respectively. The
heritability estimate was 25% in this study (Magnus et al., 2001). The effect of
maternal and paternal weight on birth weight was replicated in a UK population
(Griffiths et al., 2007). Higher effects of maternal birth weight on the offspring
birth weight may be explained by both genetic effects and the intrauterine
environment.
In a more recent study a high heritability estimate for birth weight (92%) was
reported in a Hispanic population, adjusted for gender, gestational age, birth
order, and a number of maternal factors including age or gestational diabetes
(Cai et al., 2007). It should be noted that heritability estimates are population-
specific, and can be influenced by such factors as the environment, study
population, ascertainment criteria and the covariates considered in the analysis.
A high degree of heritability can be achieved by adjusting for covariates that
explain some of the environmental factors in the analysis.
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It is not only the variation in normal birth weight which is thought to be heritable
but also the condition of low birth weight or SGA. It has been shown that the
infant birth weight pattern tends to be repeated in subsequent pregnancies (Fabio
Ghezzi, 2003, Magnus et al., 1997). In a study which included 3,505 French sibs
from term singleton pregnancies, La Batide-Alanore et a1. (2002) reported sib-sib
odds ratios for SGA to be 4.8 (95% Cl: 3.7, 6.3). The findings were significant
when SGA was defined as <10th centile as well as <5th centile corrected for
gestational age and baby's sex (La Batide-Alanore et al., 2002). This was also
reported in a recent study in the US which showed that the risk of being SGA is
25% when the older sibling was SGA compared to only 6% when the older
sibling was AGA (Ananth et al., 2009). This familial aggregation of SGA
indicated a genetic element as it remained after adjustment for maternal and
environmental factors.
Moreover, women who were themselves FGR are more likely to deliver an FGR
baby (Leff et aI., 1992, Winkvist et al., 1998). A paternal history of being SGA
was associated with doubling of the risk of fathering a SGA baby (Magnus et al.,
1997).
1.2.6 Genetic studies of FGR
It has been assumed that the genetic effects on birth weight are complex in
nature with many independently loci acting on the phenotype in an additive
fashion that can be modified by environmental factors (Lunde et al., 2007).
Several studies have been performed to examine the association between genetic
variants in biologically plausible candidate genes and FGR.
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1.2.6.1 Fetal programming and diabetes genes
Two theories have been described to explain the relation between low birth
weight and adult disease. The first was the fetal programming or Barker
hypothesis proposed two decades ago. Fetal programming postulates that a
malnourished fetus due to an adverse intrauterine environment is programmed to
exhibit a thrifty phenotype with increased food intake and fat deposition. This is
to ensure survival of the fetus in the short term, for the duration of pregnancy.
But when the situation changes after birth and the newborn is provided with
abundant nutrients, such individuals develop obesity and T2D as adults (Barker,
1995, Barker, 2002, Barker et aI., 2002). This is consistent with the observation
that these disorders are mainly manifested in low birth weight individuals who
experienced catch up growth in early childhood, not in those children who
remained lean. Excess glucocorticoids described in low birth weight babies have
also been implicated in later organ and system dysfunction. Excess
glucocorticoids lead to reduced beta cell mass in the pancreas and reduced
insulin secretion, increased hepatic glucose production, reduced hepatic glucose
uptake, increase lipolysis and increased insulin resistance of the skeletal muscles,
ultimately leading to glucose intolerance and T2D (Ross and Beall, 2008).
Animal studies indicated that epigenetic changes in the form of DNA
methylation or histone modification which alter gene expression without changes
in DNA sequence might explain fetal programming. For example in a rat model
of FGR, methylation of pancreatic duodenal homeobox-l promoter was
associated with reduced insulin secretion (Park et aI., 2008).
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In parallel with fetal programming, the fetal insulin hypothesis has been
advanced to explain the mutual association between T2D and low birth weight.
The fetal insulin hypothesis, or thrifty genotype, suggests that the same genes
which are responsible for low birth weight due to low insulin secretion and/or
insulin sensitivity lead to T2D later in life (Frayling and Hattersley, 2001). The
association between T2D in parents and the birth weight of their offspring gave
strong evidence for the role of diabetogenic genes in controlling birth weight.
Lindsay et al (2000) reported an association between paternal diabetes and low
birth weight; low birth weight in offspring conferred a 1.8-fold increased risk on
the father of developing diabetes later in life (95% Cl 1.2-2.7) (Lindsay et al.,
2000).
It is widely recognised that diabetic mothers commonly give birth to LOA
babies. However, the role of maternal diabetes susceptibility genes on the
offspring birth weight was suggested by two studies which showed that low birth
babies were born to mothers who were not diabetic at the time of pregnancy but
became diabetic or insulin resistant later in life (Hypponen et al., 2003, Lawlor et
al., 2002). These findings lend support to the fetal insulin hypothesis or thrifty
genotype, and are consistent with the fetus inheriting 50% ofhisl her genes from
the father and 50% from the mother which both predispose to diabetes and
reduced fetal growth (Figure 1-4).
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Figure 1-4: The effect of maternal and paternal diabetes genes on birth
weight
Fetal and maternal genes are interacting in relation to offspring birth weight, the fetal
programming and fetal insulin hypotheses are not mutually exclusive.
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A rare mutation in the fetal glucokinase gene (GCK), a diabetes susceptibility
gene, was associated with a 533 g reduction in birth weight and mild post natal
hyperglycemia. The effect of maternal genotype was in the opposite direction
with a 601 g increase in the offspring birth weight. When both mother and fetus
carried the mutation the effect on birth weight was nil (Hattersley et aI., 1998).
These mutations could cause impaired fetal insulin secretion, hence their
contributions to impaired fetal growth and to subsequent diabetes, whilst
maternal effects were mainly caused by the intrauterine environment associated
with hyperglycemia. Weedon et al (2005) extended the investigation into
common mutations of the GCK gene and reported that the maternal A allele of
SNP rs 1799884 was associated with a 64 g increase in birth weight. No effect of
fetal genotype was observed in this study, which included more than 2000
mother child pairs (Weedon et aI., 2005).
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Maternal T2D risk genotypes at rs7903146 of the transcription factor 7 like 2
(TCF7L2) were associated with increased offspring birth weight (Freathy et aI.,
2007). Fetal genotypes at T2D risk alleles of TCF7L2 (Mook-Kanamori et aI.,
2009, Freathy et aI., 2007, Cauchi et aI., 2007b), peroxisome proliferator-
activated receptor gamma (PPAR-'Y)and potassium inwardly-rectifying channel,
subfamily J, member 11 (KCNJ1I) genes (Bennett et aI., 2008) were not
associated with birth weight. A recent study indicated that fetal genotype at
CDK5 regulatory subunit associated protein I-like 1 (CDKALl) and homeobox,
hematopoietically expressed/insulin degrading enzyme (HHEX-IDE) was
associated with reduced birth weight, and that carriers of 4 risk alleles were 80 g
lighter compared to non-carriers, an effect that was slightly modified by maternal
genotype (Freathy et aI., 2009). This latter study gives genetic evidence for the
fetal insulin hypothesis at the genetic level which supports the epidemiological
data.
In a recent OWAS study including 10,000 individuals, 2 SNPs on fetal
chromosome 3 were associated with a 112 g reduction in birth weight, equivalent
to the effect of maternal smoking of 4 cigarettes a day. One of the SNPs,
rs9883204, was close to the adenylate cyclase 5 (ADCY5) gene. The birth
weight lowering C allele of this SNP was in (LD) with allele A of SNP
rsII708067 (r = 0.75), which is associated with a higher risk ofT2D and known
to alter insulin secretion, further supportive evidence for the fetal insulin
hypothesis (Freathy et aI., 2010).
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1.2.6.2 Genomic imprinting defects and FGR
Certain genes are subject to parent of origin specific silencing in which paternal
or maternal alleles have reduced or absent expression (Beechey, 2004). This
silencing takes place through epigenetic mechanisms, resulting in differential
levels of transcription with gene expression predominantly from one parental
allele.
The placenta is a major site for genomic imprinting. It has been hypothesised
that in the placenta maternal and paternal genes show a conflict of interest.
Paternal genes are designed to maximize the nutrient supply for the fetus, whilst
maternal genes have evolved to limit fetal growth firstly to prevent macrosomia
and birth related injury and secondly to maintain resources for subsequent
pregnancies. Consequently, imprinted genes are expected to play a significant
role in fetal growth (Reik et al., 2003).
At chromosome 11p15 is a cluster of genes that are subject to imprinting under
an imprinting control region (ICR) located downstream of insulin-like growth
factor II (lGF-1I) and upstream of H19 genes. IGF-II is growth promoting and
expressed exclusively from the unmethylated paternal allele, whilst H19 is
growth limiting and expressed exclusively from the unmethylated maternal
allele. Loss of methylation of the paternal allele of the ICR was reported in 60%
of cases of Silver-Russell syndrome, an extreme syndrome of intrauterine growth
retardation and dysmorphic features (Netchine et al., 2007). Gain of methylation
of the maternal copy of ICR was associated with another syndrome called
Beckwith-Wiedemann syndrome, a syndrome characterized by pre- and post-
natal overgrowth. The placenta from FGR pregnancies was found to exhibit
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reduced methylation of this chromosomal region compared to the AGA placenta
(Bourque et al., 2010). IGF-II knockout in mouse models leads to FOR and
small sized placenta (Sibley et al., 2004). However, IOF-II expression at the
level of mRNA in FOR placenta showed contradictory results. Lee et al (2010)
reported higher levels of rGF-I! mRNA in FGR placenta whilst Guo et al (2008)
reported lower levels (Guo et al., 2008, Lee et al., 2010).
1.2.6.3 Other candidate gene studies
Multiple genetic pathways known to regulate placentation or related to a risk
.factor for FGR have been investigated. Genes for growth factors, cytokines,
MMPs, thombophilia, and the renin-angiotensin system, represent the bulk of
genetic studies in FGR. The lack of reproducibility of these studies is typical of
candidate gene studies of complex disorders. In addition, none of the studies was
large enough to test for fetal and maternal gene interaction.
It is beyond the scope of this thesis to review these studies, but studies involving
EGF will be considered in more detail, as it is one of the candidate genes to be
investigated in chapter 3. EGF is a potential candidate gene for FGR and pre-
eclampsia. It is located near to a region on chromosome 4 which has been linked
to preeclampsia (Harrison et al., 1997) and birth weight (Arya et al., 2006). EGF
regulates many aspects of trophoblast function (Maruo et al., 1992). Dissanayake
et al (2007) tested 2 SNPs, (c.2566 G>A and c.61 A>G) in EGF in relation to
FGR (Dissanayake et al., 2007). These two SNPs are located in exon 14 and the
5' untranslated region of EGF gene (Shahbazi et al., 2002). The maternal G allele
of c.61 A>G and the A allele of c.2566 G>A were associated with lower birth
weight in healthy babies. Furthermore, the haplotype formed by these risk alleles
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was transmitted more frequently from heterozygous parents to FGR offspring.
These findings were evident in both Caucasian and Sinhalese women. The EOF
gene and polymorphisms and their role in pregnancy will be discussed in chapter
3.
1.3 Summary and hypothesis
Failure of placental development and/or maternal adaptation to pregnancy due to
genetic or environmental factors leads to both maternal and fetal complications
including preeclampsia and fetal growth restriction, complicating up to 10% of
pregnancies.
There is substantial evidence for bidirectional increased risk between T20 and
preeclampsia. Both are regarded as genetically complex disorders and share
many pathophysiological changes in terms of insulin resistance, dyslipidaemia,
and endothelial dysfunction. Low birth weight is widely accepted to be
associated with later development of T20. It is therefore tempting to speculate
that some predisposing genetic factors are shared by these conditions. Over the
last decade, investigators have focused on the effect of T20 genes on the
variability of birth weight. Very limited and underpowered studies have
investigated T20 susceptibility genes as a genetic risk factor for preeclampsia
and FOR. In view of the discovery of an increasing number of T20 susceptibility
loci, the current study will focus on the role of some of these T20 susceptibility
loci in preeclampsia and FOR in a case control genetic study (Chapter 2).
Both preeclampsia and FOR share the same placental pathological features
leading to placental ischemia, including abnormal spiral artery remodelling, and
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shallow trophoblast invasion. EGF is a biologically important growth factor
acting locally on the placenta and regulating many aspects of trophoblast
functions. Genetic polymorphisms of the EGF gene especially putatively
functional variants that can determine EGF expression may represent a genetic
risk factor for preeclampsia and fetal growth restriction. The focus of this study
is to investigate 2 putatively functional SNPs (rs4444903, and rs2237051) in the
EGF gene on the risk of preeclampsia and fetal growth restriction and to describe
the molecular genetic aspects of rs4444903 and rs2237051 SNPs on EGF
translation, transcription and splicing (Chapter 3).
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2 Type 2 diabetes susceptibility genes and the risk of
preeclampsia and fetal growth restriction
2.1 Introduction
Type 2 diabetes (T2D) is a metabolic disorder characterized by pancreatic beta
cell dysfunction and insulin resistance (Stumvoll et aI., 2005). It is estimated to
have affected 2.8% of the population worldwide in 2000 and is expected to affect
4.4% (366 million people), by the year 2030 (Cooper-DeHoff, 2007). This is
associated with considerable morbidity, mortality, and health-care expenditure.
The higher concordance of T2D in monozygotic twins than in dizygotic twins
(70% vs 30%), the higher risk of T2D in a first-degree relative of a patient with
T2D (3-fold compared to the general population) and clustering of the disease in
families indicated the clear genetic basis for developing T2D. Despite the clear
genetic basis ofT2D, early genetic linkage and candidate gene analysis validated
only a limited number of genetic variants as T2D risk variants. Two of these
susceptibility genes (PPAR, and KCNJ 11) were already targets for drug
treatment of T2D (Table 2-1). In the past three years, GWAS for human T2D
from several European populations have confirmed 25 loci to be associated with
T2D (Bonnefond et aI., 2010).
In the previous section it has been shown that a bidirectional increased risk
between T2D and preeclampsia is commonly reported. These two disorders also
share the same pathophysiological changes: hyperinsulinaemia, insulin
resistance, dyslipidaemia and endothelial dysfunction. Both preeclampsia and
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T2D are known risk factors for CAD. Together these observations suggest that
preeclampsia and T2D may share the same genetic risk factors.
For the purpose of this study 5 of the most extensively replicated T2D
susceptibility genes were selected to test the hypothesis of a shared genetic basis
between T2D and preeclampsia and fetal growth restriction. Table 2-1 presents
the genetic approach which identified the T2D susceptibility variants, the
suggested mechanisms, and the drugs which target the genes selected. More
details about each gene and the variants within each gene to be investigated are
provided in the following sections.
Table 2·1: T2D genes included in the present study
transcription factor 7 like 2 (TCF7L2), fat mass and obesity associated gene (FTO),
peroxisome proliferator-activated receptor gamma (PPAR-y), Antisense Non-coding
RNA in the INK4 Locus (CDKN2B-AS1), potassium inwardly-rectifying channel,
subfamily J, member 11 (KCNJ11)
Gene
Genetic
approach
Role in T2D Drug target
TCF7L2
Exploration
of linkage
peaks
Decreased b-cell function, decreased
incretin stimulated insulin secretion,
decreased glucose stimulated insulin
secretion
Candidate Decreased b-cell function, decreased
glucose-stimulated insulin secretion
Sulfonylurea drugsKCNJ11
gene
Candidate
Decreased insulin sensitivity ThiazolidinedionesPPARG
gene
FTO GWAS
Increased risk of obesity, increased
body mass index, decreased insulin
sensitivity.
CDKN2B-
AS1
GWAS
Decreased b-cell function, decreased
glucose-stimulated insulin secretion
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2.2 Candidate genes
2.2.1 Transcription factor 7 -like 2 (TCF7L2)
2.2.2 Introduction
Transcription factor 7 - like 2 (TCF7L2) is a transcription factor that belongs to a
family of TCF/LEF (T cell-specific factors/ lymphoid enhancer-binding factor)
transcription factors. TCF7L2 (also known as TCF-4) interacts with beta (b)-
catenin and regulates the WNT (wingless) pathway (Jin and Liu, 2008).
Consequently it is involved in growth and differentiation from embryonic life to
cancer pathology.
In the absence of WNT ligands, TCF7L2 which is localized mainly in the
nucleus acts as a repressor for WNT target genes by recruiting other repressors
like Groucho and C terminal binding protein-l(C-TBP-l) to the promoter
regions of these genes. When levels ofWNT ligands are low, the cytoplasmic b-
catenin undergoes proteolytic degradation subsequent to phosphorylation by
glycogen synthase kinase 3 (GSK-3), in the presence of adenomatous polyposis
coli (APC) and Axin. When WNT ligands are present, they bind to the seven
transmembrane domain frizzled receptors and the low density lipoprotein
receptor related protein 5 and 6 (LRP5/6) resulting in dislocalization of a
molecule called Dishevelled (Dvl) leading to disruption of the Axin-APC-GSK-3
complex. The dephosphorylated b-catenin is then transmitted to the nucleus and
complexes with TCF7L2 resulting in the induction of the target genes (Welters
and Kulkarni, 2008, Bodnar et al., 2005), (Figure 2-1).
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Figure 2-1: Canonical B-catenin pathway
A) In the absence of WNT signalling. (8) Activation of the WNT-signalling pathway.
APC: adenomatous polyposis coli, GSK3: glycogen synthase kinase 3, frizzled: cell-
surface frizzled receptors, LRP: low-density lipoprotein receptor-related protein, Dsh:
dishevelled, Lef: lymphoid enhancer factor, TCF: T-cell factor (adapted from (Welters
and Kulkarni, 2008), with permission.
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exons and exhibits a complex pattern of splicing. The protein product comprises
many binding domains which bidirectionally regulate WNT signalling pathways
(Duval et aI., 2000). As demonstrated in Figure 2-2, the b-catenin binding site is
encoded by exons 1 and 2 while the c -terminal end of the gene (exon 17) codes
the (C-TBP-1) domains. Exons 7-9 produce the binding domain for another co-
repressor, called Groucho while exons 10-12 code for the high mobility group
(HMO) box DNA binding domain (Osmark et al., 2009), (Figure 2-2) .
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Although 3 transcription start sites (TSS) have been identified, due to alternative
promoter usage, only one (TSS 1) located 536 bp upstream of the translation start
site in exon 1, can lead to a transcript with the b-catenin binding domain
(encoded by exons 1 and 2). The other two TSS located in exon 1 and intron 1
use a translation start site located in exon 3 (Figure 2-2). Exons 4, and 13-16 are
alternatively spliced, giving a high number of splice variants, although only a
few variants are expressed in each tissue. Inclusion of exons 14, 15 and 16
results in the introduction of a stop codon and consequently lack of exon 17 from
the translation product. The lack of exon 17 leads to truncated protein lacking the
co-repressor C-TBP-l binding domain (Prokunina-Olsson et al., 2009). TCF7L2
has the highest expression in pancreatic islets and lowest expression in skeletal
muscle. It is also expressed in gut, liver, peripheral blood cells, visceral and
subcutaneous fat (Osmark et al., 2009).
Figure 2-2: Genomic structure of the TCF7L2
TSS: transcription start site 1. E= exon, coloured rectangles indicate the alternative
exons (E4, E13-16). Different binding domains in relation to their coding exons are
demonstrated by open coloured boxes. The sites of the SNPs to be included in this
study are also indicated.
Et-E3 E4 ES-6 E7-9 EtO-12 E13-t6 Et7
rs7903t46
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2.2.2.2 Polymorph isms of the TCF7L2
Evidence for the contribution of TCF7L2 to the risk of type 2 diabetes was first
provided by a genome-wide linkage analysis in Icelandic pedigrees, in which a
linkage peak (10.5 Mb) on chromosome 10 was identified. A fine mapping
approach, applying high density microsatellite markers, succeeded in identifying
a tetra-nucleotide microsatellite marker (DG 1OS478) in a reasonably large
number of cases and controls of Icelandic descent (1185 cases and 931 controls)
(Grant et al., 2006). This marker has six alleles, with alleles 0, 8 and 12
represented in 98% of the population where the 0 allele is protective and non 0
allele (referred to as allele X) is the risk allele for T2D. The same findings were
replicated in European American and Danish populations with the same effect
size and same level of significance. The relative risk of all 3 population
combined was 1.56 (95% Cl 1.41-1.73, P = 4.7 x 10.18).
This microsatellite marker resides in the LD block of 92 Kb encompassing intron
3, exon 4 and intron 4 of the TCF7L2 gene on 10q25.3, with no other genes
mapped to this region. Sequencing of this region revealed 5 non coding SNPs
which were correlated with the marker. Of these SNPs, rs12255372 (~=0.95)
and rs7903146 (r=0.78) showed the same effect on the risk of type 2 diabetes as
the original marker with both an additive and a multiplicative mode of
inheritance. Population attributable risk (PAR) was 21%, given a MAF of 26%
in the study cohort of3 populations combined (Grant et al., 2006).
Replication studies are typically required in populations of the same and
different ethnic groups. This is to confirm the earlier findings regarding the
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effect size and also to test for the association with intermediate traits of T2D
which helps to understand the exact role of TCF7L2 on the pathology ofT2D.
Subsequent studies over the 2 years following the initial study by Grant et al
(2006) in European populations as well as populations of non European origin
confirmed TCF7L2 as a major T2D susceptibility gene with PAR ranging from
16-30% (Groves et al., 2006, Cauchi et al., 2006). In a case control study
selected on the basis of a history of hypo-glycaemic treatment and/or
biochemical evidence of diabetes, the T allele of SNP rs7903146 was associated
with diabetes in a UK population (Groves et al., 2006). The genotype relative
risk of heterozygous TC and homozygous TT carriers was 1.35 (95% Cl 1.19 -
1.53, P= 3.1 X 10 -6) and 1.90 (95% Cl 1.54 -2.33, P= 3.6 X 10-6), respectively,
In a French population the effect of rs12255372 and rs7903146 on the risk of
T2D was confirmed, The T allele of the SNP rs7902146 was associated with an
average decrease of 2.4 years in the age of onset of T2D (Cauchi et al., 2006).
Even in a Finnish population with lower MAF for the risk alleles (17% compared
to 26%), both rs12255372 and rs7903146 are associated with T2D (Scott et al.,
2006). A meta-analysis of candidate gene studies carried by Cauchi et al (2007)
found that the pooled OR for the T allele of the SNP rs7903146 was 1.46
(95%CI 1.42-1.51, P=5.4x 10 -140). This study included 29,195 controls and
17,202 diabetic cases from 27 studies from different ethnic groups with no
heterogeneity in genotypic distribution (Cauchi et al., 2007a).
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In addition to the findings of candidate gene studies, several GWAS have
identified the SNP rs7903146 as a diabetes risk allele (WTCCC., 2007, Saxena et
aI., 2007, Sladek et aI., 2007, Scott et aI., 2006, Zeggini et aI., 2007).
Even in populations of Asian descent in which the T allele of rs7903146 has
MAF of 0.03, compared to 0.28 in European, it showed significant associations
with T2D (Hayashi et aI., 2007). Additional independent SNPs emerged in Asian
populations including rsl1196218 in intron 4 and rs290478 in intron 7 as risk
variants for T2D in the TCF7L2 gene (Ng et aI., 2007).
Two studies found no association between TCF7L2 variants and the quantitative
traits for diabetes, fasting insulin and glucose levels (Cauchi et aI., 2006, Groves
et al., 2006). However, Saxena et al (2006) found an association between the T
allele of the SNP rs7903146 and reduced insulin secretion (50%) as measured by
an oral glucose tolerance test (DGTI) in non diabetic Scandinavian carriers
(Saxena et aI., 2006).
In relation to BMI, the T allele of rs7903146 was associated with lower BMI
both in healthy carriers and T2D subjects. Helgason et al (2007) observed that
there are two haplotypes of the TCF7L2 gene. HapB, which carries the T2D risk
allele of rs7903146 (T allele) was associated with low BMI. HapA, tagged by the
C of the rs7903146 and the T allele of SNP rs7904080 was associated with
higher BMI (Helgason et aI., 2007). Later studies did not find any association
between TCF7L2 variants and obesity measures (Pecioska et aI., 2010, Cauchi et
aI., 2008), and suggested that the lower BMI in carriers of the rs7903146 T allele
is related to recruitment criteria, and that carriers of the T allele develop diabetes
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through effects on insulin secretion, whilst obese individuals would develop
diabetes through insulin resistance.
The association between rs7903!46 and other diseases has also been tested. For
coronary artery disease the results are controversial and less clear than the results
obtained with T2D. In a mixed population from the US the T allele ofrs7901346
was not associated with either CAD or with peripheral artery disease (Bielinski
et al., 2008). In contrast, in a group of 600 non diabetic Brazilian subjects the T
allele was associated with CAD (Sousa et al., 2009).
2.2.2.3 Role of TCF7L2 gene in diabetes
TCF7L2 as an effector molecule in the WNT pathway is expected to mainly alter
insulin secretion. Oral glucose intake stimulates the secretion of gastrointestinal
hormones such as glucagon like peptide -1 (GLP-!) from the distal part of the
small intestine, which leads to an increase in glucose stimulated insulin secretion
from the b-cells of the pancreas, known as the Incretin effect. It has been
reported that TCF7L2 increases the expression of GLP-! by binding to its
promoter. It has been shown that the Incretin effect is reduced in T2D patients as
well as in healthy carriers of the diabetes risk alleles (Lyssenko et al., 2007,
Helgason et al., 2007). Depletion of TCF7L2 by siRNA leads to reduction of
glucose and GLP-! stimulated insulin secretion (Shu et al., 2008, Shu et al.,
2009). Not only was insulin secretion impaired by depletion of TCF7L2, but the
whole process of beta cell proliferation and survival were disturbed (Shu et al.,
2009). Interestingly, Exendin-4, a GLP-! receptor agonist, is now in use for the
treatment ofT2D (Van Gaal et al., 2008).
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TCF7L2 is characterized by a complex form of tissue specific splicing. Being
intronic in nature and not correlated with any coding SNPs, SNPs of the TCF7L2
gene reproducibly associated with T20 are expected to alter gene expression
through mRNA splicing. Transcripts including exon 4 (located just downstream
to SNP rs7903146 and predominantly included in the transcript from pancreatic
islets), were positively correlated with HbAlc (Osmark et al., 2009). However,
the genotype at rs7903146 showed no effect on the expression of any TCF7L2
transcripts, including exon 4 inclusive transcripts in islets taken from 17 non
diabetic individuals (Osmark et at, 2009). In another study, the T allele of
rs7903146 and the G allele of rs1225572 were negatively correlated with the
transcripts including the C terminal exons in 50 islets derived from non diabetic
individuals (Prokunina-Olsson et al., 2009). Inclusion of these alternative exons
will introduce a stop codon and eliminate the C-TBP-I binding domain which is
a negative regulator of the WNT pathway.
2.2.2.4 Role of TCF7L2 variants in pregnancy disorders
During pregnancy pancreatic b-cells undergo structural and functional changes in
response to the increased insulin requirements. Failure of the b-ceU of the
pancreas to compensate for the increased requirement for insulin during
pregnancy leads to gestational diabetes mellitus (GOM).
Some reports are currently available regarding the role of the TCF7L2 variants
and GOM. The T allele of SNP rs12255372 in TCF7L2 was significantly
associated with GOM in American Mexican women (OR 2.49, 95% Cl 1.17-
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5.31, P= 0.018) and remained significant when adjusting for age and BMI (OR
2.62,95% Cl 1.13- 6.11, P= 0.025) (Watanabe et aI., 2007). In Swedish women,
the T-allele of SNP rs7903146 was associated with an increased risk of
gestational diabetes mellitus (OR 1.49, 95% Cl 1.28-1.75, P=4.9xlO-7) (Shaat et
al., 2007). This was also reported in Danish women (Lauenborg et aI., 2009).
Freathy et al (2007) demonstrated, in large study of a Finnish birth cohort, that
the T allele of rs7903146 of both fetal and maternal origin is associated with
birth weight. As the fetal and maternal genotypes are 50% correlated, adjustment
to fetal genotype showed that the increase in birth weight is due to maternal
genotype (31 gI per risk allele, 95% Cl 9-48 g, corrected P= 0.003). The fact
that the sample size was large and the effect on birth weight was supported by
the finding that the carriers of the risk allele had reduced insulin secretion and
high fasting glucose makes this association robust (Freathy et aI., 2007).
Fetal SNP genotype did not show any effect on intrauterine weight gain or 2
years postnatal weight gain in Dutch subjects either in the general population or
in a small for gestational age cohort (Mook-Kanamori et aI., 2009). A French
study found no association between the T allele of rs7903146 and smallness for
gestational age (Cauchi et aI., 2007b). The lack of effect of fetal genotype at this
locus on birth weight was explained by the fact that even if insulin secretion was
reduced in a carrier of the risk allele it would be of a modest nature and of too
short duration to lead to SGA. Although these studies excluded an effect of fetal
genotype at this locus on birth weight or risk of SGA, they did not study the
effect of maternal genotype or the effect of other variants of this gene or
interaction with other T2D susceptibility genes on birth weight.
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TCF7L2 has not been tested in preeclampsia and it merits investigation both as a
diabetes gene and also as a part of pathway that is reported to be expressed in the
placenta and to regulate the invasive function of the trophoblast (Pollheimer et
al.,2006).
2.2.3 Fat Mass- And Obesity-Associated Gene (FTO)
2.2.3.1 Introduction
FTO, fat mass and obesity-associated gene, is ubiquitously expressed in human
tissues with high expression in the brain, especially in the region of the
hypothalamus and its nuclei that regulate energy expenditure and food intake. It
is also highly expressed in both visceral and subcutaneous adipose tissue
(Frayling et al., 2007, Boissel et al., 2009). The gene encodes a-2-oxoglutarate-
dependent nucleic acid demethylase, responsible for nucleic acid demethylation
(Gerken et al., 2007), suggesting that it may operate through epigenetic
mechanisms.
2.2.3.2 Genomic structure and polymorphisms of FrO gene
The FTO gene is a large gene formed of 417 Kb mapped to chromosome 16q. It
comprises 9 coding exons generating a 1518 bp transcript and the protein
product of 505AA.
Part of the large intron 1 (105kb) along with exon 2 (78bp) and part of the
intron 2 (15kb) form a 47 kb LD block in which all identified T2D and obesity
risk variants of the FTO gene are located (Figure 2-3). This LD block carries a
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cluster of 40 SNPs that are highly correlated (linkage disequilibrium r2 2:0.80) in
Caucasian populations. The fact that linkage disequilibrium decays markedly
beyond this region indicates that the authentic and lor causal allele lie in this
region,
Figure 2-3: Organization of the FTO gene
FTO gene id formed of 9 exons (Black boxes). A 47 Kb LD block carrying the T2D and
obesity SNPs is shown spanning intron 1, exon 2 and most of intron 2. The relative
location of the most commonly studied SNPs and a CULT1 transcription factor binding
site are shown. Adapted from (Stratigopoulos et al., 2008).
Region of associated SNPs
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2.2.3.3 Role of FTO in Diabetes, obesity and metabolic syndrome
Obesity is a major risk factor for diabetes, cardiovascular disease, metabolic
rs9939609
syndrome, hypertension, and preeclampsia. A GWAS for T2D identified 2
common variants (rs9939609, rs8050136) in the FTO gene that predispose to
diabetes through an effect on BMI (Scott et al., 2007, WTCCC., 2007). These
effects on the risk of T2D, obesity, and their related traits were evident in
children and adults of both genders and in different populations.
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The Wellcome Trust Case Control Consortium (WTCCC), that included 1924
T2D subjects and 2938 population controls (British individuals) showed that the
A allele of SNP rs9939609 in FTO was related to an increased risk ofT2D (OR
1.27, 95% Cl 1.16-1.37, P=5XlO-8) (WTCCC., 2007). This association was
replicated by genotyping of a further 3757 T2D cases and 5346 controls (OR
1.15, 95% Cl 1.09-1.23, P=9x 10-8). The association was eliminated after
adjusting for BMI (OR1.03, 95% Cl 0.96-1.10, P=0.44) (Zeggini et al., 2007).
The interaction between BMI and FTO genotype on the risk of T2D was also
replicated in a large case control study in Danish individuals (3,856 diabetic
subjects and 4,861 normal glucose-tolerant controls) in which Andreasen et al
(2008) indicated that the minor (A) allele of rs9939609 was associated with type
2 diabetes (OR 1.13, 95% Cl 1.06-1.20, P= 9xlO-s) in a BMI dependent manner
(BMI adjusted OR 1.06, 95% Cl 0.97-1.16, P=0.2) (Andreasen et al., 2008).
This suggested that the association of FTO SNPs with T2D risk is mediated
through the metabolic effects of BMI.
Many studies have confirmed an association of FTO with obesity. Dina et al
extensively studied FTO variants in relation to obesity and recorded a population
attributable risk (PAR) of 22% using a multinational study comprising 2,900
obese individuals and 5,100 controls of European ancestry (French, German,
Swiss, and Swedish). The C allele ofSNP rs1421085 and G allele ofrs17817449
gave the strongest signal for this association. Furthermore, these alleles were
transmitted more frequently from heterozygous parents to obese offspring in
French and Swedish families, confirming them as obesity risk variants (Dina et
al., 2007). Frayling et al studied the association of FTO gene variation with
increased BMI and the risk of being overweight and obese in 19,424 white
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European adults from seven general population-based studies (mean age 28 to 74
years, mean BMI 22.7-27.2 kglm2) (Frayling et al., 2007). The OR per-A allele
of SNP rs9939609 was 1.31 (95% Cl 1.23-1.39, P=6xlO-16) for obesity in the
adult general population and 1.18 (95% Cl 1.13-1.24, P=l x10-12) for being
overweight. The same effect was manifested in 10,172white European children,
mean age 7 to 14 years, mean BMI 16.1 to 19.2 kg/rrr'),
Variants of FTO have been also associated with the quantitative traits of
metabolic syndrome (MS), T2D and obesity. In 17000 individuals, FTO genetic
variants were associated with characteristics of metabolic syndrome (high fasting
insulin, glucose and triglycerides, and low HDL) (OR 1.17, 95% Cl 1.2-1.25,
P=3xlO-6) (Freathy et al., 2008). This association with metabolic traits was
abolished after adjusting for BMI, indicating that the increase in the body fat in
carriers of the risk allele may impose these metabolic changes. Similarly, Do et
al reported an association between rsl421085 and rs17817449 and elevated
fasting insulin levels and insulin sensitivity (diabetes traits) in a BMI dependent
manner (Do et al., 2008). The A allele of rs9939609 was also significantly
associated with higher plasma insulin levels (P=0.05), higher insulin resistance
index (homeostasis model assessment) (P=0.02), and higher systolic blood
pressure (P=0.003) in a French population, but these associations disappeared
after adjustment for BMI (Legry et al., 2009). In both of these large genetic
studies an association between rs17817449, rs1421085 and rs9939609 and
obesity quantitative traits was also evident (P= 0.00008 for BMI, P=0.0002 for
waist circumference, and P=0.006 for body weight) (Legry et al., 2009, Do et al.,
2008, Andreasen et al., 2008). Andreasen et al demonstrated gene environment
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interaction, such that higher insulin sensitivity attenuates and low physical
activity accentuates the effect at rs9939609 on obesity (Andreasen et al., 2008).
2.2.3.4 FrO variants and CAD risk
In relation to hypertension, Pausova et al showed that rs9939609 was associated
with higher blood pressure independent of BMI and this was evident in both an
adolescent sample and an independent adult sample (4.4 mm Hglallele,
P=0.0024), indicating that individuals at risk for hypertension may be recognized
early during development of the disease when preventive measures may still be
effective (Pausova et al., 2009). The authors suggested that the association of this
variant with higher blood pressure is related to an increase in sympathetic
vasomotor tone as it was more evident when tested under mental stress (Pausova
et al., 2009). This is consistent with the fact that FTO is expressed at higher
levels in the hypothalamic centres known to regulate blood pressure. FTO
variants were also associated with systolic blood pressure in a French population
(P=0.003, BMI dependent) (Legry et al., 2009) and with systolic and diastolic
blood pressure in Finnish women (Lappalainen et al., 2010). In this latter study,
it was also possible to show the association of this variant with increased risk of
CAD in men (OR 2.09 95% Cl 1.17-3.73, P=O.013). The association was
independent of BMI or C reactive protein levels, but was partially explained by
increased RANTES (interleukin 8 related cytokine) in these men who either
displayed impaired glucose tolerance or were diabetic (Lappalainen et al., 2010).
This confirmed the earlier findings by Doney et al who introduced for the first
time the association of FTO variants with an increase in risk of CAD in diabetic
Scottish individuals, (OR 2.0,95% Cl, 1.18 -3.45, P=O.OII) (Doney et al., 2009).
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The association was actually attenuated after adjustment for BMI but remained
significant. In both of these studies the FTO risk variant was associated with an
atherogenic lipid profile (lower HDL, high triglyceride levels), as well as with
inflammatory markers (C-reactive protein and RANTES). Besides the metabolic
changes, the atherogenic lipid profile, and inflammatory changes associated with
FTO risk variants, FTO is currently reported to be associated with altered nucleic
acid methylation, an epigenetic change that appears to be enhanced in CAD
(Sharma et al., 2008, Han et al., 20 I0).
The association of FTO variants and T2D, obesity, and metabolic syndrome was
also reported in other ethnic groups like Chinese (Han et al., 2010) and mixed
Asian population inhabitants of south Canada (AI-Attar et al., 2008).
2.2.3.5 Functional effects of the FrO variants
In view of the large number of studies that relate FTO variants to obesity, T2D,
metabolic syndrome and CAD, it is important to find out how variations in the
FTO gene contribute to disease development. Since the substrate for the FTO
encoded enzyme (a-2-oxoglutarate-dependent nucleic acid demethylase) is not
yet identified, the exact function of FTO is not fully understood. Most studies
have been directed towards identification of the function of FTO itself and few
have studied the role of the risk variants.
In humans, it appears that hyperphagia and food preference toward high energy
diet are the causes of obesity (Cecil et al., 2008, Speakman et al., 2008). Loss of
the mouse FTO gene product resulted in reduced postnatal weight gain, reduced
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adiposity, increased energy expenditure due to sympathetic stimulation, and
hypophagia (Church et al., 2009, Fischer et al., 2009). These data suggested that
variants in the human FTO gene which lead to an altered expression (up-
regulation) might render individuals more susceptible to obesity. In agreement
with this hypothesis FTO showed higher expression in the subcutaneous and
visceral fat from obese compared to control subjects (Zabena et al., 2009,
Wahlen et al., 2008). Although no impact of the genotype at rs8050136 and FTO
expression was reported in a sample of306 women (with BMI 18-53 kg/m'), the
FTO variant rs8050136 was associated with altered rates of lipolysis both in
vivo (the T allele was associated with a 30% increase of serum glycerol) and in
isolated adipocytes (Wahlen et al., 2008). Of note, the binding sites for CUTLl,
a transcriptional regulator, overlaps with rs17817449 and rs8050136; blocking
these sites was associated with altered FTO expression in fibroblast
(Stratigopoulos et al., 2008).
In summary, altered FTO expression leading to increased food intake, reduced
energy expenditure, altered lipolysis/lipogenesis, increased peripheral insulin
resistance, an increased systemic inflammatory state, and altered epigenetic
effects, are suggested mechanisms by which the association between FTO
genetic variants and disease status can be explained.
2.2.3.6 Role of FrO in pregnancy
The consistent association between the FTO gene and obesity and BMI and the
known correlation between adult BMI and birth weight render the FTO gene of
interest for birth weight association. The variant rs9939609 was not associated
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with birth weight in a small genetic study involving 214 Belgian newborns, but
was associated with postnatal weight gain at 2 weeks post partum (Lopez-
Bermejo et al., 2008). This was in agreement with an animal study showing that
inactivation of FTO was associated with normal birth weight but with reduced
weight gain postnatally. Bassols et al reported that expression of FTO in human
placental tissue correlated with birth weight (Bassols et al., 2010).
There is no evidence that FTO variants alter the risk of GDM (Lauenborg et al.,
2009) which is expected as FTO increases the risk of diabetes by increasing
insulin resistance rather than altering the b-cell function which is the main factor
in GDM. No reported studies have tested FTO or its variants in relation to
preeclampsia risk although it is a strong candidate gene, as it is associated with
BMI, T2D, CAD, hypertension, and a systemic inflammatory state, all of which
are potential risk factors for preeclampsia.
2.2.4 Peroxisome proliferator-activated receptors-gamma (PPAR-y)
2.2.4.1 Introduction
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear
hormone receptor superfamily. This family of transcriptional regulators includes
steroid hormone, thyroid hormone and Orphan receptors such as PPARs. PPARs
represent group C in subfamily 1 of the nuclear hormone receptor superfamily
(NRIC). This large subfamily also comprises for instance, All-trans retinoic acid
receptors (NRIA), the retinoic acid receptors, (NRIB), and the vitamin D3
receptor, (NRlI). There are three PPAR isotypes, namely PPAR-alpha (NRIC1),
PPAR-beta (NRIC2; also called PPAR-delta), and PPAR-gamma (NRIC3).
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PPARs are recognized in different species including humans (Escher and Wahli,
2000).
There are different functional domains in the PPAR proteins. The N-tenninal
AlB domain is a ligand-independent transactivation domain called activation
function-l (AF-l), the highly conserved C domain forms the DNA-binding
domain (DBD), and the D domain links the DBD to the c-tenninal end of the
receptor. The c-tenninal end is the ligand-binding domain (LBD), containing a
ligand-dependent transactivation function, termed activation function-2 (AF-2).
Although the DBD and LBD show 60-80% sequence similarity between
different isotypes, they still maintain a certain level of variation for both tissue
and ligand specificity (Escher and Wahli, 2000).
PPARs are ligand-activated transcription factors and form heterodimers with
retinoic X receptors (RXR) to regulate the transcription of various genes after
binding to PPAR response elements (PPREs). The PPRE consists of 2 simple
repeats of AGGTCA separated by a single nucleotide. PPARs can be activated
by natural ligands, such as prostaglandins (PGs), fatty acids and their derivatives,
as well as by synthetic ligands like thiazolidinedione drug derivatives
(troglitazone, pioglitazone, and rosiglitazone). In the absence of ligands, PPARs
induce a repressor function on the target genes by binding to the promoter region
of these genes, interacting with other co-repressors. On ligand binding, the
PPARIRXR heterodimer associates with cofactors containing histone acetyl-
transferase activity, modifying nucleosome structure and contacting general
transcription factors with induction of the target genes (Bragt and Popeijus,
2008).
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The effect of PPARs on the target promoters depends on the phosphorylation
status of the receptors (that alter the affinity of the receptor for DNA, RXR, and
ligand), type and availability of ligands, DNA allosteric constraints, promoter
context and the cell-type specific combination of transcriptional co-regulators
that bind to the PPARslRXR heterodimer (Tan et al., 2005).
PPAR isotypes are differentially expressed in tissue. PPAR-beta is ubiquitously
expressed, PPAR-alpha is expressed in tissues with a high metabolic rate like
liver, heart, kidney, and skeletal muscle, while PPAR-gamma (PPAR-y) is
mainly expressed in adipose tissue and to a lesser extent in skeletal muscle,
colon and placenta (Escher and Wahli, 2000).
PPAR-y is an important adipogenic regulator and modulator of glucose
metabolism. PPAR-y stimulates adipocyte differentiation and leads to the
formation of an increased number of small adipocytes. These small adipocytes
are able to take up free fatty acids more easily and therefore decrease the flux of
free fatty acids to the liver and muscle. The lowered flux of free fatty acids into
skeletal muscle leads to better uptake and use of glucose as a source of energy.
This adipogenic effect is mediated through activation of specific genes like
CD36, a gene belonging to the class B scavenger receptor superfamily, and
lipoprotein lipase. PPAR-y activation increases skeletal and hepatic glucose
uptake and reduces hepatic glucose production (Honka et al., 2009). PPAR-y
also has anti-inflammatory effects through reducing the production of
proinflammatory cytokines after forming complexes with Nf-KB.
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Thiazolidinediones, potent and relatively specific ligand activators of PPAR-y
currently used for the treatment of type 2 diabetes, lead to reduced fasting insulin
and glucose concentrations, and improved whole body insulin sensitivity (Bragt
and Popeijus, 2008).
2.2.4.2 Genomic structure of PPAR-y
Each of the PPAR isotypes is encoded by a different gene; for example, PPAR -
alpha is on human chromosome 22, while PPAR-beta maps to chromosomes 6.
The PPAR-y gene is located on chromosome 3, at position 3p25 spanning around
125Kb (Beamer et al., 1997). There are 6 transcripts of PPAR-y which have
been identified in humans, formed due to different promoter usage and
alternative splicing. These are PPAR-yI, PPAR-y2, PPAR-y3, PPAR-y4, PPAR-
y5 and PPAR-y7. As demonstrated in Figure 2-4, six coding exons (EI-E6) are
recognized in which exon 1 encodes for the NB domain, exons 2 and 3 encode
for DBD, while exon 5 and 6 encodes for LBD. The 5' -terminal region of the
transcript is the determinant of the PPAR-y isoform. Five alternative exons have
been identified in the 51-terminal region, referred to as exons AI, A2, B, C, and
D. They are alternatively spliced with exons 1-6 to generate the 6 transcripts of
PPAR-yas shown in Figure 2-4. PPAR-yI, PPARy-3, PPAR-y5 and PPAR-y7
are different transcripts, but encode the same protein (475 AA and 54.5 kDa) as
they share the same translation start site in exon 1. PPAR-yl consists of exon Al
and A2 spliced together with exons 1-6. The mRNA for PPAR-y2 consists of
exon B and exons 1-6. The third isoform, PPAR-y3, identified in humans,
consists of only exon A2 in its c-terminal region and exons 1--6. There is an
ATG in exon B, however in PPAR-y5 and PPAR-y7, this site is inactivated by
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stop codons present in exon D. Thus, exon 8 contributes 28 n-terrninal AA in
PPAR-y2 only (505 AA, 57.6 kDa). A translation initiating ATG is also present
in exon C resulting in an additional eight AA at the n-terrninus ofPPAR-y4 (483
AA, 55.3 KO). So the six transcripts encode a total of 3 different PPAR-y protein
isoforrns due to different promoter usage and alternative splicing (Elbrecht et al.,
1996, Chen et al., 2006). Although alternative splicing is more commonly known
to provide different proteins from the same DNA, the case here is that different
transcripts with different lengths of the 5'UTR regulate the efficiency of protein
translation from different PPAR-y transcripts (McClelland et al., 2009). Tissue
specificity is reported to govern which transcript is predominantly expressed in a
given tissue; PPAR-y2 and PPAR-y3 are predominantly expressed in adipose
tissue whereas PPAR-yl expression is ubiquitous. Expression ofisoforrn-specific
transcripts may also be regulated by PPAR-y ligands. For example, in human
macrophages, treatment with l5-deoxy-12, l4-prostaglandin Jz (15d-PGJ2)
resulted in a 22% induction of PPAR-y51-y7 transcript and a 24% repression in
PPAR-y4 transcript. Troglitazone was effective at repressing PPAR·y4levels by
23% but it did not significantly induce the PPAR·y5/y7 transcript. Interestingly,
both l5d-PGJ and troglitazone treatment significantly inhibited the expression of
PPAR-yl and PPAR·y2 by 30 and 70% respectively compared to untreated
controls (Chen et al., 2006).
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Figure 2-4: Genomic structure of PPAR-y
Upper panel showing the coding exons (E1-E6), the alternative 5' -terminal exons (A1,
A2, S, C, and D), alternative promoters (P1-P3), and the site of SNPs to be investigated
in this study. Lower panel, showing the different PPAR-y transcripts and the translation
initiation site in each transcript (black arrow). The site of the stop codon in exon D is
also shown (blue arrows).
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2.2.4.3 Polymorphisms of the PPAR-y
Multiple rare mutations have been identified in the PPAR-y gene that provided
evidence for the central role of this gene in glucose and fat metabolism. V290M,
R425C, P467L, and F388L (located in the LBD) have been associated with
PPAR ligand resistance (PLR) syndrome. This syndrome is characterized by
partial lipodystrophy (loss of subcutaneous fat from certain parts of the body and
preserved in other parts), early-onset severe insulin resistance (IR), type 2
diabetes, dyslipidaemia (high triglycerides, low HDL cholesterol), early-onset
hypertension and hepatic steatosis. These mutations render the receptor less
active. Also a frame-shift mutation that introduces a premature stop codon (186
stop located in the DBD) is described in individuals with severe insulin
resistance. P115Q, a specific mutation of the PPAR-y 2 (located on exon B), was
described in 4 German individuals with morbid obesity and type 2 diabetes. This
mutation was associated with defective phosphorylation of the receptor at serine
114 and renders the receptor more active with better adipocyte differentiation
and lipid accumulation reviewed in (Meirhaeghe and Amouyel, 2004).
Two common polymorphisms were studied extensively based on this prior
knowledge of the biological and metabolic functions of the PPAR-y2: Pro12Ala
(rsI801282, C>G) in exon Band C1431T (rs3856806) in exon 6 (Figure 2-4).
Pro12Ala is located in the specific exon B of the PPAR-y2 transcript and results
from CCG>GCG with substitution of alanine for proline in codon 12. The
frequency of the Ala allele varies across ethnic populations (1-3% in Africans
and Asians and as high as 12% in Caucasians), (Yen et al., 1997).
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Deeb et al (1998) were the first to report an association between T2D and
Prol2Ala; they showed that the Ala (G) allele is protective for T2D in a small
group of Japanese Americans (Deeb et al., 1998). This study was followed by
many studies with contradictory findings regarding the protective effect of the
Ala allele on the risk of T2D in different ethnic groups, including Danish (Ek et
al., 2001), French (Meirhaeghe et al., 2000) and Chinese (Fu et al., 2001).
The low MAF of the Ala allele, the small effect size, small sample size, the
effect of population stratification, and gene environment interaction might be the
causes of these contradictory results. Adequately powered studies, family based
studies, and the more recent genome wide association studies strongly confirmed
the Ala allele as a protective allele for T2D.
In a case control study comprising 1000 cases and 1000 controls from the UK
population, the Ala allele was found to be protective against T2D (Pro allele OR
was 1.4, 95% Cl 1.08-1.99, P= 0.01) (Zeggini et al., 2005), and similar results
were obtained in a French population (Pro allele OR was 1.37, 95% Cl 1.02-
1.87, P= 0.04) (Ghoussaini et al., 2005). It was possible to show the interaction
between obesity and genotype in relation to type T2D, as restricting the analysis
to obese subjects gave a higher OR (Pro allele OR was 1.8,95% Cl 1.5-3.13, P=
0.03) (Ghoussaini et al., 2005). Mori et al also observed the same effects in a
Japanese population (Mori et al., 2001).
By using Scandinavian family-based studies as well as conducting a meta-
analysis including over 3000 individuals, Altshuler et al (2005) reported that the
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Ala allele was indeed protective against T2D and the Pro allele was a risk factor.
The PAR was estimated as 0.25 (Altshuler, 2000).
In a study screening 114 SNPs in 76 genes previously reported to be associated
with T2D in 786 T2D cases and 617 control subjects with normal glucose
tolerance from Finland, Pro12Ala was one of 12 SNPs that replicated as a T2D
variant (OR: 1.30,95% Cl : 1.10-1.53, P= 0.009) (Willer et al., 2007). Many of
these studies demonstrated that the Ala allele reduced the risk for T2D through
improved insulin sensitivity (see below). Further supporting the role of this
variant in T2D, the Ala allele was less frequent in those who develop T2D over a
6 year follow up in two large observational and intervention studies carried out
in Finland (Lyssenko et al., 2005).
In relation to BMI contradictory results have been reported. Some studies
reported the Ala to be associated with a low BMI (Deeb et al., 1998, Doney et
al., 2002), whilst others reported a high BMI in Ala allele carriers (Meirhaeghe
et al., 2000). Masud et al (2003) showed that even though Ala allele carriers had
higher BMI, only approximately 1% of the total variance of BMI can be
explained by this polymorphism (Masud and Ye, 2003). In the same study by
Masud et al, a meta-analysis using data from 30 independent studies with a total
number of 19136 subjects, showed that the Ala allele was associated with a
higher BMI only in obese individuals (BMI>27kglm2). It has been suggested that
homozygosity for the Ala allele is associated with higher BMI in obese subjects,
but within the non obese subjects Ala allele homozygotes have a lower BMI than
Pro allele carriers (Ek et al., 1999). This suggested that there are modifiers,
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possibly environmental or genetic interaction, that alter the effect of this variant
on obesity.
The impact of Pro 12Ala on obesity is indeed modified by other SNPs in the
same gene. As shown by Doney et al (2002), the Ala allele was associated with
low BMI while the T allele of the rs3856806 (CI431T) SNP was associated with
an opposing effect(Doney et aI., 2002). Another two SNPs were also tested in
the alternative promoters of PPAR-y (Figure 2-4) in which the G allele of P3
SNP (rsl0865710, C>G) and the T allele of the P2 SNP (-689 C>T) were
associated with higher body weight in a French population. Haplotype analysis
showed that the haplotype formed of the minor alleles of P3-P2-and Pro12Ala
(G-T-Ala) was associated with higher body weight compared with the haplotype
formed of the major alleles. Interestingly SNPs in P2 and P3 were not associated
with T2D, glucose or insulin variables (Meirhaeghe et aI., 2005). A synonymous
SNP in exon 6 of the PPAR-y gene (rs3856806; C1431T) was associated with
type 2 diabetes under a dominant model (OR 1.26,95% Cl 1.05-1.51, P= 0.013)
but was no longer significant after adjustment for the Prol2Ala variant (OR 1.11,
95% Cl 0.89-1.38, P = 0.064), (Willer et aI., 2007).
Both Pro12Ala and C1431T (LD, c= 0.7) were found to be associated with
CAD. Ridker et al (2003) reported the Ala allele to be protective against CAD in
US white men (OR: 0.76, 95% Cl 0.59-0.99, P= 0.034), in a study which
included 523 cases and 2092 controls (Ridker et aI., 2003). The T allele of
C1431T SNP was also associated with CAD in an Australian white population
(Wang et aI., 1999). In both studies the allele attributable risk of CAD was
independent of diabetes, body mass index, waist-to-hip ratio, or lipid profiles.
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2.2.4.4 Mechanism of action of PPAR-y variants in T2D
Deeb et al (1998) reported that the Ala12 isoform from the PPAR-y2 transcript
bound less effectively to the PPRE and activated the PPRE-driven reporter gene
in HepG2 cells less effectively than the Pro isoform in the presence of increasing
concentrations of troglitazone (Deeb et al., 1998). This was replicated in two
other cell lines, CV-l (monocyte) and 3T3-Ll (adipocyte lineage) in both the
presence and absence of PPAR-y2 ligands. Both the Acyl-CoA oxidase and the
lipoprotein lipase promoters, previously shown to contain a functional PPRE,
were also less efficiently transactivated by the PPAR-y2 Ala isoform than the
Pro isoform in the absence of added ligand (Masugi et al., 2000).
In vivo, insulin sensitivity, as determined by a euglycaemic-hyper-insulinaemic
glucose clamp, was improved in bearers of the Ala allele. Moreover, the insulin
sensitivity of glucose disposal and insulin sensitivity of lipolysis were greater in
the subjects carrying the Ala allele (Stumvoll et al., 2001).
The fact that the less active Ala allele is protective against T2D and associated
with better insulin sensitivity is puzzling considering the use of PPAR-y agonists
for treatment of T2D. Actually, endogenous ligand free PPAR-y (known to be a
transcriptional repressor) or PPAR-y along with its natural ligand might
primarily serve to hamper insulin action and induce insulin resistance. Therefore
introducing the less active Ala variant or the use of thiazolidinediones, (most of
which are both partial agonists and partial antagonists) would restore insulin
sensitivity. Thus, reduced transcriptional activity of the Ala isoform in adipose
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tissue might enhance insulin's capacity to suppress lipolysis, leading to a
decrease in free fatty acid release into the circulation, and forcing the muscle to
use more glucose. In support of this, it has been shown that in lean glucose
tolerant subjects, there is a decrease in lipid oxidation and increase in
carbohydrate oxidation during insulin stimulation in carriers of the Ala allele
(Stumvoll et al., 2001).
2.2.4.5 The role of pp AR-y in pregnancy
PPAR-y is expressed predominantly in invasive trophoblast of the 1st and 2nd
trimester (Schaiff et al., 2000, Waite et al., 2000, Rodie et al., 2005) and in both
CT trophoblast and ST trophoblast of the 3rd trimester placenta. Although
PPAR-y is expressed in invasive trophoblast Tarrade et al showed that both
natural and synthetic PPAR-y ligands hampered the invasive function of the
primary extravillous trophoblast on matrigel, an effect which is reversed by the
use ofPPAR or RXR antagonists (Tarrade et al., 200Ib). This might indicate that
PPAR-y is required in the quiescent state during which PPAR-y is known to
repress target genes by interacting with promoter-bound co-repressor complexes
(this is in keeping with the proposed effect on insulin sensitivity discussed in the
previous section).
Augmentation of trophoblast differentiation has important implications for
placental function as ST trophoblast is more resistant to hypoxic injury, and
carries out important secretory and transport functions in the placenta. Tarrade et
al (2001) showed that ligands for PPAR-y and RXR stimulate differentiation of
the ST trophoblast and secretion of human chorionic gonadotrophin (hCG), and
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hPL. The authors also demonstrated that the promoter region of the hCG beta
gene carries a PPRE and can bind to recombinant RXR and PPAR-y
heterodimers (Tarrade et al., 2001a, Tarrade et al., 200Ib). It has been shown
that troglitazone stimulates differentiation while 15DPGJ2 inhibits
differentiation and increases apoptosis of the trophoblast (Schaiff et al., 2000).
This is of great importance as diseases known to be associated with enhanced
apoptosis of the trophoblast might benefit from inhibition of 15DPGJ2
production and lor the use oftroglitazone (Tarrade et al., 200Ia).
The major alterations of glucose and lipid metabolism during pregnancy to meet
the increased fetal requirements for glucose indicate that up-regulation of the
PPAR-y system is typically required. Waite et al showed that maternal serum
from pregnant women exhibited unidentified factors which stimulate PPAR-y
activity in the Jeg-3 cell line transfected by a luciferase reporter gene under the
effect of a PPRE; these factors are absent from the serum of non-pregnant
women (Waite et al., 2005). This was interpreted as maternal adaptation for
increased glucose metabolism during pregnancy. Later studies by the same group
showed that the suspected PPAR-y activators (probably eicosanoid or fatty acids
derivatives as they are resistant to heat coagulation and were extracted from the
organic phase of the serum of pregnant women) were expressed at lower
concentrations in women with preeclampsia compared to normal pregnancy
several weeks before the clinical diagnosis of preeclampsia (Waite et al., 2005).
In support of these findings it is well known that the lipid profile of pregnant
women is altered markedly during pregnancy with a remarkable increase in
prostacyclin (vasodilator) and decrease in prostaglandins (vasoconstrictor) which
is reversed in preeclampsia. Changes of free fatty acids and triglyceride levels
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and shift in the lipid profile towards oxidized forms are reported in preeclampsia,
and may lead to changes in the ligand profile ofPPAR-y as fatty acids are typical
ligands for this receptor. Furthermore, PPAR-y natural (15dPOJ2) and synthetic
ligands (troglitazone) were shown to reduce the release of POE and
prostaglandin F2 alpha from the placental and amniotic tissues, POE and
prostaglandin F2 alpha are markers of oxidative stress which are increased in
women with preeclampsia (Lappas et al., 2006).
However Rodie et al found no variation in the expression of PPAR-y in PE,
IUOR, or normal placenta by immunohistochemistry and q-PCR (Rodie et al.,
2005). It appears that it is the activity of PPAR-y rather than the level of
expression which influences the role in pregnancy related conditions. This
activity is governed by the availability and the nature of the ligands for PPAR-y.
These ligands might originate from the maternal circulation, placenta, fetal
membranes, amniotic fluid, or decidua.
As PPAR-y regulates multiple pathways in placental development and function,
genetic variations in the PPAR-y gene might alter the risk ofPE. A rare mutation
in exon 6 of the PPAR-y, Pro467Leu was reported in a woman who developed
T2D, hypertension, and two pregnancies complicated by preeclampsia (Barroso
et al., 1999). Although Pro 12Ala was identified years ago, it has only been tested
in relation to preeclampsia in a small genetic study in a Finnish population (133
cases and 115 controls), which showed no association between Pro12Ala and
preeclampsia (Laasanen et al., 2002). The association between preeclampsia and
this variant as well as other variants in PPAR-y merit investigation in a larger
study. This is not only in the view of the biological function of PPAR-y but also
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because PPAR-y variants are reported as risk factors for T2D, CAD, and
alteration in BMI, all of which are associated with preeclampsia.
In relation to birth weight Eriksson et al (2002) showed no association between
birth weight and Pro12Ala in a relatively small study (470 participants) of
Finnish subjects (Eriksson et al., 2002). The lack of association between birth
weight and Pro12Ala was replicated in two larger studies (from Finland and
Germany) that were adequately powered to detect down to 8% genotype
attributable variation in birth weight (Bennett et al., 2008, Pfab et al., 2006).
There was no association between Pro12Ala and SGA (171 SGA compared to
233 AGA) in a French population (Jaquet et al., 2002). Further investigation is
required in this specific area, including testing of the maternal genotype at this
locus.
Shaat et al showed no association between Pro12Ala and GDM in Scandinavians
in a large study (Shaat et al., 2007). The same findings were reported in a Korean
population (Cho et aI., 2009). However Lauenborg et al (2009) included the
Pro12Ala polymorphism in a study of 11 T2D variants in Danish women. The
increased risk for GDM associated with the Ala allele was not significant (OR
1.16, 95% Cl 0.82-1.52, P= 0.3), but when they tested 11 T2D variants, they
found a highly statistically significant additive effect of multiple alleles on risk of
the GDM (OR: 1.18'95% Cl 1.10-1.27, P= 3.2 x 10-6), (Lauenborg et aI., 2009).
In summary, cumulative evidence indicates the central role of a common alanine
for proline substitution at codon 12 and C1431T in exon 6 ofPPAR-y in T2D,
obesity, CAD, and atherosclerosis. This observation is of considerable interest
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because patients with these disorders are at increased risk of pregnancy related
disorders like GDM, and preeclampsia, and growth restriction in the offspring.
2.2.5 Cyelin dependent kinase inhibitor 2 B- (CDKN2B) antisense
RNA 1(CDKN2B-ASl)
2.2.5.1 Introduction
Cyclin dependent kinase inhibitor 2 B antisense RNA 1 (CDKN2B-ASI), also
known as (Antisense Non-coding RNA in the INK4 Locus- (ANRIL) maps to
chromosome 9p21, just downstream of the CDKN2N2B genes. In 2008,
Broadbent et al showed that CDKN2B-AS 1 is expressed in many cell lines of
vascular lineage including umbilical vein endothelial cells, microvascular
endothelial cells, coronary smooth muscle cells, and in biopsies from carotid
endarterectomy and abdominal aortic aneurysm, marking this gene as an
important factor in vascular pathophysiology (Broadbent et al., 2008).
CDKN2B-AS 1 has been classified as a long non-coding RNA (LncRNA).
LncRNAs are empirically considered to be RNA molecules longer than 200
nucleotides that lack an open reading frame (ORF). They often overlap with, or
are interspersed between, multiple coding and non-coding transcripts (Mercer et
al., 2009). The LncRNAs have diverse origins. They may arise from frame shift
disruption of a protein-coding gene, following a chromosomal rearrangement,
duplication of a noncoding gene or neighbouring repeats. Lastly they can arise
from insertion of a transposon element (Ponting et al., 2009). The LncRNAs
regulate neighbouring protein-coding genes via cis-acting mechanisms, and
target distant genes via trans-acting mechanisms. So, LncRNAs such as
114
CDKN2B-AS1 have been implicated in a variety of cellular pathways and may
influence gene transcription through multiple mechanisms that might include
RNA interference, gene silencing, chromatin remodelling, or DNA methylation
(Mercer et al., 2009).
2.2.5.2 Genomic structure ofCDKN2B-ASl
The CDKN2B-ASI gene is formed of about 126.5 Kbp and maps to
chromosome 9p21. It is formed of 20 exons of which exon 13 is alternatively
spliced from the long intron 12. Four transcripts have been identified for this
gene; the longest transcript is formed of exons 1-12 and 14-20. The transcripts,
both long and short, have been detected in many tissues; of interest for this
study, these include placenta. Exon 1 of the CDKN2B-AS1 gene is overlapping
with exon 1 (5' end) of the cyclin dependent kinase inhibitor 2A (CDKN2A)
gene. Also the entire CDKN2B gene is overlapping with the 1st intron of the
CDKN2B-AS1 gene (Figure 2-5). CDKN2A1andCDKN2B genes are implicated
in the regulation of cell cycle and senescence.
Exons of this gene vary in their length between 670 bp down to 70 bp and are
formed of multiple simple repeats. Conserved non coding regions have been
identified within primates, and less conserved sequences were noticed with
orthologous species, indicating that this gene has evolved recently in mammals
with new functions or underwent marked evolutionary changes with degenerate
function (Jarinova et al., 2009).
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Figure 2-5: Schematic presentation of chromosome 9p21 region
The CDKN2B-AS1 gene showing exons (open rectangles) with the alternatively spliced
exon 13 (red), and CDKN2AJB genes in green and blue respectively. CAD and T2D loci
are shown in grey in black rectangles respectively. The black arrows indicate the
direction of transcription. The red arrows refer to SNPs included in this study, rs1333049
(right) and rs10811661 (left).
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2.2.5.3 Polymorphisms of CDKN2B-ASl
Genetic polymorphism in this region has been consistently associated with
coronary artery disease (CAD) in European populations, with suggested a
population attributable risk of around 20% for heterozygous and 30% for
homozygous carriers of the risk allele (McPherson et al., 2007).
In a population of European descent from Canadian and US residents McPherson
et al (2007) carried out a genome wide study testing 100,000 SNPs for
association with CAD, which included a group of SNPs located on chromosome
9p21. From within this group the two SNPs which gave the strongest signals for
association with CAD were rs10757274 (OR 1.29, 95% Cl 1.09-1.52, P=O.OI)
and rs2383206 (OR1.26, 95% Cl 1.09-1.46, P=0.04). These two SNPs are 20 kb
apart and in strong linkage disequilibrium (r2 = 0.89) (McPherson et al., 2007).
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The CAD risk locus on chromosome 9 is represented by a haplotype spanning
approximately 58 kb carrying 37 highly correlated SNPs from rsl0757269 to
rs1333049. The region is flanked by 2 recombination hotspots with no evidence
of long range linkage disequilibrium (LD) on chromosome 9, consequently the
causative allele most likely resides within this region (McPherson et al., 2007,
Broadbent et al., 2008).
Further studies including thousands of CAD cases and controls from British,
Dutch, Italian, and US-Icelandic populations replicated the findings of
McPherson et al, with the C allele ofrsl333049 SNP (MAF of the C allele 0.45)
showing the strongest and most reproducible association (Gori et al., 2010,
Samani et al., 2007, Helgadottir et al., 2007). This locus was also reported as a
risk factor for CAD in the WTCCC GWAS (OR 1.47, 95% Cl 1.27-1.7,
P=1.16xlO-13) (WTCCC., 2007). A meta-analysis including 12004 cases and
28949 controls from 7 European case control studies replicated the strong
association of the C allele ofrs1444049 SNP and CAD, (OR 1.24,95% Cl 1.20-
1.29, P= 6.04xlO-IO) (Schunkert et al., 2008).
The data on gene environment interaction at this locus is not conclusive. The risk
conferred by this genetic variant for CAD was not altered when adjusting for
age, gender, smoking, plasma lipid levels, blood pressure, diabetes, and plasma
C-reactive protein concentrations, indicating these factors did not modify the
genetic effect (Broadbent et al., 2008). In contrast, Doria et al (2008) reported
that the magnitude of effect of the CAD locus on chromosome 9 was doubled in
T2D patients and the risk was doubled again in patients with poor glycaemic
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control (defined by average Haemoglobin Al in the 9 years before study entry)
(Doria et al., 2008).
It has been noted that the association between these SNPs and CAD was stronger
in patients with CAD who had not experienced myocardial infarction (MI),
excluding this gene from being a thrombosis or plaque rupture gene (Helgadottir
et al., 2007). The risk allele was associated with abdominal aortic and
intracranial aneurysm and stroke independently of CAD, and it has therefore
been proposed that the risk allele increases the atherosclerotic process
(Helgadottir et al., 2008). It has been suggested that changes in the collagen
and/or elastin content of the vessel wall may be the underlying mechanism for
the association of this region with arterial diseases (8jorck et al., 2009).
The same region of chromosome 9p21 was repeatedly associated with T2D in
OWAS in a UK population (WTCCC., 2007), Scandinavians (Saxena et al.,
2007), and in Finns (Scott et al., 2007). The T allele (major allele frequency of
80% in the European population) ofrsl081I661 has been shown as the strongest
and most consistently associated SNP in a meta-analysis of T2D OWAS, (OR
l.19, 95% Cl l.11-1.28, P=4.9xI0-7) (Zeggini et al., 2007). The association of
this marker with T2D was also replicated in a case control study in French
subjects (OR 1.43, (95% Cl 1.24-l.64 0 P= 3.8 X 10_7)(Duesing et al., 2008).
Many pathological features ofT2D and the metabolic syndrome are predisposing
factors for atherosclerosis and CAD. For example, increased oxidative stress and
hyperlipidaemia associated with T2D and metabolic syndrome lead to
endothelial damage and atheroma formation. It is therefore potentially the same
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chromosomal locus which has been associated with both CAD and T2D,
suggesting joint genetic and pathophysiological mechanisms. Nevertheless T2D
SNPs at chromosome 9p21 are different from those of CAD. The rsl0811661
SNP is located 10 kbp downstream of the haplotype reported as a CAD
susceptibility locus (Figure 2-6). Analysis of Hap Map data showed that
rs 10811661 and rs1333049 are located in different LD blocks (Figure 2-6). A
simultaneous test of CAD and diabetes susceptibility with CAD and T2D-
associated SNPs indicated that these associations were independent of each other
(Broadbent et al., 2008, Gori et al., 2010). Furthermore, none of the quantitative
traits of the metabolic syndrome have been associated with the CAD locus.
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2.2.5.4 Functional effects of the CAD risk variant ofCDKN2B-ASl
The association between the 9p21.3 locus and CAD and T2D risk is robust and
investigation of the molecular basis for a causal relationship is currently
ongoing. The high-risk CAD haplotype overlaps exons 12 to 20 of CDKN2B-
AS 1 that is expressed in many cell types known to be affected by atherosclerosis
(Gonzalez-Navarro et al., 2010).
Jarinova et al (2009) examined four conserved non-coding regions of
chromosome 9p21 for enhancer activity using a luciferase reporter gene. A
region termed CNS3 (chr9:222108881-22111116) showed an enhancer activity
compared to the other 3 regions within the 58kbp CAD locus. The CNS3
sequence cloned from a homozygous carrier of the C of rsl333045 (risk allele)
exhibited 73% higher enhancer activity compared to the same sequence cloned
from a reference homozygote in aortic smooth muscle cells. SNP rsl333045 was
in high linkage disequilibrium with rs1333049 (~0.86) that repeatedly
associated with CAD (Jarinova et al., 2009). This enhancer activity might affect
the expression of the CDKN2B-AS 1 gene itself or it might affect the expression
of other neighbouring genes, CDKN2AIB as well as distant genes (upstream and
downstream). Interestingly the SNP rs1333049 was the most significantly
associated SNP in relation to CAD in a 100 Kb susceptibility region identified in
the WTCCC (2007) study.
Deletion of the orthologous 70-kb non-coding interval on mouse chromosome 4
results in enhanced proliferation properties of vascular cells, increased tumour
incidence, and increased weight of the knock out mice (Visel et al., 2010).
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Being implicated in T2D and CAD, this locus on chromosome 9p21 would be of
interest for investigation in preeclampsia and FGR.
2.2.6 Potassium Inwardly-Rectifying Channel, Subfamily J, Member
11, KCNJl1
2.2.6.1 Introduction
Fifteen inwardly rectifying potassium (Kir) subunit genes have been identified
and classified into seven subfamilies (Kir1.x to Kir7.x). These subfamilies are
categorized into functional groups: 1) classical Kir channels (Kir2.x); 2) G-
protein-gated Kir channels (Kir3.x); 3) ATP-sensitive channels (Kir6.x), to
which KCNJ 11 belongs; and 4) K-transport channels (Kir1.x, Kir4.x, Kir5.x,
and Kir7.x). They share the basic Kir subunit, discussed later (reviewed in
(Hibino et al., 2010).
ATP-sensitive channels are proposed to link the cellular metabolism and
electrophysiology of the cell membrane. They are expressed in different tissues
throughout the body, including pancreatic alpha and beta cells, cardiacmyocytes,
vascular smooth muscles, skeletal muscles and in neurons. These channels are
responsible for regulating diverse processes including cellular excitability,
vascular tone, heart rate, and insulin release.
The KATP channel is formed of two different subunit types arranged as a hetero-
octamer: 4 Kir6.x subunits located at the centre (pore forming) and 4
sulfonylurea receptor subunits (SURx) located at the periphery, (Figure 2-7);
(Shyng and Nichols, 1997). Subunits cannot reach the cell membrane alone as
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they carry an endoplasmic reticulum retention signal, which needs to be masked
by the other subunits to guarantee that only fully functional KATP channels are
trafficked to the surface membrane. Different combinations of Kir6.x and SURx
in different tissues have been identified, based on both mRNA and protein
expression data. The KATP channel is formed of SURI +Kir6.2, SUR2A+Kir6.2,
SUR2B+Kir6.1, and SUR2B+Kir6.2 in pancreatic b-cells, cardiac muscle,
vascular smooth muscle, and non-vascular smooth muscle channels, respectively
(Olson and Terzic, 2010).
ATP is the main regulator of the KATP channel; it closes the channel and
maintains its activity in the presence of Mg+2. In pancreatic b-cells for example,
when serum glucose levels are high, abundant cellular ATP leads to closure of
the KATP channel. As a result K+ influx into the cell is diminished, and the cell
membrane undergoes depolarization. This is followed by opening of the Ca+2
channels with increase in cytoplasmic Ca+2and subsequent exocytosis of insulin
(Figure 2-7). KATP channels in b-cells regulate insulin secretion by linking the
metabolic state of the cell to membrane potential (reviewed in (Hibino et al.,
2010).
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Figure 2-7: Structure of KATP channel in the b-cell of the pancreas
The role of KATP channel in insulin secretion as well as the effect of sulfonylurea drugs,
adapted from (Gloyn et al., 2004), with permission.
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2.2.6.2 Genomic structure and polymorphism of the KCNJll
The KCNJ 11 (Kir6.2) gene is mapped to chromosome 11p. It is formed of one
exon encoding 390 AA. This gene is located approximately 4.5 Kb away from
the 3' end of the ABCC8 (SUR 1) gene. The ABCC8 gene encodes the second
structural part of the KATP channel, spans more than 84 kb of genomic DNA
and encodes a 1,582 amino acid protein from 39 exons. The entire KCNJ11 gene
and the 3' end of the ABCC8 gene are enclosed in single LD block. This LD
block harbours a group of highly correlated SNPs, some of which are coding
SNPs and designated as T2D risk variants (Figure 2-8).
124
L{)
..-
N
L{)
m
I./')
a::
('.l
cri ~
0.... N
Z :t:t
CJ) C.
0>
ro
.~
::2
"0 C.
0 ro
o I
Q) >.
....
.0ro
c
3=
m 0
0.... J::
Z m
CJ) ~
ro
"0Q) co
c. 0
~ 0
o CO
~ «
0> c
Cl)
Cl)
e
Cl)
C)
00
o
m
m
c:r: m
.s a::
"0 "0
Q) C
C ro
§ ~
C ..-
o -,(.)Z
~ 0
ro ~
Q) .~
~ ~
0> 0
CO l:::
o ro
o
CO
<
'I""
......
""')
Z
o
~
J:
'0
.Q
C
en
D..
Z
en
"eca
~
(J
o
:a
c
~
CO
I
N
e
:1
.~
LL
2.2.6.3 Role of KCNJll variants in type 2 diabetes
KCNJll was linked to the pathology of T2D based on three factors: the
association of rare inactivating mutations of the gene with hyperinsulinaemic
hypoglycaemia of infancy; the association of activating mutations with neonatal
diabetes (Gloyn et al., 2004, Meissner et al., 1999); and the successful use of
sulfonylureas which target the KATP channels in the treatment in T2D
(Mannhold, 2004).
Conflicting early reports about the association of KCNJll variants with T2D
were probably due to the small sample sizes. However, in a large UK study
including 850 T2D cases and 1200 controls, Gloyn et al (2003) demonstrated
that the K allele of E23K (rs5219) is a risk variant for T2D (OR 1.18, 95% Cl
1.04 -1.34, P= 0.01), (Gloyn et al., 2003). They also carried out a meta-analysis
including 5 earlier studies, and confirmed the association of this variant with
T2D (OR 1.23,95% Cl 1.12-1.36, P= 0.000015).
In a study of more than 3000 Scandinavians, Florez et al (2004) replicated the
association of E23K with type 2 diabetes (OR 1.17, 95% Cl 1.05-1.32, P=
0.003). The authors indicated that E23K along with S1369A (rs757110),
(~> 0.9) in a large LD block representing KCNJ11 and the 3' end of the ABCC8
gene, are the true signals for the association. Testing multiple haplotypes, using
15 tagging SNP in this LD block, gave no signals stronger than the E23K variant
for the association with T2D (Florez et al., 2004).
Replication in different populations including Korean (Koo et al., 2007),
Japanese (Doi et al., 2007) and Russian (Chistiakov et al., 2009) confirmed a true
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association. Two markers, rs5215 (I337V) and rs5219 (E23K), were associated
with T2D in GWAS for T2D (WTCCC., 2007).
Prospective studies were also carried out to test the role of this variant on the
conversion from normal glucose tolerance (NGT) to impaired glucose tolerance
(IGT) and T2D and also to assess the interaction of this variant with lifestyle
intervention and medication on the conversion to glucose intolerance. Laukkanen
et al (2004) was the first to test such a hypothesis using around 450 IGT Finnish
subjects with 3 years follow up. This study indicated that the E23K alone was
not associated with conversion from IGT to T2D (Laukkanen et al., 2004). When
combined with other variants from within the ABCC8 gene it increased the risk
of conversion to 6-fold in comparison to the 2-fold increase in risk conferred by
the ABCC8 genetic variants alone. A more recent study by Florez et al (2007)
which included 3500 subjects with IGT followed up for 3 years, reported that the
K allele of E23K was associated with a lower risk of developing T2D in the
placebo and in the life style intervention groups (Florez et al., 2007). These
findings suggested that the K allele might be associated with the earlier stage of
b-cell dysfunction (from normal glucose tolerance (NGT) to IGT) rather than the
deterioration of b-cell function leading to conversion from IGT to T2D. It is
possible that the use of lOT and obese subjects who carry a baseline genetic and
environmental risk of T2D might weaken or obscure the actual association of
conversion from lOT to T2D. This was not the case in the study carried out by
Lyssenko et al (2008) that included more than 15000 NOT subjects with 23 years
follow up in which the K allele was associated with increased risk of conversion
from both NGT and IGT to T2D (Lyssenko et al., 2008).
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Both in vivo and in vitro studies showed that the E23K SNP is functional, with
the K allele causing lower insulin secretion. Neilson et al (2003) reported that in
a group of 519 NOT individuals, the K allele was associated with lower insulin
secretion in response to OGTT testing (P =0.022, adjusted for BMI), (Nielsen et
al., 2003). Florez et al (2004) reported that a 20% -30% reduction in insulin
release was explained by genotype at E23K when tested in 500 NGT individuals
and 39 sibling pairs (Florez et al., 2004).
In agreement with in vivo studies, Schwanstecher et al (2002) were the first to
examine the mechanism by which E23K variants lead to reduced insulin
secretion. They suggested that the K allele, located at the transmembrane domain
of the subunit and not directly related to ATP binding of the receptor, was
associated with reduced ATP sensitivity of the Kir6.2/SURI channel complex.
This results in increased probability of an open KATP channel, and subsequent
suppression of insulin secretion (Schwanstecher et al., 2002). Moreover failure to
inhibit glucagon release by alpha cells after glucose stimulation was suggested as
an alternative mechanism by which this polymorphism leads to glucose
intolerance (Tschritter et al., 2002).
Although the E23K variant of KCNJIl is the strongest T2D candidate within the
LD block, which includes KCNJ 11 and the 3' end of ABCC8 gene, the impact of
the neighbouring ABCC8 gene cannot be ruled out, in particular the non-
synonymous Sl369A substitution. This polymorphic site is also reported to
reduce the KATP channel activity (Hamming et al., 2009).
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Because the KATP channel of the pancreatic b-cells is a target for sulfonylurea
drugs as a treatment for T2D, testing the effects of genetic variants encoding this
receptor on response to treatment was of interest. Sulfonylurea drugs interact
with SURl and KIR6.2 to inhibit K influx through the receptor leading to
membrane depolarization with subsequent opening of Ca+2 channels that
stimulate insulin secretion. An initial report by Glyon et al (2001) using a cohort
of 364 newly diagnosed diabetic UK patients did not find any significant
association of the E23K variant with the response to sulfonylurea therapy (Gloyn
et al., 2001). A second study by Sesti et al (2006) using 552 patients, indicated
that the K allele was more common in those who failed to respond to
sulfonylurea or a combination of sulfonylurea and metformin treatment than
those who responded to this treatment (OR 1.45, 95% Cl 1.01-2.09; P= 0.04)
(Sesti et al., 2006).
2.2.6.4 Role of KCNJll variants in pregnancy disorders
Because insulin is a growth regulator, Weedon et al (2003) tested the effect of
the E23K variant in relation to birth weight. They showed that the fetal genotype
at E23K was not associated with reduced birth weight in about 1000 UK subjects
and suggested that it does not affect insulin secretion in utero (Weedon et al.,
2003). In support of this Bennett et al (2008) showed the same lack of effect in a
large Finnish cohort of 5000 individuals (Bennett et al., 2008). On the other hand
this variant was reportedly associated with GDM (OR 1.17, 95% Cl 1.02-1.35;
p=0.027) in a large study of Scandinavian women (Shaat et al., 2005)and was
marginally associated in a small study of Danish women (OR 1.20, 95% Cl 0.99
-1.45, P= 0.07), (Lauenborg et al., 2009). Both of these studies are in line with
the notion that b-cell dysfunction is a key factor in the development of GDM.
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KCNJ11 is an important T2D candidate gene, and merits investigation in relation
to preeclampsia and FGR.
2.3 Aim of the study
1- To test the shared genetic basis between T2D and preeclampsia in white
Caucasian women from the UK by comparing genotype and allelic
frequencies of 11 SNPs in 5 T2D susceptibility genes in normotensive
pregnant women and in women with preeclampsia.
2- To investigate the effect of maternal genotype at these 11 loci in 5 T2D
susceptibility genes on the risk of having growth restricted pregnancies.
3- To determine whether genotype at these loci in women with healthy
pregnancy are associated with their own BMI and/or birth weight of their
babies, in Caucasian women from the UK.
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2.4 Methods
2.4.1 Patient recruitment
Our cases and controls were recruited from three different collections which are
described below. The numbers from each study are shown in (Figure 2-9).
Figure 2-9: Number and frequency of participant women from different
collections
VIP: Vitamins in preeclampsia, NottFGR: Nottingham FGR collection, NottPE:
Nottingham preeclampsia collection.
090,7%
VIP
• NottFGR
a NottPE
.205,16%
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2.4.1.1 Vitamins in Preeclampsia (VIP) trial
In this study the role of the antioxidant vitamins C and E in the prevention of
preeclampsia were investigated in a randomised controlled trial to which women
with known risk factors for preeclampsia from 25 UK hospitals in ten
geographical areas were recruited from 2003 to 2005 (Poston et al., 2006).
Women were eligible for recruitment for the VIP study if they were pregnant at
gestational age 12-20 weeks with one or more factors known to increase risk for
preeclampsia. They included preeclampsia in the pregnancy preceding the index
pregnancy requiring delivery before 37 weeks of gestation; a diagnosis of
HELLP syndrome and/or eclampsia in any previous pregnancy at any stage of
gestation; diastolic blood pressure of 90 mm Hg or more at or before 20 weeks
gestation in the current pregnancy; multiple pregnancy; and abnormal uterine
artery Doppler waveform. Women with the following systemic risk factors were
also eligible: hypertension requiring medication currently or previously; pre-
gestational diabetes requiring insulin or oral hypoglycaemic therapy; anti-
phospholipid syndrome; chronic renal disease; primiparity with BMI at the first
antenatal appointment of 30 kg/m" or more. Ethical approval from The South
East Multi Regional Research Ethics Committee and written informed consent
from the participants were obtained.
The results of the original study showed that preeclampsia and SGA, the primary
and secondary outcomes in this study, were unaffected by the use of 1000 mg
vitamin C and 400 IU vitamin E daily from the second trimester of pregnancy
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until delivery. 970 women representing 49% of the white western European
women from the VIP study were included in this genetic study (Figure 2-9).
From the VIP collection 343 and 574 women were included as preeclampsia
cases and controls respectively, of which 49 and 63 % were presented with one
of the above mentioned risk factors. 110 and 471 women were considered as
FGR cases and controls respectively, of which 56 and 53 % were presented with
one of the aforementioned risk factors. But when BMI > 30 (kg/m') in primiparous
women was considered as a risk factor 100% of the VIP particepants were
considered as women with risk factors. This methos of recruitment was the basic
and major difference between participants from the VIP study and the other 2
studies. Clinicopatholigical features are presented in Table 2-2.
2.4.1.2 Nottingham FGR collection
This collection comprised DNA samples from volunteers recruited between 2000
and 2002 from Nottingham City Hospital and the Queen's Medical Centre,
Nottingham after approval of the ethics committees of both hospitals. Written
consent was obtained from participants who were self identified as being of
white western European descent.
FGR cases were identified antenatally when ultrasound scan estimated the
abdominal circumference S 5th centile for gestational age using locally derived
charts, and confirmed postnatally by individualized birth weight centile S 5th
centile using GROW software (http://www.gestation.netlregister/growreg/
grow_reg. asp). Controls were chosen from women undergoing Caesarean
section, induction of labour for causes not related to fetal growth, or normal
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delivery, with babies' birth weight above the 10th centile and below the 96th• 205
participants from this collection were included in the present study (Figure 2-9).
All women were normotensive at booking, at less than 20 weeks gestation dated
by ultrasound scan, had no medical problems (other than pregnancy induced
hypertension), and had a structurally and chromosomally normal singleton
infant. Pregnancies complicated by infection, anaemia and drug use were
excluded. From the NottFOR collection 99 mothers were included as controls for
both the FOR and preeclampsia studies, 106 mothers were included as FGR
cases, of whom 15 also developed preeclampsia, as defined by the ISSHP.
Demographic and clinical data are presented in Table 2-2.
2.4.1.3 Nottingham preeclampsia collection
Ninety women (78 nulliparous) from the Nottingham preeclampsia collection
were included in this study (Figure 2-9). They comprised previously healthy
women with preeclampsia, recruited during pregnancy for genetic case control
studies between 1993 and 1996. Preeclampsia was defined as a diastolic blood
pressure exceeding 90 mmHg and a systolic blood pressure exceeding 140
mmHg in a previously normotensive woman, which returned to normal within
three months of delivery, and was associated with proteinuria in excess of
300mg IL in a 24 h collection or two pluses on testing a random sample with
Multistix (Bayer, Newbury, UK). Clinical and demographic data are presented in
Table 2-2
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Table 2·2: Clinical and demographic data for participants in preeclampsia
and FGR genetic case control studies stratified by collection
VIP: Vitamins in pregnancy, NottFGR: Nottingham FGR collection, NottPE: Nottingham
preeclampsia collection ... Data are presented as median (interquartile range) for continous data
and number and percentage for categorical data. In preeclampsia study, data on smoking habits
were available for 99 and 98 % of cases and controls of the VIP women and 93 % of
NottPEcollection. In FGR study, data on smoking habits were available for 98 and 97 % of cases
and controls of the VIP women and 93 % of the NottPE ..... 100% of the VIP participants carried at
least one risk factor if BMI> 30 (kg/m2) in primiparous women was considered as a risk factor.
I· Preeclampsia study
VIP NottFGR NottPE
Cases Controls Cases Controls Cases
N=343 N=574 N=15 N=99 N=90
Maternal age 32 (28-36) 31 (26-35) 25 (19-29) 29 (20-34) 28 (24-32)
Nulliparous 81(24) 402 (70) 13 (86) 56 (56) 78 (87)
BMI(kglm) 27 (24-33) 31 (24-35) 22 (20-26) 24 (22-27) 25 (23-28)
Smoking hablts=
Never smoker 189 (55) 291 (52) 6 (40) 74 (74) 70 (83)
Previous smoker 111 (33) 183(33) 3 (20) 11 (11) 2 (2.5)
Current smoker 39 !12l 86 !15l 6 !40l 14 !14l 12 !14l
Systolic blood 142 120 160 110 160
I!ressure ~mmHg~ {120-160~ {llO-130l !150-172l !101-12Ol !150-166l
Diastolic blood 95 70 101 65 100
I!ressure !mmHg} !91-106l !64-8Ol !98-104l !60-7Ol !97-106l
Gestational age at 268 273 224 273 259
delive!:I !dal:sl !258-275l !263-285l !189-238l !266-28Ol !238-273l
Fetal Weight (gm) 3140 3345 1095 3370 2545
!2550-358Ol !2940-376Ol !670-153Ol !3120-366Ol !1885-314Ol
Risk factors.· 167 (49) 359 (63)
II·FGR study
VIP NottFGR NottPE
Cases Controls Cases Controls Cases
N=ttO N=471 N=106 N=99 N=27
Maternal age 32 (28-36) 31 (26-35) 27 (21-30) 29 (20-34) 27 (24-32)
Nulliparous 50 (46) 343 (73) 65 (61) 56 (56) 18 (67)
BMI(kglm2) 29 (24-35) 32 (27-36) 23(21-25) 25 (22-27) 2S (21-28)
Smoking habits.
Never smoker 64 (59) 237 (52) 47 (45) 74 (74) 23 (92)
Previous smoker 29 (27) 150 (33) 10 (9) 11 (11) 1 (4)
Current smoker 15 !142 72 !15l 49 !46l 14 !14l q4l
Systolic blood 149 120 110 110 160
I!ressure !mmHgl !130-17Ol !110-13°l !104-124l !101-12Ol !155-171l
Diastolic blood 99 72 65 60 105
I!ressure !mmHgl !77-11Ol !68-8Ol !60-72l !60-7Ol !99-11Ol
Gestational age at 262 277 259 273 238
deliverl: {dal:sl !240-275l !268-286l !224-266l !266-28Ol !224-259l
Fetal Weight (gm) 2210 3356 2110 3370 1720
!1690-2565l P180-386Ol !1377-2472l P120-366Ol !1120-218Ol
Risk factors • • 62 (56) 251 (53)
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2.4.2 Preeclampsia and fetal growth restriction phenotype definition
From within the three collections a unifying definition of preeclampsia that
fulfils the ISSHP criteria was applied. Preeclampsia was defined as diastolic
blood pressure of;:::90 mm Hg and! or systolic blood pressure of:::140 mm Hg
measured twice at least 4 h and up to 7 days apart at or after the 20th week of
gestation, associated with proteinuria of :::300 mg protein over 24 hours or two
readings of 2+ or more on dipstick analysis of mid-stream urine. In women in the
VIP study with hypertension before pregnancy or before 20th weeks of gestation
the development of new proteinuria was required for the diagnosis of
preeclampsia. In women with pre-existing proteinuria diastolic blood pressure of
90 mm Hg or more occurring after 20 weeks of pregnancy was required for the
diagnosis of preeclampsia. HELLP syndrome and eclampsia were included as
cases only if they were hypertensive and proteinuric.
Fetal growth restriction (FGR) is defined as a singleton baby with birth weight
S5th centile using an individualized birth weight centile (correcting for maternal
height, weight, and parity, and fetal gestation and sex). Ninety nine (22.1%) of
preeclampsia cases were also FGR.
Controls for preeclampsia were lacking all of the above criteria in the current
pregnancy and did not suffer from preeclampsia, eclampsia, or HELLP in any
previous pregnancies. Controls for the FGR study were defined as a singleton
baby with birth weight :::10thand S90th centile using individualized birth weight
centile, excluding mothers with preeclampsia, eclampsia, or HELLP in the
current or previous pregnancy (s), data are presented in Table 2-2
represents how many cases and controls were included from the 3 collections.
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2.4.3 Power calculation
The preeclampsia study included 448 cases and 673 controls. The FGR study
included 243 mothers with pregnancies complicated by FGR and 570 controls.
For an average MAF of 0.3, this study had a power of 80% to detect a genotype
relative risk of 1.3 for preeclampsia and 1.4 for FGR at a P value of 0.05
assuming an additive model of inheritance. Detailed power calculations are
presented in (Table 2-3). Quanto software Vl.2.3 was used for this calculation
. (http://hydra.usc. edu/ gxe/) (Gauderman, 2002).
Table 2-3: Power calculations for case control studies
These calculations were based on a sample size of 673 controls and 448 cases for
preeclampsia and 570 controls and 243 cases for the FGR study. The calculation
assumed an additive model of inheritance, at a P value of 0.05. Percentage power is
shown outside brackets for preeclampsia, and inside brackets for FGR.
Allele Genotype relative risk
frequency 1.1 1.2 1.3 1.4 1.5 2
0.1 10 (8) 25 (18) 47 (33) 69 (50) 85 (67) 99.9 (99)
0.2 14 (11) 40 (28) 70 (52) 89 (77) 97(88) 99.9 (99)
0.3 17 (12) 49 (34) 80 (61) 95 (82) 99 (93) 99.9 (99)
2.4.4 DNA extraction
DNA extraction from VIP samples was carried out using the Wizard® Genomic
DNA Purification Kit from Promega according to the manufacturer's protocol
(www.promega.com). Wizard® Genomic DNA Purification is based on a four-
step process. The process starts with a cell lysis which ruptures red and white
blood cells using Cell Lysis Solution. The second step is lysis of the nuclei of the
white blood cells using the Nuclei Lysis Solution. This is followed by salt
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precipitation of the proteins and cell debris in the Protein Precipitation Solution.
The supernatant is then treated with isopropanol to precipitate DNA, followed by
a further washing step using 70% ethanol. DNA is then suspended in the
rehydration solution provided with the kit. The concentration was measured by
absorbance at 280 nm using a Nanodrop instrument (ND-IOOOV3.7.1; Nanodrop
1000 spectrophotometer; Thermo Scientific). The average yield from a 4-5 ml
blood sample was 150 J.lgof high quality DNA which was stored at -70°C.
Archived DNA from the FOR collection was previously extracted from
leukocytes using the QIAamp blood maxi kit (Qiagen, Crawley, UK;
www.qiagen.com). Stored DNA from the Nottingham preeclampsia collection
was previously extracted from peripheral leucocytes using Nucleon II extraction
kits (Scotlab, UK).
2.4.5 Genotyping
Genotyping was carried out by Kbiosciences using their in house developed
technology, Kbiosciences Competitive Allele Specific PCR (KASPr), described
in detail below. DNA samples were plated as 50J.lI of 20ng/J.lI for each well in
deep v-shaped bottom 96 well plates, sealed and sent on dry ice for genotyping.
Samples sent for genotyping by Kbiosciences included 970 samples from the
VIP study, 205 maternal samples from the Nottingham FOR collection, 90
samples from the Nottingham preeclampsia collection of DNA. 78 samples were
chosen at random and included as duplicates. Two no template controls (NTC)
per 96 well plate, comprising PCR grade water were also included. For quality
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control purposes, 2 SNPs were also genotyped in a subset of the samples in
Nottingham laboratory using mutagenically separated PCR (MS-PCR).
2.4.5.1 The Kbioscience Competitive Allele Specific PCR (KASPr)
The KBioscience Competitive Allele ~ecific fCR genotyping system (KASPar)
is a fluorescent-based genotyping technology (Figure 2-10).
The KASPr genotyping system comprises two components:
(1) The SNP specific assay consists of two allele specific forward primers, each
with a unique unlabelled tail sequence at the 5' end, and one common (reverse)
pnmer.
(2) The universal Reaction Mix, which contains specially developed Taq
polymerase, two 5' fluorescently labelled oligonucleotides; one labelled with
FAM and one with CAL Fluor Orange 560 one specific for each allele, two
oligonucleotides with quenchers bound at the 3' ends. These oligonucleotides
sequences are complementary to each other and to sequences of the tails of the
allele specific primers. ROX is also included in the reaction mixture to be used
as a reference dye that allows data to be normalised for the variation in the liquid
volume and plate reader.
In the early stages of PCR, the quenched oligonucleotides bind their
fluorescently labelled complementary oligonucleotides and all fluorescent
signals are quenched. In the later stages of PCR, the fluorescently labelled
oligonucleotide, corresponding to the amplified allele also gets incorporated into
the template, and hence the fluorescence is no longer quenched. The generated
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fluorescent signal can be detected by a FRET (Fluoresence resonance energy
transfer) reader (http://www.kbioscience.co.uk/reagents/KASP.html). If the
genotype at a given SNP is homozygous, only one or other of the possible
fluorescent signals will be generated. If the individual is heterozygous, the result
will be a mixed fluorescent signal.
Figure 2-10: KASPar genotyping technology
Early stages of peR, showing the DNA template (black), one of the forward allele
specific primers with its unique unlabelled tail (green) and the common reverse primer
(yellow). The FAM labelled oligo (red) binds its complementary quencher oligo (Blue)
early during the peR reaction. B) Late in the peR reaction the allele specific forward
primer with non labelled tail, after being incorporated into the peR product, binds to the
FAM labelled oligo and gives rise to fluorescent energy.
A
B
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The data can be viewed graphically by software (KlusterKaller) in which the
FAM and Cal Fluor 560 data are plotted on the x and y axes, respectively. Data
were supplied by KBioscience as a spread sheet with the genotype already
specified, which were double checked on receipt using the SNPviewer
(http://www.kbiosciences.co.ukldownload/snpviewer) according to sample
clusters (Figure 2-11). An average of 4 samples per plate was re-called as a result
of this manual checking procedure.
Figure 2-11: SNPviewer of samples genotyped for SNP rs1333049
The left hand panel shows one of the plates in which all samples were successfully
genotyped. The right hand panel shows 2 ambiguous samples; sample (a) was
heterozygous GC for SNP rs1333049, as it was close to the heterozygous cluster,
sample (b) could not be re-called as it was close to the NTC samples.
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2.4.5.2 Mutagenically separated PCR (MS.PCR)
Ms-peR is a single step peR based genotyping method, which relies on the
instability of the primer when annealing with the DNA template if there is a
mismatch at the 3'terminal base. To increase the specificity of primer annealing
another mismatch is created at the third base from the 3'end of the primer (Rust
et al., 1993).
There are 2 methods of primer design for MS-PCR, the three-primer and four-
primer methods. The three primer method was used for genotyping the TeF7L2-
rs7903146, e>T polymorphism. By using allele specific primers of different
length, two peR products of differing size can be generated in the same reaction.
This difference in length is achieved by the use of a non specific tail at the 5'end
of one primer (Figure 2-12). The four-primer method was used for genotyping of
the PPAR-y rs18012182, C>G polymorphism. In the four-primer method, the
primer locations were selected to ensure that the peR products generated by the
2 allele specific primers and the 2 external primers are of differing size (Figure
2-13). The PCR products can be viewed on agarose gel directly without the need
for further manipulation.
The sequence of the primers used for genotyping of SNPs rs7903146 and
rs 18012182 are presented in
• Each primer set was designed using Primer3 software
(http://www.primer3plus.comlcgi-binldev/primer3plus.cgi).
• The specificity of each primer pair was tested using both the blast function
embedded in primer 3 (http://www.ncbLnlm.nih.gov/toolslprimer-blastl) and
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the blat function in the UCSC genome browser (http://genome.ucsc.edu/cgi-
binlhgBlat?command=start).
• Specific software was used to test whether primers were located over other
polymorphic sites which could interfere with primer annealing using
diagnostic SNPcheck from Manchester (https:llngrl.manchester.ac.uk/SNPCheck
V2/snpcheck.htm).
• All primers were supplied by Eurogentec S.A., Belgium.
• Primers were kept at a stock concentration of 1OO~.mol/J.1I,and working
aliquots of 10J.1mol/J.11were prepared to avoid contamination.
Table 2-4: Primers used for MS-peR
Two SNPs were genotyped using MS-PCR. A three-primer method was used for
genotyping TCF7L2 rs7903146 and four-primer method for genotyping PPAR-y
rs18012182. The SNPs and the third base at the 3'end mismatch of the primer are
shown in bold. The non specific tail at the 5'end the T allele primer is underlined.
Primer Sequence
TCF7L2 rs7903146 (C>T)
Common forward primer 5' -AAAGGGAGAAAGCAGGATTG-3'
C allele reverse primer 5' -GCCTCATACGGCAATT AAATTATCAG-3'
T allele reverse primer 5' -CACT AAGGACGCAA TGA TTGTGCCTCATA
CGGCAATT AAATI ATGAA-3'
PPAR-y rs18012182(C>G)
Common forward primer 5' - GTACAGITCACGCCCCTCAC-3'
Common reverse primer 5' -TGCIT AGCTCGTTGCT ATCG-3'
C allele specific reverse primer 5'-GTGAAGGAATCGCTTICAGG-3'
G allele specific forward primer 5'-TGGGAGATTCTCCTAITGTCG-3'
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Figure 2·12: MS-peR, three-primer method
Three-primer MS-PCR applied to the CIT polymorphism at rs7903146 (in red bold)
using a common forward primer (black arrow) and 2 allele specific reverse primers. The
terminal 3' base is allele specific, and the 3rd base at the 3' end (underlined) is
mismatched to increase the specificity of annealing. To discriminate between PCR
products a 20 bp tail of scrambled sequence is added at the 5' end of the T allele
reverse primer (red arrow), so that the C allele will yield PCR product of 212 bp, while
the T allele will yield peR product of 232 bp.
5'---------- TTA----------
3'AA~
3'
(common forward primer)
3' ----.5'
5'---------- CTA------------------3
3' GAC +---- 5'
3'----+ 5'
5'
(20 bp scrambled sequence)
232 bp T allele peR fragment
212 bp e allele peR fragment
144
Figure 2-13: MS-peR, four-primer method
Four-primer MS-PCR applied to the C/G of polymorphism rs12812182 (in red bold)
using a forward (black arrow) and reverse primers (green arrow) and 2 allele specific
primers, a C allele specific reverse primer (red arrow) and a G allele specific forward
primer (blue arrow). The terminal 3' base is allele specific, and further mismatch is
introduced at the 3rd base at the 3' end (underlined) to improve the specificity of
annealing. The primer locations were selected to ensure that the PCR products
generated by the 2 allele specific primers and the external primers are of different sizes.
(common forward primer)
5'----------ACCCA---------3'
3'GGA 5'
(C allele specific reverse primer) (common reverse primer)
5'----------------------------ACGCA
_---....:rCG
-------3'
3'5'
(G allele specific forward primer) (common reverse primer)
574 bp common peR fragment
396 bp e allele peR fragment
218 bp G allele peR fragment
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2.4.5.3 peR reaction and condition
PCR reactions were optimized for annealing temperature and pnmer
concentration. The final PCR reagent concentrations and reaction conditions are
shown in Table 2-5 and Table 2-6.
Table 2-5: MS-peR reaction for SNP rs7903146, and rs18012182
SNP rs79023146 SNP rs18012182
IX PCR buffer (750 mM Ix Paq5000®Hotstart PCR master
Buffer
Tris-HCI, 200 mM mix(optimized PCR buffer,
(~)2S04' 0.1% (v/v) dNTPs, Mg ci, DNA
Tween20) polymerase)
dNTPs 200 JlM ImM
MgClz l.SmM 2.2SmM
Other additives Ix Q-solution S%DMSO
DNA polymerase 2U Taq polymerase
Paq5000®Hotstart DNA
polymerase
DNA 200 ng genomic DNA 200 ng genomic DNA
Forward primer(s) 1 IlMTCF-F
0.5 IlM common forward primer
0.5 IlM G allele forward primer
Reverse primers
1 JlM TCF-C primer 0.5 JlM common reverse primer
0.3 IlM TCF-T primer 0.25 IlM C allele reverse primer
peR grade water To 30111total volume To 30lll total volume
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Table 2·6: peR and electrophoresis conditions for SNP rs7903146 and
rs1801282
SNP rs79023146 SNP rs12812182
rcn conditions
Initial denaturation 94°C 15min
Number of cycles 35
Denaturation 94°C/40s
Annealing 61°C /Imin
Extension noc /Imin
Final extension step nOC/lOmin
30
nOC/lOmin.
Thermal cycler
MJ Research PTC 225 Thermal Veriti™ 96-Well thermal
Cycler, GMI Inc, USA cycler/Applied Biosystems
Electrophoresis conditions
Agarose gel
3.5% in IxTAE with 5J1l 1% in IxTAE with 5J1lof
ethidium bromide ethidium bromide
Electrophoresis 60V/45min 80V/25min
SizeofPCR 212bp for c allele
574 bp common PCR fragment
product 232bp for T allele
396bp for C allele
218bp for G allele
2.4.5.4 Gel electrophoresis
MS-PCR products were resolved by electrophoresis on agarose gel (Eurogentec)
prepared in lxTAE (Tris acetate EDTA) buffer and stained with ethidium
bromide 5J.lV25 ml. The 1xTAE was diluted from a 50xTAE stock solution
(242gTris base, 57.1 ml glacial acetic acid, 100 ml O.5M EDTA
(Ethylenediaminetetraacetic acid) pHS.O) per litre). lOll1 of PCR product were
mixed with 2J.llof 6x DNA loading dye (Fermentas). A 100 bp DNA ladder was
used as a size marker (Fermentas, Gene Ruler™). An image of the gel was
captured on a UV transilluminator (AlphaDigiDoc™).
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2.4.5.5 DNA sequencing
PCR products were cleaned using ExoSAP-IT®, which contains shrimp alkaline
phosphatase to remove un-used dNTPs and an exonuclease to digest the primers
that can interfere with the sequencing reaction. 2J.11ExoSAP were added to sJ.11of
the PCR reaction and incubated at 37°C for 15 min. ExoSAP was inactivated by
heating to 80°C for 15 min.
The sequencing reaction was carried out in a lOfll reaction in which 3fll of
cleaned PCR product was mixed with 2.SX Big Dye 3.1 reaction mix (containing
the fluorescent labelled ddNTPs and polymerase enzyme) Sx big dye terminator
buffer (Applied Biosystems), and Spmol of the common forward primer. Cycling
conditions were as follows, 96°C for 1 min followed by 25 cycles of 96°C for
30 seconds, 50°C for ISs, and 60°C for 4 min for the SNP rs7903146. The
cycling condition for SNP rs1801282 was 1 min at 97°C, followed by 25 cycles
of lOs at 96°C, 5s at 50°C and 4 min at 60°C. The difference in the cycling
conditions was related to the use of different PCR blocks. The samples were then
held at 10°C until collection.
Samples were centrifuged at 5000 rpm for 3 min through PERFORMA® Spin
Columns (Edge Biosystems).The eluent containing the DNA was then
transferred into 0.5 ml tubes and dehydrated on a heat block at 90°C. Prior to
sequencing on an AB! 3130 genetic analyzer (Applied Biosystems), the samples
were treated with 20J.11template suppression reagent, denatured at 95°C degrees
for 2 min, chilled on ice, then loaded for capillary electrophoresis. Sequencing
results were viewed by Chromas Lite V2.01 (http://www.technelysium.com.aul
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chromas_lite.html), and sequence alignment was carried out by ClustalW web
based software (http:/www.ebLac.ukITools/clustalw2/index.html).
2.4.6 Genotyping quality control
.
Several procedures were put in place to ensure that the genotyping was carried
out correctly.
2.4.6.1 Quality control for Kbioscience genotyping
• 5% of the samples were included as inter and intra plate duplicates.
• Two NTC samples per plate were included.
• Case and control samples were randomly dispensed into the plates.
• Any plate or any SNP with <90% call rate was repeated.
• Allele frequency and concordance with Hardy Weinberg equilibrium (HWE)
were calculated for each SNP on individual plates by Kbiosciences.
• Each plate was checked on the SNPviewer to assure accurate calling of the
genotype. Itwas possible using this strategy to call an additional 4 samples in
some plates (Figure 2-11).
• 200 and 300 samples for SNP rs7903146 and rs1801282 respectively were
genotyped in house by MS-PCR and checked for concordance with the
Kbiosciences results.
2.4.6.2 Quality control for in house genotyping
• A DNA-free negative control was included in each PCR run to detect
contamination of the reagents.
• Heterozygous samples confirmed by DNA sequencing, were included in each
peR run as positive controls.
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• Genotypes were assigned by two independent investigators, who were
blinded to which samples were cases and which were controls. Samples
assigned discordant genotypes were re-genotyped,
• 6 and 13 samples for rs7903146 and rsl801282 respectively representing all
three genotypes were selected for sequencing as a quality assurance measure.
• The whole sample set and the controls were tested for Hardy Weinberg
equilibrium (HWE) using the web based Hardy Weinberg equilibrium
calculator (http://www.oege.org/sofiware /hwe-mr-calc.shtml),
2.4.7 Statistical analysis
Genotype frequency and genotype relative risk were analyzed using an additive
model of inheritance after scoring the genotypes as 1, 2, 3 for major allele
homozygous, heterozygous, and minor allele homozygous respectively, using
binary logistic regression (SPSS version 16). The UNPHASED program was
used for the analysis of allelic OR and haplotype analysis. This program uses the
maximum likelihood ratio in a log linear model for the analysis of allelic and
haplotype effects. SPSS was used for phenotypic and quantitative analysis. A P
value of ~ 0.01 was selected as the threshold for statistical significance, after
adjusting for testing multiple hypotheses. Bonferroni correction to adjust for
each of the SNPs tested in the 2 conditions studied (preeclampsia and FGR) was
considered over conservative due to lack of independence between SNPs and the
claimed relationship between preeclampsia and FGR.
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2.5 Results
2.5.1 Quality control and population genetics results
The genotype call rate for the loci investigated was> 98%, (Table 2-7). Within
the Kbiosciences genotyped samples, duplicates were 100% concordant.
Initially, 15 (7.5%) and 6 (2%) of the samples genotyped by MS-peR for SNPs
rs7903146 (Figure 2-14) and rs1801282 (Figure 2-15) respectively, were not
concordant with the Kbiosciences mainly due to poor visibility on the agarose
gel, as illustrated in figure 2-14, lanes A and E. These samples were subjected to
regenotyping and sequencing (Figure 2-16). Two and one samples for SNPs
rs7903146 and rs 1801282 respectively, remained discordant and were excluded
from the study.
Figure 2-14: Electophoresis banding pattern for SNP rs7903146
MS-PCR for rs79023146 C>T polymorphism. S, C and D are homozygous CC
heterozygous CT, and homozygous TT samples respectively. A and E are samples that
were difficult to recall. F is a sequenced heterozygous sample used as a positive
control, showing the T allele at 232-bp and the C allele at 212-bp. G is a DNA free
negative control.
300bp
232bp
212bp
200bp
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Figure 2-15: Electrophoresis banding pattern for SNP rs1801282
MS-PCR for rs1801282 C>G polymorphism. A, B, and C are homozygous CC,
heterozygous CG and homozygous GG samples respectively. D is a sequenced
heterozygous sample used as a positive control showing the 574bp common PCR
product, 396bp C allele product and the 218bp G allele product. E is a DNA free
negative control.
200bp
574bp
396bp
21Sbp
574bp
Figure 2-16: Electropherogram showing CC and TT genotypes for SNP
rs7903146
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The observed genotype frequencies of the polymorphisms investigated were in
agreement with HWE within individual plates, in the control group and within
the whole sample set (P >0.05). The MAF for the loci investigated were similar
to that reported in the Hap Map project for the European population, and with
that recorded in OWAS studies (Table 2-7).
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Table 2-7: Minor allele frequency and quality control data for study
variants
Chr = Chromosomal location based on Hap Map release#24. * Major allele confers risk
for T2D. MAF: minor allele frequency ** Hardy Weinberg Equilibrium calculated for the
entire sample.
Gene SNP Location Majorl MAF Success Hardy
Minor rate Weinberg**
allele (%) (Pvalue)
TCF7L2 rs7903146 chrl0: 114748339 CIT 0.29 98.0 0.06
rs7924080 chrl0:114777002 TIC 0.47 98.6 0.45
rs12255372 chr10:114798892 Grr 0.29 99.5 0.18
FTO rs17817449 chr16:52370868 TIG 0.41 98.6 0.65
PPAR-7 rs1801282 chr3:12368125 C/G· 0.12 98.6 0.22
rs3856806 chr3: 12450557 CIT· 0.13 98.8 0.51
rsl0865710 chr3: 12328198 CIG 0.24 98.8 0.64
CDKN2B- rs10811661 chr9:22 I24094 TIC· 0.17 98.6 0.05
AS1 rs1333049 chr9:22115503 GIC 0.49 99.0 0.51
KCNJ11 rs5215 chr11: 17365206 TIC 0.35 98.4 0.32
rs5219 chrl1:17366148 crr 0.35 98.2 0.27
2.5.2 Preeclampsia cases and controls: Phenotypic Data
Tables 2-8 and 2-9 present details of phenotypic data for the preeclampsia case
control study. There were no significant differences in the maternal age between
preeclampsia cases and controls. Women with preeclampsia had significantly
lower BMI (Table 2-8), reflecting the inclusion of obesity as a risk factor for
preeclampsia in the VIP study. By definition systolic and diastolic blood
pressure measures were higher in preeclampsia cases compared to controls
(Table 2-8). Unsurprisingly, preeclampticwomen delivered at earlier gestational
ages and gave birth to babies with lower birth weight compared to controls
(Table 2-8).
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Table 2-8: Phenotypic data for preeclampsia and healthy pregnancy
IQR = interquartile range. P values were calculated using the Mann Whitney U test as
the data were not normally distributed.
Controls (N=673) Preeclampsia (N=448) P
value
Median IQR Median IQR
Maternal age (years) 31 26-35 32 27-35 0.46
BMI(kglm2) 30 24-35 28 24-32 <0.001
Maximum systolic blood 120 110-130 147 120-162 <0.001
~ressure !mmHg!
Maximum diastolic 70 60-80 98 72-106 <0.001
blood ~ressure !mmllg!
Gestational age at 273 265-283 266 252-275 <0.001
delive!l !dals!
Fetal Weight (gm) 3350 2989-3730 3040 2299-3540 <0.001
Birth weight centile 47 25-77 38 5-73 <0.001
More primiparous women were present in the preeclampsia group compared to
controls, with primiparity conferring risk for preeclampsia (OR = 2.15, 95%CI =
1.60-2.87, P<O.OOl). Data on smoking habits was available for 659 (98%)
controls and 433 (97%) preeclampsia cases. Preeclamptic mothers were more
likely to be non-smokers and less likely to be previous or current smokers,
although this was not statistically significant. The proportion of offspring of each
sex did not differ between cases and controls (Table 2-9).
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Table 2-9: Parity, smoking habit and baby's sex in preeclampsia and
healthy pregnancy
P values were calculated using Chi-squared test. * Data on smoking habits was
available for 659 (98%) controls and 433 (97%) preeclampsia cases, ** fetal sex
included for singleton pregnancies only.
Controls Preeclampsia
N(%) N(%)
Parity Primiparous 459 (68.2) 368 (82.1)
SmOking habit* Never smoker 365 (55.4) 260 (60.0)
Stoppedsmoking 194 (29.4) 116 (26.8)
Current smoker 100 (15.2) 57 (13.2)
Baby's sex** Male 336 (52.7) 227 (51.7)
Female 301 (47.3) 212 (48.3)
P value
<0.001
0.306
0.737
343 preeclampsia cases and 574 controls were volunteers with risk factors for
preeclampsia, recruited to the VIP study. Within this subgroup the rate of
chronic hypertension, diabetes, abnormal uterine artery Doppler, chronic renal
disease and anti-phospholipid syndrome were similar in cases and controls and
similar to the original VIP study. However, the rate of multiple pregnancies and
women with BMI >30 in the first pregnancy were higher in the original VIP trial
and in controls compared to preeclampsia cases. The distribution of risk factors
in preeclampsia cases, controls, and in the original VIP trial is presented in Table
2-10. 240 women with a history of preeclampsia in the pregnancy preceding the
VIP pregnancy were considered cases for the purpose of the genetic study (Table
2-10).
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Table 2-10: Frequency of risk factors in preeclampsia and control groups
recruited from the VIP collection
Data are presented as Number (%). P values were calculated using the Chi-squared
test for the comparison between cases and controls. Previous Preeclampsia. HELLP or
eclampsia were considered as cases for the purpose of genetic studies.
Risk factor VIP study Genetic stud~ P
N=1988 Controls Preeclampsia value
N=574 N=343
Previous Preeclampsia, 548 (23) 240 (70.0) <0.001
IIELLP or eclaml!sia
Chronic hypertension 869 (36) 185 (32) 128 (37) 0.12
Diabetes 199 (8) 56 (10) 23 (7) 0.11
Abnormal uterine artery 80 (3) 10 (2) 7 (2) 0.75
DOl!I!Ier
Multiple pregnancy 503 (16) 103 (18) 21 (6) <0.001
Chronic renal disease 47 (2) 7 (1) 8 (2) 0.20
Anti-phospholipid 52 (2) 12 (2) 8 (2) 0.80
s~ndrome
BMI > 30(kglmz) in 804 (33) 274 (48) 40 (12) <0.001
I!rimil!arous women
Multiple risk factors 503 (21) 71 (12) 114 (33) <0.001
43 women had preeclampsia in both the pregnancy preceding and during the VIP
study implying a 17.9% recurrence rate. Amongst women with chronic
hypertension, 128 ,\0.6%) women developed preeclampsia. Preeclampsia
developed in 23 (29.1%) and 8 (53.3%) diabetic women and in women with
chronic renal failure respectively. Seven (41.8%) and 8 (40.0%) women with
abnormal uterine Doppler and antiphospholipid syndrome respectively
developed preeclampsia. The rate of preeclampsia in women with risk factors in
this study and in the original VIP study is reported in Table 2-11.
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Table 2·11: Rate of preeclampsia in women with risk factors recruited from
the VIP collection
VIP study recruited 1988 white western European women, from which 917 were
included in the preeclampsia case control genetic study. Data are presented as Number
(%).
VIP study Preeclampsia
N(%) genetic study
N%
Previous Preeclampsia, HELLP or eclampsia 124 (23) 43(18)
Chronic hypertension 192 (23) 128 (41)
Diabetes 34 (16) 23 (29)
Abnormal uterine artery Doppler 16 (25) 7 (42)
Multiple pregnancy 41 (11) 21 (17)
Chronic renal disease 15 (32) 8 (53)
Anti-phospholipid syndrome 6 (23) 8 (40)
BMI > 30(kg/m2) in primiparous women 87 (12) 40 (13)
Multiple risk factors 127 (26) 114 (33)
2.5.3 Preeclampsia case control genetic association study
The G allele of the marker rs 17817449 on the FTO gene was found to be
potentially protective against preeclampsia (OR 0.84,95% Cl 0.71-1.00, P value
0.05) an effect which was abolished after adjustment for parity, BMI, smoking
habit and risk factors including chronic hypertension, diabetic status, chronic
renal disease, abnormal uterine artery Doppler, and multiple pregnancy (OR
0.89,95% Cl 0.74-1.09, P value 0.27), (Table 2-12).
There were no differences in the genotype, allele or haplotype frequencies
between the preeclampsia and control groups in TCF7L2, PPAR-,)" CDKN2B·
AS 1 or KCNJl1 variants. The 95% Cl for the unadjusted and adjusted OR all
span 1 and P value was>0.05 (Table 2-12 and Table 2-13).
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Table 2·12: Genotype and allele distributions of T2D alleles and
corresponding odds ratios for preeclampsia
Genotype OR was calculated using binary logistic regression, using SPSS v.16. *
adjusted for parity, smoking habit, BMI and the risk factors including chronic
hypertension, diabetic status, chronic renal disease, abnormal uterine artery Doppler,
and multiple pregnancies. ** when the genotype frequency was < 5% the heterozygotes
and the rare homozygotes were pooled for analysis. Allelic OR was calculated using
UNPHASED software release 3.1.5.
Genotype Genotype Unadjusted
SNP Controls Cases unadjusted adjusted allelic ORGene rs number N=673 N=448 OR OR· (95% Cl)Genotype (95%CI) (95%CI) P value
P value P value
rs7903146
CC 53.2 50.2 1.05 1.08 1.05CT 37.3 41.0 (0.88-1.27) (0.88-1.31) (0.87-1.27)TT 9.5 8.8
T 28.3 29.3 0.58
·0.44 0.60
rs7924080
TCF7L2 TT 30.8 28.3 1.01 1.04 1.01TC 47.6 51.8 (0.85-1.20) (0.87-1.25) (0.85-1.20)CC 21.6 19.9
C 45.4 45.8 0.89 0.68
0.88
rs12255372
GG 51.0 54.3 0.87 0.89 0.87
GT 39.1 37.8 (0.72-1.05) (0.73-1.091 (0.72-1.05)
TT 9.9 7.9 0.157 0.27 0.14
T 29.3 26.4
rs17817449
TT 30.6 34.5 0.84 0.89 0.84
FTO TG 49.1 48.7 (0.71-1.00) (0.74-1.09) (0.71-1.00)
GG 20.3 16.8 0.05 0.27 0.05
G 43.7 39.6
rs1801282
CC 78.2 79.0 1.15 1.17 1.11
CG 20.4 19.3 (0.87-1.53) (0.86-1.59) (0.86-1.43)
GG"'''' 1.4 1.7 0.33 0.30 0.44
G 13.1 12.0
PPAR-y rs3856806
CC 75.8 77.8 1.09 1.14 1.12
CT 23.2 19.7 (0.82-1.44) (0.8451.54) (0.87-1.43)
TT"'''' 1.1 2.5 0.555 0.38 0.39
T 12.7 14.0
rs10865710
CC 57.8 57.3 1.05 0.965 1.06
CG 37.6 36.4 (0.83-1.34) (0.743-1.25) (0.87-1.28)
GG 4.6 6.3 0.67 0.79 0.58
G 24.2 25.2
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Genotype Genotype Unadjusted
SNP unadjusted adjusted
Gene rs number Controls Cases OR OR·
allelic OR
Genotype N=673 N=448 (95%CI) (95%CI) (95% Cl)
P value P value P value
rsl0811661
IT 70.8 64.6 1.16 1.12 1.08
TC 25.4 30.8 (0.89-1.50) (0.84-1.50) (0.86-1.36)
CC·· 3.7 4.6 0.28 0.45 0.52
CDKN2 C 16.1 17.2
B-ASI RS1333049
GG 26.1 30.1 0.92 0.912 0.92
GC 48.6 47.3 (0.77-1.08) (0.76-1.10) (0.77-1.08)
CC 25.4 22.6 0.30 0.32 0.29
C 50.4 48.1
Rs5215 1.08IT 42.9 42.3 1.09 1.10 (0.91-1.29)
TC 44.3 43.6 (0.81-1.29) (0.91-1.33)
CC 12.8 14.1 0.36 0.32
0.38
KCNJll C 35.2 37.07
Rs5219
CC 42.9 41.8 1.09 1.10 1.09
CT 44.1 44.4 (0.91-1.29) (0.91-1.33) (0.91-1.29)
IT 13.0 13.8 0.34 0.31 0.36
T 35.2 37.1
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Table 2-13: Haplotype frequency for T20 susceptibility genes in
preeclampsiacases and controls
Haplotype with frequency <5% were pooled as rare haplotypes, P values were
calculated using likelihood ratio Chi-squared for the common haplotypes only.
UNPHASEDV3.1.5 was used for this analysis.
TCF7L2
C T 0
Cases Controls
0.52 0.52
0.17 0.17
0.24 0.23
0.07 0.08
0.99
Rs7903146 (Crr) Rs7924080 (TIC) Rs12255372 (OIT)
C C 0
T C T
Rare haplotypes
P value
PPAR-y
C C o
Cases Controls
0.71 0.73
0.11 0.11
0.09 0.08
0.09 0.08
0.77
Rs1801282 (C/O) Rs3856806 (CIT) RsI0856710 (C/O)
C C C
G T G
Rare haplotypes
P value
CD KN2B-AS I
T C
Cases Controls
0.42 0.42
0.41 0.42
0.09 0.09
0.08 0.07
0.63
RsI0811661 (TIC) RsI333049(G/C)
T G
C o
C C
P value
KCNJll
Rs5215
(TIC)
Rs5219
(Crr)
Cases Controls
T C 0.63 0.65
C T 0.37 0.35
Rare haplotypes 0.012 0.015
P value 0.39
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2.5.4 Fetal growth restriction (FGR) phenotypic data
There were no significant differences between FGR cases and controls regarding
maternal age. Mothers with FGR cases had lower BMI, (Table 2-14). Maternal
BMI was positively correlated with birth weight in FGR cases (r = 0.15) and
controls (r= 0.19), P<O.OOI.Systolic and diastolic blood pressure measures were
higher in FGR cases compared to controls (Table 2-14). FOR mothers were
delivered at earlier gestational ages. By definition birth weight and birth weight
centile were lower in FGR cases compared to controls (Table 2-14).
There was no variation in the frequency of primiparity in FOR cases and
controls. Data on smoking habits was available for 540 (95%) of the controls
and 239 (98%) of the FOR cases. Smoking was associated with a higher risk of
FGR (OR=1.2, 95% Cl 0.99-1.45, P=0.05). Male and female babies were equally
distributed in FGR cases and controls. Female babies were lighter than male
babies by about 140 gm (P=O.OOl) in FOR controls but did not differ within the
FOR cases. These data are summarized in Table 2-15.
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Table2·14: Phenotypic data for FGRand healthy pregnancy
lOR = interquartile range. P values were calculated using the Mann Whitney U test as
the data were not normally distributed.
Controls (N=570) FGR(N=243) P value
Median IQR Median IQR
Maternal age (years) 30 26-34 30 24 -34 0.11
BMI(kg/m2) 31 25-35 25 22-30 <0.001
Maximum systolic blood 120 110-130 124 110-160 <0.001
pressure (mm Hg)
Maximum diastolic blood 70 64-80 74 60-104 0.001
pressure (mm IIg)
Gestational age at delivery 275.5 267-285 259 231-273 <0.001
(days)
Fetal WT (gm) 3430.0 3176- 2145 1432.5- <0.001
3803 2492
Birth weight centile 52 28-80 1 0-2 <0.001
Table 2·15: Parity. smoking habit and baby's sex in FGR and healthy
pregnancy
P values were calculated using Chi-squared test. • Data on smoking habits was
available for 540 (95%) of the controls and 239 (98%) of the FGR cases.
Controls FGR
N(%) N(%)
Parity Primiparous 399 (70.0) 163 (67.l)
Smoking habit* Never smoker 311 (55.7) 134 (56.1)
Stopped smoking 161 (28.9) 40 (16.7)
Current smoker 68 (15.4) 65 (27.2)
Fetal sex Male 310 (54.4) 121 (49.8)
Female 259 (45.4) 122 (50.2)
P value
0.41
<0.001
0.38
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110 FOR cases and 471 controls were volunteers with risk factors for
preeclampsia, recruited to the VIP study. Within the subgroup used in our study
the rates of previous preeclampsia, HELLP syndrome, and eclampsia, and
chronic renal disease were higher in FOR cases than controls. Predictably, the
proportion of women with BMI >30 in the first pregnancy was higher in controls
compared to FOR cases. The frequency of chronic hypertension, diabetes, anti-
phospholipid syndrome and abnormal uterine artery Doppler were similar in
FOR cases and control. Distributions of risk factors in preeclampsia cases,
controls, and in the original VIP trial are presented in Table 2·16.
Table 2·16: Frequency of risk factors in FGR and control groups recruited
from VIP collection
Data are presented as Number (%). P values were calculated using the Chi-squared
test for the comparison between cases and controls. Previous Preeclampsia, HELLP or
eclampsia were excluded from the control group.
VIP study Controls FGR P value
N=t988 N==471 N=ttO
Previous Preeclampsia, 548 (23) 0 36 (32) <0.001
lIELLP or eclam(!sia
Chronic hypertension 869 (36) 178 (38) 50 (45) 0.14
Diabetes 199 (8) 54 (12) 9 (8) 0.32
Abnormal uterine artery 80 (3) 10 (2) 5 (4) 0.15
DO};!l!ler
Chronic renal disease 47 (2) 7 (2) 7 (6) 0.003
Anti.phospholipid syndrome 52 (2) 12 (3) 3 (2) 0.92
BMI > 30 (kg/mz) in 804 (33) 267 (58) 36 (32) < 0.001
erimi};!arous women
Multiple risk factors 503 (21) 57 (12) 32 (29) < 0.001
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32 women who had preeclampsia in the pregnancy preceding the VIP study
developed FGR during the course of the VIP trial. Within the chronically
hypertensive women, 50 (22.0%) developed FGR. FOR developed in 9 (14%)
and 7 (50%) diabetic women and in women with chronic renal disease
respectively. 5 (33%) and 3 (20.0%) women with abnormal uterine Doppler and
women with antiphospholipid syndrome respectively had pregnancies
complicated by FOR. The rate of FOR in women with risk factors in this study
and in the original VIP study is reported in Table 2-17.
Table 2·17: Rate of FGR in women with risk factors within the VIP
collection
Data are presented as Number (%).
VIP study FGR
N ~0/o) N~%)
Previous Preeclampsia, HELLP or eclampsia 124 (23) 36 (33)
Chronic hypertension 192 (23) 50 (22)
Diabetes 34 (35) 9 (14)
Abnormal uterine artery Doppler 16 (25) 5 (33)
Chronic renal disease IS (32) 7 (50)
Anti-phospholipid syndrome 6 (23) 3 (20)
BMI >30(kg/m2) in primiparous women 87 (12) 36 (12)
Multiple risk factors 127 (26) 32 (29)
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2.5.5 Fetal growth restriction (FGR) case control genetic association
study
The C allele of rs10811661 of the CDKN2B-ASI gene showed suggestive
association with FGR (OR=1.33, 95% Cl 0.97-1.84, P=0.08), (Table 2-18). This
effect was lessened after adjustment for smoking habit and risk factors including
chronic hypertension, diabetic status, chronic renal disease, abnormal uterine
artery Doppler, (OR=1.26, 95% Cl 0.91-1.75, P=O.l7), (Table 2-18), (note that
adjustment for parity, BMI and fetal sex is included in the calculation of birth
weight centile). SNP rsl333049 alone showed no effect on FGR risk (OR=0.88,
95%CI (O.71-1.08),P=0.22), (Table 2-18). The CG haplotype of the CDKN2B-
AS1 gene formed of the diabetes protective allele of SNP rs10811661 and the
coronary artery disease protective allele ofSNP rsl333049 was associatedwith a
higher risk for FGR (P 0.005), (Table 2-19). When compared with the TG
haplotype (formed of the major alleles), the CG haplotype had an OR of 1.98,
(95% Cl 1.33-2.95, P=0.0008). The observed haplotype effect suggests
interaction between the 2 loci under investigation as the 2 variants of the
CDKN2B-AS1gene lie in different LD blocks (r = 0.0003), (Figure 2-6).
Variants of TCF7L2, FTO, PPAR-y, and KCNJIl showed no association of
genotype, allele or haplotype frequencies with FGR before or after adjustment
for possible confounding factors (Table 2-18 and Table 2-19)
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Table 2·18: Genotype and allele distributions of T2D alleles and
corresponding odds ratios for fetal growth restriction (FGR)
Genotype OR was calculated using binary logistic regression (SPSS v.16). * Adjusted
smoking habit, and risk factors including chronic hypertension, diabetic status, chronic
renal disease, and abnormal uterine artery Doppler. ** When the genotype frequency
was < 5% heterozygotes and rare homozygotes were pooled for analysis. Allelic OR
was calculated using UNPHASED release 3.1.5.
SNPrs
number
Genotype
Controls
N=570
FGR
cases
N=243
Genotype
unadjusted
OR
(95%CI)
Pvalue
Genotype
adjusted
OR*
(95%CI)
P value
Unadjusted
allelic OR
(95% Cl)
P value
rs7903146
CC
CT
TT
T
53.1
37.3
9.6
28.2
51.3
41.0
7.7
28.3
0.99
(0.79-1.26)
0.98
0.99 0.99
(0.79-1.27) (0.79-1.27)
0.99 0.98
rs7924080
TT
TCF7L2 TC
CC
C
30.8
47.6
21.6
45.2
23.5
54.6
21.8
49.7
1.16
(0.94-1.44)
0.17
1.15 1.17
(0.93-1.43) (0.94-1.44)
0.21 0.16
rs12255372
GG
GT
TT
T
51.0
39.2
9.9
29.5
54.4
37.8
7.9
26.8
0.88
(0.69-1.11 )
0.29
0.88 0.88
(0.69-1.11) (0.69-1.11)
0.28 0.27
FTO
rs17817449
TT
TG
GG
G
30.6
49.1
20.3
43.9
34.5
48.7
16.8
41.1
0.86
(0.69-1.07)
0.18
0.85 ().89
(0.68-1.06) (0.73-1.09)
0.15 0.25
PPAR-y
rs1801282
CC
CG
GG··
G
78.2
20.4
1.4
11.8
79.0
19.3
1.7
11.3
0.89
(0.62-1.23)
0.53
0.95
(0.65-1.39)
0.80
0.97
(0.69-
1.361
0.87
rs3856806
CC
CT
TT··
T
75.8
23.2
1.1
12.7
77.8
19.7
2.5
12.3
0.89
(0.62-1.23)
0.53
0.89
(0.62-1.29)
0.54
0.97
(0.70 -
1.34)
0.86
rsl0865710
CC
CG
GG··
G
57.8
37.6
4.6
24.5
57.3
36.4
6.3
23.4
1.02
(0.75-1.39)
0.90
0.89
(0.62-1.29)
0.54
1.06
(0.83-1.36)
0.64
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Genotype Genotype UnadjustedSNPrs Controls FGR unadjusted adjusted allelic OR
number N=570 cases OR OR* (95% Cl)Genotype N=243 (95%CI) (95%CI)
P value P value P value
rsl0811661
IT 70.8 64.6 1.33 1.26 1.27
TC 25.4 30.8 (0.97-1.84) (0.91-1.75) (0.97-1.67)
CC 3.7 4.6 0.08 0.17 0.09
CDKN2B- C 16.5 20.0
ASI rs1333049
GG 26.1 30.1 0.87 0.86 0.87GC 48.6 47.3 (0.71-1.08) (0.69-1.07) (0.70-1.08)CC 25.4 22.6 0.17 0.21
C 49.7 46.3 0.22
rs5215
IT 42.9 42.3 1.04 1.07 1.04
TC 44.3 43.6 (0.84-1.30) (0.85-1.33) (0.84-1.30)
CC 12.8 14.1 0.72 0.58 0.71
KCNJll C 34.9 35.9
rs5219
CC 42.9 41.8 1.04 1.06 1.04CT 44.1 44.4 (0.83-1.29) (0.85-1.32) (0.83-130)IT 13.0 13.8 0.61 0.73
T 35.1 36.0 0.40
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Table 2·19: Haplotype frequency of type 2 diabetes genes in FGR cases
and control
Haplotype with frequency <5% were pooled as rare haplotypes, P value was using
likelihood ratio Chi-square for common haplotypes only. UNPHASED V3.1.S was used
for this analysis.
TCF7L2
rs7903146 (CIT) rs7924080 (TIC) rs12255372 (GIT) Cases Controls
C T G 0.50 0.52
C C G 0.21 0.17
T C T 0.25 0.24
Rare haplotypes 0.04 0.07
Pvalue 0.35
PPAR-y
rsl801282 (C/G) rs3856806 (CIT) rs10856710(C/G) Cases Controls
C C C 0.73 0.73
C C G 0.11 0.11
G T G 0.09 0.08
Rare haplotypes 0.07 0.08
P value 0.99
CDKN2B-ASl
rs10811661 (TIC) rs1333049 (G/C) Cases Controls
T G 0.39 0.42
T C 0.41 0.41
C G 0.15 0.08
C C 0.05 0.08
P value 0.005
KCNJll
rs5215 (TIC) Rs5219 (CIT) Cases Controls
T C 0.64 0.65
C T 0.36 0.35
Rare haplotypes 0.02 0.09
P value 0.70
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2.5.6 The effect of T2D variants on maternal BMI and fetal birth
weight
The G allele of the FTO SNP rsI7817449 was associated with obesity defined by
BMI>30Kglm2 (OR=1.43 95% Cl (1.15 - 1.78), P=O.OOI) in the control group.
Linear regression analysis showed that the G allele of the rsI7817449 was
significantly associated with maternal BM! regarded as a continuous variable in
the control group (Beta= 1.15, 95% Cl 0.46 - 1.87, P=O.OO1). The diabetes risk
alleles of the markers rs5215 and 5219 in the KCN] 11 gene were associated with
lower BMI (P= 0.05 and 0.03 respectively). None of the other loci were
associated with BMI. None of the loci tested were associated with baby's birth
weight in the control group (Table 2-20).
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Table 2-20: Effect of genetic variants on maternal body mass index and
baby's birth weight in control groups
Data represent mean (SO) of the trait investigated. The regression coefficient beta,
(95% Cl), and P values from linear regression are shown. * Adjustment for age, parity,
and smoking habits does not alter the findings for maternal BMI, and adjustment for
smoking habits did not alter the findings for birth weight (data not shown).
Gene SNP rs number Maternal BMI* Fetal birth weight*
Genotype (kg/m2) (g)
TCF7L2 rs7903146
CC 29.7 (6.9) 3455 (618)
CT 30.0 (7.1) 3467 (562)
TT 30.0 (6.1) 3473 (637)
Beta (95%CI) 0.20 (- 0.59 to 0.1) 10.07 (- 65.04 to 85.18)
P value 0.61 0.79
rs7924080
TT 29.9 (6.9) 3467 (590)
TC 29.8 (6.8) 3454 (619)
CC 30.2 (7.0) 3476 (572)
Beta (95%CI) 0.23 (- 0.47to 0.93) 2.89 (- 66.44 to 72.18)
P value 0.52 0.94
rs12255372
GG 29.8 (7.0) 3435 (627)
GT 30.0 (7.0) 3498 (541)
TT 30.2 (6.2) 3443 (653)
Beta (95%CI) 0.22 (- 0.56 to 1.0) 25.23 (- 49.02 to 99.62)
P value 0.57 0.5t
FTO rs17817449
TT 28.8 (7.0) 3445 (614)
TG 30.1 (6.7) 3447 (588)
GG 31.1 (7.0) 3499 (592)
Beta (95%CI) 1.15 (0.45 to 1.86) 24.48 (- 45.76 to 94.72)
P value O.OOt 0.86
PPAR-y rs1801282
CC 29.8 (6.7) 3453 (593)
CG 30.3 (7.4) 3484 (623)
GG 29.3 (8.3) 3513 (362)
Beta (95%CI) 0.27 (- 0.86 to 1.39) 30.07 (-78.57 to 138.71)
P value 0.65 0.58
rs3856806
CC 30.0 (6.8) 3457 (597)
CT 29.7 (7.1) 3495 (595)
TT 29.0 (8.4) 3112 (637)
Beta (95%CI) - 0.32 (- 1.46 to 0.82) 1.04 (- 106.76 to 108.84)
P value 0.58 0.98
rsl0865710
CC 30.0 (6.7) 3455 (585)
CG 30.0 (7.2) 3479 (625)
GG 27.4( 5.4) 3442 (449)
Beta (95%CI) - 0.62 (- 1.48 to 0.25) 4.47 (- 72.83 to 95.78
Pvalue 0.t6 0.78
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Gene SNP rs number Maternal BMI* Fetal birth weight*
Genotype (kg/m') (g)
CDKN2B- rsl0S11661
ASI IT 29.9 (7.0) 3463 (595)
TC 29.7 (6.6) 3434 (625)
CC 30.9 (6.8) 3569 (438)
Beta (95%CI) 0.09 (- 0.19 to 0.20) - 1.91 (- 89.33 to 85.52)
P value 0.85 0.96
RS1333049
GG 30.2 (7.2) 3418 (602)
GC 29.8 (6.S) 3483 (578)
CC 29.9 (6.8) 3463 (626)
Beta (95%CI) 0.10(- 0.59 to - 0.805) 22.66 (- 46.22 to 91.55)
P value 0.77 0.52
KCNJll rs521S
IT 30.5 (7.0) 3477 (562)
TC 29.6 (7.0) 3424 (629)
CC 28.8 (6.2) 3519 (588)
Beta (95%CI) - 0.75 (-1.5 to - 0.01) 0.12 (- 72.22 to 72.45)
P value 0.05 0.99
Rs5219
CC 30.5 (7.0) 3481 (563)
CT 29.6 (7.0) 3427 (636)
IT 28.9 (6.2) 3520 (584)
Beta (95%CI)
- 0.86 (- 1.62 to - 0.09) - 1.29 (- 73.92 to 71.35)
P value 0.03 0.98
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2.6 Discussion
2.6.1 Type 2 diabetes genes in preeclampsia case control study
It is widely reported that diabetic women are at increased risk of preeclampsia
(Rosenberg et al., 2005), and also that women with a history of preeclampsia are
at a higher risk for developing diabetes (Lykke et al., 2009, Libby, 2007) and
coronary artery disease (Ray et al., 2005, Lykke et al., 2009) later in life. This
led to the term "metabolic syndrome of pregnancy" being applied to
preeclampsia. A large body of evidence is currently available indicating a
genetic basis for preeclampsia, diabetes and CAD.
Variants in TCF7L2, FTO, PPAR-y, CDKN2B-ASl, and KCNJ11 genes were
reproducibly associated with T2D in candidate gene studies and GWAS in
Caucasian and other ethnic groups, marking these genes as authentic
susceptibility genes for T2D. While variants of FTO and PPAR-y genes confer
risk for T2D by altering insulin sensitivity in the peripheral tissues, mainly
adipose tissue (Honka et al., 2009, Do et al., 2008), variants of TCF7L2,
CDKN2B-AS! and KCNJ!1 are considered to confer risk for T2D via changes
in pancreatic beta cell function, mainly insulin secretion (Lyssenko et al., 2007,
Schwanstecher et al., 2002). These genetic variants are also associated with
metabolic changes which precede overt T2D such as hyperglycaemia and
hyperinsulinaemia and markers of metabolic syndrome like dyslipidaemia.
Indeed, variants of PPAR-y, FTO, and CDKN2B-AS1 genes have been
associatedwith CAD, and atherosclerosis (McPherson et al., 2007, Samani et al.,
2007, Doney et al., 2009, Ridker et al., 2003).
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Using 11 SNPs in 5 confirmed T2D genes (Table 2-7), this study has tested the
hypothesis of shared genetic origins between preeclampsia and diabetes in a case
control study. The association was tested in a collection of women who were at
higher risk for preeclampsia (Table 2-10). By including women with diabetes,
hypertension and obesity which are known risk factors for preeclampsia, the
study does not exclude genetic factors related to these disorders which might be
shared with preeclampsia. This is in contrast with previous investigations of
women with no medical or obstetric risk factors, which may select against those
with susceptibility genes shared by preeclampsia and related medical conditions.
In the present study, there was no evidence for any association between these
T2D genetic variants and preeclampsia (Table 2-12). To the best of our
knowledge, this is the largest study, in terms of sample size and number of
variants, to assess the role of common variants in genes predisposing for T2D
and their putative role in preeclampsia. This is also the first study to investigate
variants ofTCF7L2, FTO, and KCNJ11 in relation to preeclampsia.
Similar to the findings of this study, a Finnish group found no association
between PPAR-y Prol2Ala (rsI801282) and preeclampsia in a small study of
133 cases and 115 controls (Laasanen et aI., 2002). A lack of association
between the Ala (G allele) variant of SNP rs1801282 of the PPAR-y and
preeclampsia was also reported in a recent study by a German group
(Wiedemann et aI., 2010). In both of these studies the power to detect a genetic
effect was limited by both the sample size and the low MAF of the variant
investigated. Although this study has 85% power to detect an OR of 1.5 at P
value <0.05 for this specific variant with MAF 0.12, power to detect OR as low
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as 1.2 and 1.1 (the effect size reported for T2D for this specific variant) is limited
(50% and 25%, respectively). The results of this study suggest that the Ala allele
(0 allele of SNP rs1801282), the diabetes protective marker that is reportedly
associated with higher insulin sensitivity and low BMI, is a risk allele for
preeclampsia (OR 1.15, 95% Cl 0.87-1.53) although this was not significant
(Table 2-12). Interestingly in the Finnish study the Ala allele was associated with
early age at delivery and was more common in severe than milder forms of
preeclampsia (Laasanen et al., 2002).
Polymorphisms in the promoter of the PPAR-y (C-681G; rsl0856710) and in
exon 6 of the gene (CI431T; rs3856806) have been associated with higher body
weight and plasma LDL concentrations respectively (Doney et al., 2002,
Meirhaeghe et al., 2005). The effect of the Ala allele on obesity was found to be
altered by these 2 variants which are in LD with it. A haplotype formed of the 3
polymorphisms was associated with the metabolic syndrome (Meirhaeghe et al.,
2005). However haplotype analysis in the present investigation revealed no
association with preeclampsia, or obesity (Tables 2-13 and 2-20).
PPAR-y is a ligand-activated transcription factor playing an important role in
adipocyte differentiation and glucose homeostasis. PPAR-y also has anti-
inflammatory effects through reducing the production of pro-inflammatory
cytokines after forming complexes with Nf-KB. PPAR-y agonists increase the
size of LDL particles and decrease the number of atherogenic small dense LDL
particles. It is also reported that it has a blood pressure lowering effect probably
through an inhibitory effect on thromboxane A2 and the RAS system (Sugawara
et al., 2010). PPAR-y also exhibited anti-inflammatory on human gestational
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tissues as both natural (15dPGJ2) and synthetic ligands (troglitazone) were
shown to significantly decrease lipopolysaccharide stimulated secretion of
proinfiammatory cytokines from gestational tissues (Lappas et al., 2002).
In vitro studies have shown that the PPAR-y Ala12 allele of SNP rs1801282
decreases PPAR-y transactivation of reporter genes and the -681 G allele of SNP
rsl0856710 is associated with lower PPAR-y promoter activity (Meirhaeghe et
al., 2003) suggesting that carriers of these alleles might have a lower PPAR-y -
mediated activation of target genes than non carriers. So it is biologically
feasible that the Ala allele may confer risk for preeclampsia through these
functional effects, and larger studies will be needed to exclude a small effect
size.
The CDKN2B-AS 1 gene encodes long non-coding RNA with no specific
function attributed to it. It is suggested that polymorphisms in this region are
implicated in many diseases through altering the expression of CDKN2B-AS 1
and the nearby genes such as CDKN2A1AB, tumour suppressor genes and cell
cycle regulators (Cunnington et al., 2010). CDKN2B-ASI in the region on
chromosome 9p21 harbours 2 SNPs in 2 adjacent LD blocks (Figure 2-6). The
first is associated with T2D (rsl0811661) and the second (rs1333049) is
associated with CAD, with no overlap in the risk conferred by either of the SNPs
towards T2D and CAD (Broadbent et al., 2008, Gori et al., 201 0). In the current
study no association was detected between either of the 2 SNPs and
preeclampsia (Table 2-12 and Table 2-13). This region on chromosome 9p13-21
was linked to preeclampsia in a Finnish family study (Laivuori et al., 2003) In a
recent case control study, extensive investigation of this region testing 23 SNPs
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including the two tested in the present study, showed two markers (rs7044859
and rs496892) to confer risk for preeclampsia in Finnish women (Peterson et al,
submitted for publication). A subset of samples used in the present study and an
Australian family study did not reproduce these finding. The number of UK
samples was small, but an almost 2 fold increase in sample size in the present
study failed to confirm the findings from the Finnish women. It is possible that
this was a spurious finding, or that the causal variant in this region has a pattern
of LD with the markers investigated which differs in UK and Finnish
populations, and consequently was not tagged by the 2 markers used in the
present study.
Surprisingly, the G allele of marker rs 17817449 of the FTO gene, the allele that
was reportedly associated with higher BMI, T2D, CAD, and hypertension and
their intermediate metabolic measures exhibited a borderline protective effect
against preeclampsia (OR 0.84, 95% Cl 0.708-1.0, P=0.05), (Table 2-12). This
variant (or variants in LD with it) not only increases T2D risk but also increases
inflammatory mediators like CRP and is associated with an atherogenic lipid
profile (Doney et al., 2009), all of which are related to the pathogenesis of
preeclampsia. FTO gene expression was correlated with the expression of
hypoxia inducible factor-la (HIF-la) in adipose tissue, and with high-mobility
group protein B1 (HMGB 1), a cytokine mediator of inflammation (Lappalainen
et al., 2010) both of these pathways have a pivotal role in preeclampsia.
However this apparent protective effect is spurious and confounded by the
higher BMI in controls than in preeclampsia cases as evidenced by elimination
of this effect after adjusting for BMI (OR 0.89, 95% Cl 0.74-1.09, P=0.27),
(Table 2-12). In agreement with previous studies the G allele was associated with
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obesity, defined by BMI>30Kglm2 (OR=1.15, 95% Cl 0.46 - 1.87, P=O.OOI)and
BMI (beta =1.43; 95% Cl 1.15-1.78, P=O.OOI),(Table 2-20).
No association could be detected between preeclampsia and variants in the
TCF7L2 or KCNJ11 genes (Table 2-12). Risk conferred by these 2 genes for
T2D is primarily related to beta cell function, reduced insulin secretion and
processing, while insulin resistance, hyperglycaemia and hyperinsulinaemia are
the pathological feature of preeclampsia.
The lack of association between T2D genetic variants and preeclampsia may be
due to inadequate power to detect small genetic effect sizes below 10%, and
replication is required in larger studies to narrow down the 95% Cl. No attempt
was made to capture all variation in each gene, as the selected SNPs were those
shown to alter T2D risk. The possibility remains that other genetic variants
carried on these genes can affect the risk of preeclampsia. Each of these genes
has pleiotropic functions that might be tissue or organ specific so that variants
that confer risk for T2D may have a different effect on the risk of preeclampsia.
It is also possible that preeclampsia and diabetes do not share the same genetic
risk factors, and that the bidirectional risk between them is mainly due to shared
biochemical and pathological changes. It is worth noting that the study pooled 3
cohorts, VIP, NottFGR and NottPE. In the later 2 collections, both cases and
controls were recruited from otherwise healthy women with no known risk factor
for preeclampsia or FGR. By contrast, in the VIP study recruitment was from
women with known medical and/or obstetric risk factors for preeclampsia. In
addition to this difference between the cohorts due to risk factor enrichment in
the VIP study, maternal age and BMI were higher while frequency of nulliparity
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was lower in VIP study. So by pooling these 3 collections of women elements of
phenotypic heterogeneity have been introduced, which may reflect underlying
genetic heterogeneity. This would weaken the power of the study if genetic and
pathophysiological determinants of preeclampsia differ between women with
and without high risk factors. However the detection of markers of endothelial
dysfunction early in pregnancy in women who subsequently develop pre-
eclampsia casts doubt on the two stage hypothesis of pre-eclampsia (defective
placentation followed by endothelial dysfunction). Moreover, this study was
based on the hypothesis that preeclampsia and the cardio-metabolic diseases are
parts of a continuum of disorders with possible shared genetic risk factors for
both conditions. Pooling of the 3 cohorts is therefore justifiable, and meets the
aim of the present study to discover shared genetic risk factors between T2D and
preeclampsia. Indeed, attempts to analyze samples from VIP collection
separately yielded the same findings. No attempt was made to analyze the other
2 groups as even if pooled together the sample size is insufficient for an
adequately powered study.
In conclusion, none of the 11 loci on TCF7L2, FTO, PPAR-y, KCNJll, or
CDKN2B-AS1 genes showed variations in the frequency between preeclampsia
cases and controls, and therefore the hypothesis that the bidirectional risk
between T2D and preeclampsia is of genetic origin was not confirmed.
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2.6.2 Type 2 diabetes genes in FGR case control study
Many studies have investigated the effect of fetal genotype at T2D loci on birth
weight in an attempt to provide support for the fetal insulin hypothesis, advanced
as an explanation for the interaction between low birth weight and T2D in adult
life. This hypothesis states that the genetic variants that lead to T2D in adult life
due to reduced insulin secretion and/or increased insulin resistance will lead to
low birth weight (Frayling and Hattersley, 2001) as insulin is a major regulator
of fetal growth, and fetal insulin levels are positively correlated with birth weight
(Verhaeghe et al., 1993). Previous studies have indicated that mothers who give
birth to small sized babies developed insulin resistance and / or T2D later in their
lives (Hypponen et al., 2003, Lawlor et al., 2002). These findings imply that
those mothers, potential carriers of T2D diabetes risk alleles, were at risk of
having growth restricted pregnancy. As 50% of fetal genes are maternally
inherited, we investigated the effect of maternal genotype at T2D susceptibility
loci on the risk of having a growth restricted pregnancy.
There was a marginal association between the C (diabetes protective) allele of
the rslOS11661 of the CDKN2B-ASI gene and the risk for FGR (OR = 1.33,
95% Cl 0.97-1.S4, P =0 .OS) that was abolished after adjusting for the risk
factors and smoking habit (OR = 1.26,95% Cl 0.91-1.75, P=0.17), (Table 2-18).
Haplotype analysis using the 210ci in this region showed that the haplotype (CG)
formed of the diabetes protective allele and CAD protective allele was more
common in FGR cases than controls (14.7% vsS.6%, P=0.005), (Table 2-19).
Mothers who carried the ca haplotype were at double the risk of having a
growth restricted pregnancy (OR 1.9S, 95% Cl 1.33- 2.95, P = 0.0008) compared
to mothers who carried the TG haplotype (the reference haplotype formed of the
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two major alleles). As the variant rs1333049 alone showed no alteration in the
risk of FOR it seems that interaction between the two loci (C allele of the
rsl0811661 and the 0 allele ofrs1333049) lies behind this association.
Jarinova et al (2009) showed that the C allele of the SNP rs1333045 (in
complete LD with rs1333049) had an enhancer effect on the expression of
luciferase in a reporter gene construct and was associated with a 2 fold increase
in the expression of the CDKN2B-AS1 in primary aortic smooth muscle cells
(Jarinova et al., 2009). In this study, CDKN2B-ASI expression was correlated
with CDKN2B gene expression. It has been suggested that variants on
chromosome 9p2l affect the expression of CDKN2B-ASI and CDKN2N2B
genes (Burd et al., 2010, Cunnington et al., 2010). Reduced expressions of
CDKN2N2B, which are tumour suppressor genes and cell cycle regulator genes,
have been implicated in atherosclerosis and apoptosis (Jarinova et al., 2009).
This is the first study to investigate the CDKN2B-AS1T2D variants and the risk
of FOR. Animal studies indicated that deletion of the CDKN2B-AS1 locus in
mice was associated with higher birth weight in offspring (Visel et al., 2010);
these studies suggest a putative role for CDKN2B-AS1 in growth regulation.
Interestingly, neither of the 2 variants in the CDKN2B-AS1 gene was associated
with birth weight in the control group (Table 2-20). These findings are in line
with many previous studies (Freathy et al., 2009, Freathyet al., 2010, Andersson
et al., 2010) and contradict a single study that indicated high birth weight in
relation to fetal genotype of the diabetes risk allele of rs10811661 (Pulizzi et al.,
2009). The authors did not report on the maternal genotype or glycaemic status.
180
The suggestion that this locus of the CDKN2B-ASI gene is a potential candidate
for FGR but is not related to birth weight in healthy pregnancies may reflect
differences in the genetic factors governing variations in birth weight and those
determining growth restriction. FGR should not simply be regarded as the lowest
extreme of birth weight; it is the result of aberrant pathophysiological
mechanisms in pregnancy, and possibly an altered genetic architecture .. Many
healthy babies are small at birth simply because they are constitutionally small;
others show features of growth restriction even though their birth weight lies
within the normal range. It is for this reason that defining FGR pregnancy is
challenging. Haplotype analysis with birth weight as a quantitative trait may be
considered although it carries some statistical limitations. The difficulty is that
haplotypes are not observed; instead, they are inferred. Case control studies rely
mainly on estimated haplotype proportions among cases and controls, without
clear haplotype assignment for individuals (Balding, 2006). When analysing
quantitative traits it is necessary to assign haplotypes to individuals, which
cannot be done unequivocally in those who are heterozygous at more than one
SNP. For this reason, single locus analysis is more powerful than haplotype
analysis for a quantitative trait such as birth weight, even when the locus is not
causative but is in LD with the causal locus (Schaid, 2004).
There was no evidence for an association between the maternal T2D risk alleles
in the TCF7L2 gene and FGR (Table 2-18 and Table 2-19) or birth weight
(Table 2-20) in healthy pregnancies. This study is the first to investigate maternal
T2D risk alleles in FGR. Previous studies reported no association between fetal
genotype at TCF7L2 rs7903146 and smallness for gestational age (Cauchi et aI.,
2007b, Mook-Kanamori et aI., 2009). Similarly, the study by Cauchi et at
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(2007b) reported no effect of maternal or fetal genotype at the TCF7L2
rs7903146 locus on birth weight (Cauchi et al., 2007b). In contrast, a large study
by Freathy et al, (2007) found that each maternal T2D T allele at this locus was
associated with a 40g increase in birth weight (Freathy et al., 2007).
There was also no association between maternal genotype at FTO, PPAR-y, and
KCNJll variants and FGR, or birth weight in the control group (Table 2-18 to 2-
20). Previous well powered studies of fetal genotype have not detected any
association between T2D risk alleles of PPAR-y, KCNJ1I, or FTO genes
(Bennett et al., 2008, Mei et al., 2010, Kilpelainen et al., 2011).
The reported lack of association between with many T2D variants and FGR can
be related to many factors. First is the sample size. The sample size used in this
study had limited power to detect small effects in the range of 10-20% (Table
2-3). A sample size of 1000 cases and 2000 controls is required to detect a 20%
change in the risk of FGR at 80% power, P =0.05, for variants with MAF of 0.2.
Second is that maternal genotypes at T2D risk alleles might be expected to have
similar effects on the risk of fetal growth restriction as fetal genotypes, but only
if it were possible to test them independently of their metabolic effects on the
mother. The impact of these loci on maternal glycaemic control makes it difficult
to separate the influence of genes transferred from mother to offspring from that
of the maternal environment, and could result in apparently opposing effects of
maternal and fetal genotype. Consequently, it cannot be excluded that, when the
risk allele is present in both the mother and the baby, small effects could be
masked. Previous studies have shown that maternal genotype modulated the
effect of fetal genotype on birth weight. An important example is variants of the
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GSK gene (Weedon et aI., 2005, Freathy et aI., 2007) and TCF7L2 (Freathy et
aI., 2007). Lastly we pooled 3 collections of women, the NottFGR cases were
very tightly defined; NottmPE FGR cases almost certainly had growth restricted
pregnancies, on the basis that PE and FGR share similar placental mechanisms;
VIP FGR cases, unless they had PE during the VIP pregnancy, are SGA, and
only a minority of these will have FGR. This might create phenotypic
heterogeneity that reduces the statistical power of the study and hampers the
effort to detect and association.
In summary, this study suggested a region on chromosome 9p21, at the
CDKN2B-AS1 gene locus, as a potential risk locus for FGR, which merits
further investigation. There was no evidence for any association of the T2D risk
alleles of TCF7L2, FTO, PPAR-y, or KCNJ11 with fetal growth restriction.
183
3 Role of epidermal growth factor genetic variants in
preeclampsia and fetal growth restriction
3.1 Introduction
Epidermal growth factor (EGF) is an autocrine/paracrine modulator of cell
growth, differentiation, and function in many tissues of mammalian species
(Fisher and Lakshmanan, 1990). It was first discovered in the mouse
submaxillary gland, and later in human, where it was initially named urogastrone
(Bell et al., 1986).
EGF is secreted as a membrane bound protein (prepro-EGF) formed of 1207 AA.
This precursor protein is subjected to enzymatic cleavage of 970 and 180 AA
from the amino-terminal and carboxy-terminal ends respectively, to give the
mature EGF. Eight cysteine rich repeats were identified in this precursor protein
and termed EGF-like motifs. The prepro-fonn of EGF shows similarity with
LDL receptors, and it was suggested that it may act as a receptor for an
unidentified ligand especially in the kidney. PreproEGF was found to be
biologically active, binding to and activating the EGF receptor (EGFR) and
maintaining cellular growth in culture (Mroczkowski and Reich, 1993).
The mature EGF protein has a molecular weight of 6.3 kDa and is formed of 53
AA with 3 disulfide bonds between 6 cysteine residues. These disulfide bonds
are conserved along with 66% of the AA sequence between human and mouse
EGF. EGF is a member ofa growth factor family that shares the EGF-like motif
and includes transforming growth factor-a (TGF-a), betacellulin, amphiregulin,
heparin binding EGF, and epiregulin.
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The EGF gene occupies around 100Kb of chromosome 4 between bases
111053449- 111152868, forming one large LD block. Human EGF has only one
known transcript and is expressed from a TATA box promoter located 42 bp
upstream of the transcription start site. The EGF gene is formed of 24 exons. The
1SI and one of the largest exons of the EGF gene contains the 442 bp 5'
untranslated region (5'UTR) and the start of the coding sequence which encodes
the signal peptide responsible for targeting the protein to the cell membrane. The
mature EGF is encoded by exons 20 and 21. Exons 6-9 and 15-19 code for the 8
cysteine rich EGF-like motifs, with sequence similarity to LDL receptors (Figure
3-1).
Figure 3·1: Genomic structure of the epidermal growth factor gene
The EGF gene is formed of 24 exons (numbered). The encoded protein domains are
also shown. The 2 SNPs included this study are arrowed.
rs4444903, (c.61A>G)
+
rs2237051, (c.2566G>A)
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A large body of biological and genetic evidence suggests EGF as a candidate
gene for preeclampsia and FGR. This chapter includes 4 sections: the first
focuses on the role of variants of the EGF gene as risk factors for preeclampsia
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and FGR; the second and third sections explore the functional effects of the
SNPs rs2237051 and rs4444903 on EGF gene expression. The last section of this
chapter describes how these variants alter the expression of EGF and EGFR in
the placenta of normal pregnancy and pregnancy complicated by preeclampsia
andFGR.
3.2 Aims of the study
• To investigate the risk conferred by 2 EGF genetic variants In
preeclampsia and FGR in a case-control study.
• To explore the mechanisms whereby these variants affect EGF
expression.
• To do a preliminary investigation how these variants affect the
expression of EGF and EGFR in the placenta of normal pregnancy and
pregnancy complicated by preeclampsia and FGR.
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3.3 Genetic association study
3.3.1 Introduction
Considering the close proximity of the EGF gene (4q25-27) to the loci on
chromosome 4 linked to preeclampsia (4q32) (Harrison et al., 1997, Laivuori et
al., 2003) and birth weight (4q31) (Arya et al., 2006) and the biological
properties of EGF in trophoblast function, EGF is considered as a potential
candidate gene for preeclampsia and FGR.
3.3.1.1 Epidermal growth factor and placental development
EGF is a growth factor that is expressed in a wide variety of tissues and organs
including the reproductive tissues (Hofinann et al., 1991). Multiple studies have
shown that EGF is actually expressed in placental tissues. By immunostaining,
EGF expression was noted in decidua and placenta throughout gestation. In
decidua it was more prominent around the spiral arteries; in early placenta it was
abundant and localized to syncytiotrophoblast, while light to moderate staining
was localized to both trophoblast layers in late pregnancy (Hofinann et al.,
1991). EGF mRNA and protein were also detected in primary trophoblast cells
along with its receptor (Amemiya et al., 1994). Moreover EGF was detected in
culture media of early placental explants (Maruo et al., 1995). EGF in the
placenta was suggested to be of maternal and fetal origin. Bass et al (1994)
failed to show expression of EGF from either 1st trimester and term
cytotrophoblast or villous fibroblast in culture media using radioimmunoassay,
although addition of EGF to culture media increased cytotrohoblast invasiveness.
This study suggested that it is EGF, mainly of maternal origin, which regulates
trophoblast properties during early pregnancy, when the embryo also expresses
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EGF receptors (Bass et al., 1994). This lack of expression is probably related to
the short duration of culture (2 days) that may have resulted in EGF production
being below the detection level of the method applied (15 pg/7 million cells).
EGF has been shown to increase 1st trimester CT trophoblast cell proliferation in
culture (Li and Zhuang, 1997, Maruo et al., 1995). EGF also induces trophoblast
invasion. Addition of EGF caused dispersion and formation of pseudopodia in 1st
and 2nd trimester CT trophoblast cells (Bass et al., 1994, Staun-Ram et al., 2004).
The enhancement of invasive properties was also evident in a model of
extravillous trophoblast cells SGH-PL4 (LaMarca et al., 2008). EGF appears to
exert two different actions independently in a stepwise manner on the
proliferation and functional differentiation of trophoblast. EGF enhances CT
trophoblast proliferation in culture of very early (4-5 week) placental tissues,
without affecting the ability to secrete hCG and hPL. This is in contrast to the
effect of EGF observed on older placental tissues in culture (6-12 weeks), in
which EGF stimulated hCG and hPL secretion without affecting proliferation
(Maruo et al., 1992). Morrish et at (1997) demonstrated that EGF enhanced
syncytium formation from term CT trophoblast in culture (Morrish et al., 1997).
Activation ofMAPK11114 (P38) by EGF was implicated in the differentiation of
CT trophoblast into ST trophoblast (Johnstone et al., 2005).
Control of trophoblast invasiveness by EGF involves activation of multiple
cellular pathways. EGF stimulates MMP-2 and -9 secretion from trophoblast cell
lines in a differential, dynamic manner in which MMP-2 is dominant in early 1st
trimester and both MMP-2 and 9 late in the 1st trimester (Staun-Ram et al.,
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2004, Qiu et al., 2004). It also induces urokinase-type plasminogen activator and
plasminogen activator inhibitor-1 activity in trophoblastic cells, thereby inducing
cell invasion. Besides altering the extracellular matrix degrading enzymes, EGF
also changes the extracellular matrix composition. EGF was found to alter
trophoblast migration/invasion through induction of a2 integrin expression
(Nakatsuji et al., 2003) and down regulation of connexin 40 (Wright et al.,
2006).
Apoptosis, an important process in the maintenance of the ST trophoblast layer
during healthy pregnancy, is shown to be exaggerated in placenta from
preeclampsia and FGR complicated pregnancy (Ishihara et al., 2002, Crocker et
al., 2003). EGF was found to reduce the apoptotic process in a trophoblast cell
lineage exposed to hypoxia, reactive oxygen species or cytokines (Humphrey et
al., 2008, Moll et al., 2007, Smith et al., 2002).
3.3.1.2 EGF and fetal growth
EGF is regarded as an important factor not only for decidualization, implantation
and placental function during the course of pregnancy but also for fetal growth,
organ development and maturation.
In animal models, the body weight of fetuses whose mothers had undergone
sialoadenectomy (removal of the submaxilary gland, a major source of EGF) or
had been administered EGF antibody were significantly lower than that of
controls (Odaka et al., 1993, Masuyama et al., 1996). The offspring of rats
administered EGF during pregnancy were larger than controls (Masuyama et al.,
1996). The fetomaternal amino acid concentration ratio (fetal blood/maternal
blood) was higher in the EGF-treated group than in the control group
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(Masuyama et al., 1996). EGF promoted amino acid transport in placental
microvillus explants and pregnant rats, influencing fetal growth as a result
(Bonkobara et al., 2002). Moreover, maternal EGF deficiency during the latter
half of pregnancy led to reduced placental expression of the glucose transporter
GLUT3 and selectively impaired the transplacental glucose supply, resulting in
intrauterine growth retardation in mice. These findings suggest that EGF may
play an important role in regulating placental function and fetal growth (Kamei
et al., 1999).
EGF has also been implicated in growth and maturation of different fetal tissues
and organs. Intestinal epithelium exhibits its highest EGF binding capabilities
between 8 and 12 weeks of fetal life, which is a critical period of intestinal
morphogenesis and differentiation. EGF exerts important effects on epithelial
cell proliferation of human jejunum and duodenum during the fetal period
(Menard et al., 1988, Beaulieu et al., 1985). In support of these findings,
supplementation of amniotic fluid by EGF normalizes fetal weight and intestinal
proliferation in growth restricted fetal rabbits (Buchmiller et al., 1993, Cellini et
al.,2004).
Epidermal growth factor also influences fetal lung development. It was
demonstrated that the weight of the lungs was low in the offspring of EGF·
immunized rats. A picture suggesting a delayed lung maturation resulting in mild
respiratory distress syndrome was also noted (Raaberg et al., 1995). This was in
agreement with other studies which reported the positive effect of EGF on
enhancing maturation of fetal lung in animal models, by increasing the
production of various surfactant components (Ma et al., 2009).
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By stimulating the prostaglandin H2 synthetase enzyme in human amnion cells
(Caseyet aI., 1988) and up regulation of cyclooxygenase 1 (COX1) and COX2
in amniotic fluid and umbilical cord, EGF was suggested to maintain a steady
state of blood supply to the growing fetus by maintaining the tone of the
umbilical blood vessels (Rao et al., 1995). In addition, EGF may constrict
umbilical blood vessels immediately after delivery to prevent bleeding of the
fetus.
3.3.1.3 Epidermal growth factor levels during pregnancy
Many studies have measured and traced EGF levels in maternal urine and in
amniotic fluid throughout pregnancy. Maternal EGF urinary levels increased
from early pregnancy until mid term, when they declined to a level at term
similar to non-pregnant controls (Moharam et aI., 1992, Hofmann and
Abramowicz, 1990,Watanabe, 1990).By contrast amniotic fluid and cord serum
EGF concentrations were higher near term than mid-gestation (Hofmann and
Abramowicz, 1990, Ichiba et aI., 1992). The lack of correlation between
amniotic fluid and maternal urinary EGF concentrations suggests that probably
there is a different source of EGF in the two compartments. In contrast, other
studies have demonstrated that EGF levels in both amniotic fluid and urine
increased with advancing gestation, and reported that levels in FGR cases were
lower compared with normal pregnancy (Watanabe, 1990, Lindqvist et aI.,
1999).
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3.3.1.4 Polymorphisms of the EGF gene and the risk of preeclampsia and
FGR
Two SNPs in the EGF gene have attracted interest. The first one, located in the
5'UTR of the gene (c.61A>G or rs4444903), has a MAF (0 allele) of 0.44 in
Caucasians and is a potentially functional SNP. Shabahzi et al (2002)
demonstrated that the 0 allele was associated with an increased risk of malignant
melanoma (OR 2.7, 95% Cl 2.9-4.0, P=O.OOOI)and showed more EOF
production from peripheral blood mononuclear cells with the 0 allele compared
to the A allele (Shahbazi et al., 2002). This SNP has also been associated with
other types of malignancies. For example the 0 allele conferred higher risks for
gliomas (OR, 1.32; 95% Cl, 1.04-1.67), and glioblastomas (OR, 1.47; 95% Cl,
1.02-2.10) (Costa et al., 2007). It also was associated with an increased risk for
hepatocellular carcinoma, (Tanabe et al., 2008), and oesophageal carcinoma
(Lanuti et al., 2008), but was not associated with breast cancer (Wang et al.,
2008).
The second SNP in the EOF gene is located in exon 14, with a MAF ofO.37 in
Caucasians. It is a non-synonymous SNP that leads to a change in the encoded
amino acid from methionine to isoleucine (c.25560>A or rs2237051) (Semina et
al., 1996).This substitution does not affect the mature EOF encoded by exons 20
and 21, but it can potentially affect the properties and functionality of the
preproform of the EGF. However, as they are both neutral, non-polar AA,
methionine and isoleucine share similar physiochemical properties, lessening the
probability that this variation alters the properties of the protein.
The impact of these EOF variants on birth weight variability has been previously
investigated (Dissanayake et al., 2007). They showed that the maternal O-A
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haplotype formed of the minor alleles of markers rs4444903 and rs2237051 was
associated with low birth weight in healthy pregnancies in Caucasian women and
was transmitted more frequently from parents to babies affected by FOR. They
subsequently reported that the GA and OG genotypes of the marker rs2237051
were associated with higher risk for preeclampsia in Sinhalese women compared
to the AA genotype (OR 1.7 (95% Cl 1.0-2.8) and OR 1.8, (95% Cl 1.0-3.2)
respectively (Dissanayake et al., 2009).
Based on the aforementioned biological and genetic findings, the aims of this
study were to investigate the maternal genetic variants of EGF as risk factors for
preeclampsia and FGR in a case control study, and to test the effect of these
variants on the maximum blood pressure measured during pregnancy in healthy
pregnant women, and birth weight variability of their offspring.
3.3.2 Methods
Patients and samples used for this investigation were identical to those described
in the previous chapter (Section 2.4.1). The subset of 105 cases and 90 controls
from the Nottingham FOR collection were also included in the study carried out
by Dissanayake et al (Dissanayake et al., 2007).
A total of 673 women with normal pregnancies, 448 women with preeclampsia
and 234 mothers with FGR pregnancies were genotyped at the EOF SNPs
c.61A>G (rs4444903) and c.2556 G>A (rs2237051) by Kbiosciences using the
KASPr technique.
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3.3.3 Results
Demographic and clinical characteristics of the study population were presented
in chapter 2 (Table 2-8, Table 2-9, Table 2-14 and Table 2-15).
The call rate for the genotyping of markers rs4444903 and rs22370S1 was 98.2%
and 98.6% respectively. Both were in HWE within individual plates, the control
group and within the whole sample set (P >0.05). The MAF was 0.41 and 0.37
for rs4444903 and rs22370S1 respectively, similar to those reported in the
HapMap project for the European population (Table 3-1). In the study by
Dissanayake et aI., (2007) SNP c.6IA>G (rs4444903) was genotyped by
restriction fragment length polymorphism and c.2SS6 G>A (rs2237051) by MS-
peR. 100% concordance was observed between the results for the 200 samples
genotyped by both Dissanayake et al. and the current study.
The 2 markers were in linkage disequilibrium (~ = 0.81). The A-G and G-A
haplotypes formed of the 2 major and 2 minor alleles respectively accounted for
95% of the observed haplotypes (Table 3-4).
Table 3·1: Genotyping quality control indices
Chr = Chromosomal location based on HapMap release#24
Majorl Success HardySNP Location Function Minor MAF
rate% Weinberg
allele !P value~
rs4444903 Chr.4 5'UTR AlG 0.42 98.2 0.41111.053.559
rs2237051 Chr.4 Exon 14 G/A 0.39 98.6 0.32111.120.647 EreEroEGF
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3.3.3.1 Association of EGF variants with preeclampsia
The G allele of rs4444903 was less frequent in preeclampsia cases (0.38)
compared to controls (0.42). The allelic OR was 0.84, (95% Cl 0.71-1.00, p=
0.06). Comparison of the genotype at this locus showed a protective effect for
the GG genotype of marginal significance (OR 0.84, 95% Cl 0.70- 1.00, P=
0.05). This protective effect was not statistically significant after adjusting for
parity, smoking habit, BMI and the risk factors including chronic hypertension,
diabetic status, chronic renal disease, abnormal uterine artery Doppler, and
multiple pregnancies (OR 0.88, 95% Cl 0.73-1.07, P = 0.20), (Table 3-2)
There was no significant association between the A allele (OR 0.90, 95% Cl
0.76-1.07) and AA genotype (OR 0.90,95% Cl 0.76-1.07) ofrs2237051, before
or after adjustment for confounding factors (Table 3-2).
The haplotype G-A formed of the minor alleles of the 2 variants was represented
more frequently in controls (38%) than preeclamptic cases (35%), but this was
not statistically significant (P = 0.11; Table 3-4).
3.3.3.2 Association of EGF variants with FGR
In the FGR case-control comparison, there was no significant association
between the G allele ofrs4444903 (OR 0.84,95% Cl 0.68- 1.05, P = 0.13). The
allelic OR for the A allele ofrs2237051 was also non-significant (OR 0.92, 95%
Cl 0.74-1.145, P = 0.45). The same was observed when genotype was analyzed
both before and after adjustment for smoking habit, and the risk factors including
chronic hypertension, diabetic status, chronic renal disease, and abnormal uterine
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artery Doppler (Table 3-3). We did not adjust for parity, maternal age,
gestational age or maternal BMI in this analysis, as those are corrected in the
calculation of the GROW centile used in the identification of cases and controls.
Multiple pregnancy was excluded by definition.
The haplotype G-A formed of the minor alleles of the 2 variants was represented
more frequently in controls (38%) than FOR cases (35%), but this was
statistically non significant (P = 0.24; Table 3-4).
Table 3-2: Genotype and allele distributions for EGF variants and
corresponding odds ratios for preeclampsia
Genotype frequency was calculated using cross tabs, and genotype OR was calculated
using binary logistic regression, both using SPSS v.16. * Adjusted for parity, smoking
habit, BMI and the risk factors including chronic hypertension, diabetic status, chronic
renal disease, abnormal uterine artery Doppler, and multiple pregnancies. Allelic OR
was calculated using UNPHASED software release 3.1.5.
Genotype Genotype Unadjusted
unadjusted adjusted
allelic ORLocus Genotype Allele OR OR· (95% Cl)(9So;oCI) (95%CI) P valuePvalue Pvalue
rs4444903 AA AG GG G
Preeclampsia
38.0 49.1 13.0 0.38 0.84 0.88 0.84
~N=448~ (0.70-1.00) (0.73-1.07) (0.71-1.00)
Healthy 0.05 0.203 0.06
33.3 50.2 16.5 0.42
rs22370S1 GG GA AA A
Preeclampsia
139.5 47.0 13.4 0.37 0.90 0.94 0.90
~N=448~ (0.76-1.07) (0.78-1.14) (0.76-1.07)Healthy 0.25 0.54 0.24
37.0 47.3 15.8 0.39
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Table 3-3: Genotype and allele distributions of the EGF variants and
corresponding odds ratios for fetal growth restriction (FGR)
Genotype frequency was calculated using cross tabs, and genotype OR was calculated
using binary logistic regression, both using SPSS v.16. * Adjusted for, smoking habit,
and the risk factors including chronic hypertension, diabetic status, chronic renal
disease, and abnormal uterine artery Doppler. Allelic OR was calculated using
UNPHASED software release 3.1.5.
Locus Genotype Allele
Genotype
unadjusted OR
(95%CI)
P value
Genotype
adjusted
OR·
(95%CI)
P value
Unadjusted
allelic OR
(95% Cl)
Pvalue
rs4444903 AA AG GG G
FGR (N=243) 9.3 5.6 5.1 0.38
Healthy(;;:;;~)y 33.5 49.2 17.3 0.42
0.84
(0.68-1.05)
0.13
0.85
(0.68-1.06)
0.15
0.84
(0.68- 1.05)
0.13
rs22370S1 GG GA AA A
FGR (N=243) 40.0 45.0 15.0 0.38
37.3 46.4 16.3 0.40
0.92
(0.74-1.14)
0.46
0.93
(0.74-1.15)
0.49
0.92
(0.74-1.15)
0.45
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Table 3-4: Haplotype frequency of the EGF variants in preeclampsia and
fetal growth restriction cases and controls.
~: linkage disequilibrium between the two alleles in control group. Haplotype with
frequency <5% were pooled as rare haplotypes. P value was using likelihood ratio Chi-
square. UNPHASED V3.1.S was used for this analysis.
Preeclampsia FGR
rs 4444903 (AlG) rs2237051 (G/A) rl
Cases Controls Cases Controls
A G 0.81 60.16 57.23 59.77 56.89
G A 0.81 34.58 38.14 35.08 38.24
Rare haplotypes 5.26 4.63 5.15 4.87
P value 0.11 0.24
3.3.3.3 Association of EGF variants with maternal blood pressure
In the control group, the GG genotype at locus rs4444903 was associated with
the highest systolic blood pressure but not diastolic blood pressure (P= 0.04 and
0.26 for systolic and diastolic blood pressure respectively; Table 3-5). Systolic
blood pressure (SBP) was (Mean 124.2 mm Hg, SO 17.8) and diastolic blood
pressure (OBP) was (Mean 74.0 mm Hg, SO 13.0) for GO compared to the (SBP
119.7 mm Hg, SO 13.9; OBP 71.9 mm Hg, SO 12.0) and (SBP 119.0 mm Hg,
SO 15.2; OBP 71.2 mm Hg, SO 11.3) for AA and AO genotypes respectively.
The AA genotype at locus rs2237051 was not associated with either systolic or
diastolic blood pressure in the control group. Systolic blood pressure for GG,
GA, and AA genotypes respectively was 120.2 mm Hg, SD 14.7; 118.6 mm Hg,
SO 14.7; and 123.5 mm Hg, SD 17.9 (P = 0.25) and diastolic blood pressure was
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72.0 mm Hg, SD 12.2; 70.8 mm Hg SD 10.9; and 74.2 mm Hg, SO 13.3 (P =
0.35) (Table 3-5).
3.3.3.4 Association of EGF variants with offspring birth weight
Maternal homozygosity for the minor allele at both loci was associated with the
lowest birth weight, but this was not statistically significant. Birth weight was
3442 g, SO 635; 3499 g, SO 579; and 3400 g, SO 572 respectively in mothers
with AA, Aa and GO genotypes at locus rs4444903 (P= 0.31). At locus
rs2237051 birth weight was 3453 g, SO 615; 3491 g, SO 592; and 3396 g, SO
590 for genotypes GO, GA, and AA respectively (P = 0.71), (Table 3-5).
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Table 3·5: Maternal systolic and diastolic blood pressure and fetal birth
weight as a function of the genotype of EGFvariants in the control group.
Data represent mean (SO) of the trait investigated. The regression coefficient beta,
(95% Cl), and P values from linear regression are shown. * Adjustment for age, parity,
and smoking habits did not alter the findings for maternal blood pressure, and
adjustment for smoking habits did not alter the findings for birth weight (data not shown).
Locus Systolic blood Diastolic blood* Fetal birth weight*
pressure*(mm IIg) pressure (mm JIg) (g)
(N=673) (673) (N=570)
rs4444903
AA 119.7 (13.9) 71.9 (12.0) 3441 (635)
AG 119.0 (15.2) 71.2 (11.3) 3499 (579)
GG 124.2 (17.8) 74.0 (13.0) 3400 (572)
Beta(95% I) 1.7 (0.55 to 3.44) 0.75 (-0.56 to 2.6) -8.30 (-79.56 to 62.96)
P 0.04 0.26 0.82
rs2237051
GG 120.1 (14.7) 72.0 (12.2) 3453 (615)
GA 118.6 (14.7) 70.8 (10.9) 3491 (592)
AA 123.5 (17.9) 74.2 (13.3) 3396 (590)
Beta(95% I) 0.99 (-0.68 to 2.68) 0.62 (-0.69 to 1.92) ·15.42 (-86.68 to 55.85)
p 0.25 0.35 0.67
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3.3.4 Discussion
In this study of women of white western European descent, the results reported
here provide no evidence that the EGF genotype GG at marker rs4444903 confer
protection against preeclampsia (Table 3-2). Homozygosity for the A allele at
marker 2237051, which is in LD with the G allele at rs4444903 (~=0.81),
showed the same effect, both fell short of statistical significance. Dissanayake et
al (2009) reported the haplotype formed of the G allele of rs4444903 and the G
allele of marker rs2237051 as a risk factor for preeclampsia in Sinhalese. The
authors suggested that this association is mainly related to the G allele of
rs2237051, the minor allele in Sinhalese (Dissanayake et aI., 2009). It is difficult
to compare results from different ethnic groups when the MAF is variable. It is
noteworthy that small effects at or below 10-15 %, outside the margins of the
effect detectable by this sample size with adequate statistical power, cannot be
excluded. Therefore, results should be interpreted with caution, and confirmation
in a larger sample is mandatory.
Interestingly, the maternal genotype at rs4444903 was significantly associated
with the highest systolic blood pressure measured during pregnancy in the
control group of pregnant women (Table 3-4). Previous studies have indicated
that higher EGF levels are correlated with diastolic blood pressure in humans
(Lundstam et aI., 2007) and with hypertension in experimental animals (Florian
and Watts, 1999). Several studies have demonstrated the effect of EGF on
vascular smooth muscle contraction through MAPK signalling, increase in
intracellular calcium, and prostaglandin production. EGF also potentiates the
vasoconstrictor effect of angiotensin II and vasopressin on the vasculature. So
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whilst EGF acting locally in the placenta may lowers the risk of preeclampsia,
maternal systemic EGF may lead to higher blood pressure in healthy
pregnancies. It is noteworthy that previous reports suggested EGF levels in
maternal blood and urine are not correlated with EGF levels in amniotic fluid,
indicating different sources for systemic maternal EGF and EGF in the
fetoplacental compartment (Hofmann and Abramowicz, 1990).
Maternal genotypes at rs4444903 and rs22370S1 of the EGF gene were not
associated with fetal growth restriction, consistent with the findings of
Dissanayake et al (2007). That study also reported a significant association
between maternal genotype at these loci and birth weight in healthy pregnancies
in Caucasian and Sinhalese women. The present study also found that women
homozygous for rs4444903 allele G or rs223 70S1 allele A gave birth to babies
with lower birth weights, although this was statistically non significant, in spite
of the larger numbers genotyped. Note that 90 of the 570 controls in the FGR
study were also included in the study by Dissanayake et al (Dissanayake et al.,
2007). The failure to replicate the significant genetic association reported by
Dissanayake et al. may be related to the greater complexity of genetic and non-
genetic determinants of birth weight in the maternal controls reported here,
which included women with diverse medical and obstetric histories.
These findings add to the picture of contradictory data regarding the maternal
levels ofEGF and fetal birth weight. Moharam et al (1992) found no variation in
maternal urinary EGF levels comparing appropriate and small for gestational age
pregnancies (Moharam et al., 1992). In contrast Lindqvist et al (1999)
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demonstrated that EGF levels in maternal urine were lower in FGR cases
compared to controls (Lindqvist et al., 1999). None of these studies considered
the genetic background that might alter EGF expression. Besides favourably
affecting the placentation process, a protective effect of a maternal EGF
genotype reportedly associated with higher EGF production can be explained by
the enhancement of metabolite transfer across the placenta. In an animal model,
EGF deficiency induced by maternal sialoadenectomy caused intrauterine growth
retardation. Lower maternal EGF levels adversely affected fetal growth through
decreasing the expression of placental GLUT3 mRNA which leads to reduced
transplacental transfer of glucose and lower glucose concentration in fetal
plasma. These effects were corrected by EGF supplementation (Kamei et al.,
1999). Furthermore, in humans EGF levels in maternal and cord serum were
higher in diabetic pregnancies characterized by high birth weight (Loukovaara et
al., 2004, Grissa et al., 2010). However in a transgenic mouse model, offspring
over-expressing human EGF were growth retarded, an affect attributed to a
reduction in the levels of insulin like growth factor binding protein-3 (IGFBP-3)
(Chan and Wong, 2000). It is therefore possible that the association of a maternal
EGF genotype characterized by higher EGF production with low birth weight is
mediated by the transfer of high-expression alleles to the fetus. Interestingly, the
study by Dissanayake et al (2007), which included 105 mother-father-baby trios
from UK pregnancies affected by FGR, showed that the fetal G-A haplotype
composed of the minor alleles of the two loci was transmitted more frequently
from heterozygous parents to their FaR offspring (P = 0.02), supporting a role
for fetal EGF genotype in the pathogenesis of low birth weight (Dissanayake et
al., 2007). This also suggests differences in the genetic and pathophysiological
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backgrounds controlling variability of birth weight in normal pregnancies and
growth restricted pregnancies.
Previous reports indicated that the G allele of rs4444903 is associated with
higher EGF production (Shahbazi et al., 2002, Bhowmick et al., 2004, Vauleon
et al., 2007). From biological point of view, maternal EGF locally present in the
placenta in early pregnancy could be favourable for the mother and the fetus and
protect against preeclampsia by enhancing trophoblast proliferation,
differentiation, and invasion and acting as an antiapoptotic factor for the
trophoblast cell lineage, so helping in the establishment and maintenance of the
placenta. However the current genetic association study did not provide
statistically significant support for the protective effect of this variant of EGF
against preeclampsia or FGR.
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3.4 The effect of c.2556G>A (rs2237051) on EGF mRNA
splicing
3.4.1 Introduction
Pre-mRNA splicing is a critical step in gene expression in which intron
sequences are removed and exons are aligned together to generate a mature
mRNA transcript (House and Lynch, 2008) legible for translation. Exon
recognition by assembly of large ribonucleoprotein complexes known as
spliceosomes is the key step in the splicing process. The formation of the
spliceosome involves the step-wise assembly of four small nuclear
ribonuc1eoproteins (snRNPs VI, V2, V41U6 and US) and many non-snRNP
splicing factors on a pre-mRNA (Blencowe, 2000). The proteins of the
spliceosome bind initially to the core splicing signals which include the donor 3'
splice site (3' SS) and acceptor (5' SS) splice sites, the polypyrimidine tract
(PPyT), and the branch point (BPS) (Figure 3-2). These core splicing signals are
found to carry only a small amount of the information required for exonlintron
definition (Wang et al., 2008), and proper exon definition requires additional
information nested in cis acting elements called splicing regulatory elements
(SREs). SREs are sequence motifs (6-8 nuc1eotides) identified both in introns
and exons which function by either facilitating (enhancers) or suppressing
(silencers) splicing. Exonic splicing enhancers (ESE) have been largely
characterized and reported to be present in most, if not all, mammalian exons
(Cartegni et al., 2002, Fairbrother et al., 2002). Purine-rich ESEs promote the
recognition of exons through binding of SR proteins (serine-arginine rich
proteins) and SR related proteins via their N-terminal RNA Recognition Motif
(RRM), and thus facilitating the recruitment of the spliceosome to the vicinity of
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exon-intron junctions by protein-protein interaction through C-terminal argirune
serine rich domain (RS domain) (Shen and Green, 2006).
Figure 3-2: Core and cis- regulatory splicing elements
Upper figure: Pre-mRNA sequences important for splicing. Consensus mammalian 5'
splice site (5' SS), branch site (8S), poly-pyrimidine tract (PPyT) and 3'SS sequences
are shown. ESE, exonic splicing enhancer; R, purine; Y, pyrimidine, adapted from
(8Iencowe, 2000). Lower figure: A proposed mechanism of the action of ESE and SR
protein in mRNA splicing, SR protein binds to an exonic splicing enhancer (ESE)
through its RNA-recognition motifs (RRM) and contacts the various splicing factors at
the adjacent splice sites through its RS domain. The three sets of splicing-factor-pre-
mRNA interactions (U2AF-3'splice site, U1snRNP-5'splice site and SR protein-ESE) are
strengthened by the protein-protein interactions that are mediated by the RS domain,
adapted from (Cartegni et al., 2002).
IntronExon Exon
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3.4.1.1 Role of mRNA splicing in human diseases
There is a growing body of evidence that ESE disruption by deletion, mis-sense,
nonsense or even translationally silent mutations and the use of cryptic splice
sites are associated with many diseases and phenotypic abnormalities due to
exon skipping or aberrant exon inclusion. For example a C->T mutation at
position 6 in exon 7 of survival of motor neuron 2 (SMN2) gene causes skipping
of exon 7 due to disruption of an ESE (Cartegni and Krainer, 2002) or creation
of an exon splicing silencer (ESS) (Kashima et al., 2007). The protein product of
the mRNA lacking exon 7 is unstable and leads to spinal muscular dystrophy.
Another example is the microtubule associated protein tau gene encoding the tau
protein. Multiple mutations of exon 10 result in inclusion or exclusion of exon
10 with the production of abnormal protein that is easily precipitated in
neurofibrillary tangles, the hallmarks of several neurodegenerative diseases such
as Alzheimer's disease (Liu and Gong, 2008). Disruptions of functional ESEs are
also the principal causes of exon skipping in neurofibromatosis type 1 (Zatkova
et al., 2004).
Previous studies in our laboratory showed statistically significant variations in
birth weight as a function of genotype at this locus in 3 independent collections
of samples from UK Caucasians and Sinhalese from Sri Lanka (Dissanayake et
al., 2007). They also showed a distortion in transmission of the G-A haplotype
formed of the minor alleles of the rs4444903and rs2237051 to growth restricted
babies. The G allele (minor allele in Sinhalese) of SNP rs2237051 is also
implicated in the risk of preeclampsia. The GA and GG genotype of this marker
was associated with a higher risk of preeclampsia in Sinhalese women compared
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to the AA genotype (OR 1.7 (95% Cl 1-2.8) and OR 1.8, (95% Cl 1-3.2)
respectively (Dissanayake et al., 2009).
The current study focuses on the functional analysis and elucidation of the
mechanisms underlying this association. One of the proposed mechanisms is that
rs2237051 (G>A) causes exon 14 skipping due to disruption of an ESE motif.
3.4.1.2 Analysis of splicing regulatory elements
Analysis of exonic sequence for the presence of putative ESE motifs usually
starts using in silico analysis tools such as ESE-Finder and RESCUE-ESE to
identify putative elements (Cartegni et al., 2003, Fairbrother et al., 2004). ESE-
Finder is a program based on the sequence from a library of oligonucleotides that
showed favourable splicing after multiple rounds of a splicing assay. The
sequences were used to produce scoring matrices for splicing regulatory proteins
ASF/SF2, SC35, SRp40, or SRp55 (Liu et al., 1998, Cartegni et al., 2003).
RESCUE-ESE motifs were predicted by selecting hexamers that were enriched
in exons versus introns and in exons with weak versus strong splice sites.
However, the presence of a high-score motif in a sequence does not necessarily
indicate that the sequence acts as a functional ESE. Functional assessment of the
identified motifs can be carried out by using a minigene technique.
A minigene is a vector that contains at least 2 exons with a known splicing
pattern flanking a multiple cloning site for insertion of the genomic segment
from the gene of interest. The insert represents the exon carrying the ESE motif
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to be investigated and the flanking intronic sequences that carry the pnmary
splicing signals (usually 200-300 of the adjacent introns) amplified from the
genomic DNA by PCR. Transient transfection, RNA extraction, and RT-PCR
(reverse transcriptase-polymeras chain reaction), using vector specific primers is
performed (Cooper, 2005). If a given exon carries a mutation that might affect
splicing by disrupting an ESE sequence, 2 minigene constructs with each allele
sequence should be tested. If the motif functions as an ESE the PCR product will
include both the vector specific exons and the test exon. If the mutation disrupts
that ESE motif the PCR product will include vector specific exons only (Figure
3-3).
Figure 3-3: Outline of the minigene technique
Blue boxes are the vector exons, MCS is the multiple cloning site and the black arrows
represent minigene specific primers. Genomic DNA is represented by the white boxes
(exons) and the connecting line (introns). the yellow box is the test exon, SRE: splicing
regulatory element.
PCR - from aenomlc DNA
cYoLo
Test exon
Transfection- RNA-extraction- RT-PCR using
RT-PCR with test exon skipping RT-PCR with the test exon inclusion
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3.4.2 Methods
3.4.2.1 EGF exon 14 sequence bioinforrnatic analysis
Two programs designed to find exonic splicing enhancers were used to examine
EGF exon 14: ESE-Finder and RESCUE-ESE. ESE-Finder (http://rulaLcshl.
edu/tools lESE!) is a web-based resource that facilitates rapid analysis of exon
sequences to identify binding motifs for four SR proteins: SF2/ASF, SC35,
SRp40 and SRp55.20. The RESCUE-ESE program (http://genes.mit.edu
!burgelab/rescue-ese!) uses a computational method that identifies exonic
splicing enhancers in human genomic sequences by searching for specific
hexanucleotides. Further sequence analysis was done to test for the strength of
the splice site (http://www.fruitfly.orglseq_tools/splice.html) and other SR and
SR related protein binding sequence as well as ESE and ESS motifs using the
Splicing Sequences Finder (http://www.umd.be/SSF). The default thresholds of
these programmes were used as reference values.
3.4.2.2 Minigene constructs
EGF exon 14 and flanking intronic sequence representing major and minor
alleles respectively (rs2237051 G and rs2237051 A) were derived by PCR
amplification of genomic DNA (gDNA) from homozygous subjects. The primers
used were: EGF_EI4S,5'-TCCCATGTCGACGTGACGTTCCCTCCTCATGT-
3' and EGF_EI4AS, 5'-GGTGAATCTAGAGGGATAAAGCCCCAATTACC-3'
forward and reverse primers respectively. These primers introduced Sal I and
Xba I restriction sites (underlined) in the 5' and 3' ends of the fragment
respectively, to be used for further cloning. The PCR reaction was performed in
a 30p.lreaction volume containing 200ng of gDNA, lXTaq buffer containing 1.5
mM MgCh, 200 p.M dNTPs, 0.5 p.M of each primer, and I unit of Taq
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polymerase. The conditions were 94°C for 40 s, and 35 cycles of denaturing at
94°C for 30 s, primer annealing at 60°C for 1 min, and extension at 72°C for 1
min, with a final extension of 10 min at 72°C. PCR products were visualized by
electrophoresis on 1% agarose gels stained with ethidium bromide. The PCR
fragment was 574 bp long (202 bp ofintron 13, 168 bp of exon 14, and 204 bp of
intron 14), ensuring that all splicing signals for exon 14 were included. The PCR
products were TA cloned into a TOP02.I vector followed by transformation of
One Shot® TOPIO Chemically Competent E. coli according to the
manufacturer's protocol (Invitrogen).
After DNA mini-preparation (QIAGEN), inserts were sequenced. The reactions
were carried out in 10J.lI using 5pmol M 13 reverse primer 5' -
CAGGAAACAGCTATGAC-3' and l x Big-dye 3.1 reaction mix, lx Big Dye
terminator buffer (Applied Biosystems) and 400 ng DNA. These underwent 25
cycles on a thermo-cycler as follows: denaturation at 96°C for 30 s, primer
annealing at 50°C for 15 sec and extension at 60°C for 4 min. The reaction
products were purified as described earlier (Section 2.4.5.5). Sequencing was
performed using an ABI-automated sequencer. Sequencing alignment was done
using EBI-tools- CIustalW web-based software (http://www.ebi.ac.ukffools/clu
stalw2/index.html) to confirm that the inserts were identical apart from the base
at rs2237051 (G>A).
Restriction digestion of the TA constructs and destination vector (RCHGLO
minigene kindly provided by Prof. T. Cooper (Ray et al., 2006) was carried out
in lOJ.lIreaction volumes containing 5 units each of Sal I and Xbal, l x digestion
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buffer, and 2 ug DNA for 2 hours at 37°C. The reaction was heat inactivated at
65°C for 10 min and the fragments were gel extracted using gel extraction kits
(QIAGEN). 100 ng of the vector and 30ng of the insert (1:3 ratio) were subjected
to a ligation reaction using IU T4 DNA ligase, lx ligation buffer in 10111at 4°C
overnight. Transformation of Xl-blue super-competent cells was carried out
according to the manufacturer's protocol (Stratagene). The colonies containing
the recombinant vector were selected by restriction enzyme treatment using Sal I
and Xba I, and were sequenced as above using vector primer TNIE4: 5'-
AGGTGCTGCCGCCGGGCGGTGGCTG-3' and the insert primer EGF_EI4AS:
5'-GGTGAA TCTAGAGGGATAAAGCCCCAA TTACC-3. For the RCHGLO
constructs containing the correct sequence (RCHGLO-EGF-G and RCHGLO-
EGF-A), a large plasmid preparation was made using Plasmid Purification
endotoxin-free Midi Kit (QIAGEN).
3.4.2.3 Cell culture and transfection
HepG2 (hepatoma cell line) cells were maintained in Eagle's minimal essential
medium (EMEM) with 10% FCS, 10 mM L-glutamine, penicillin (lOOU/ml),
streptomycin (100 pg/ml), Amphotericin B (2.5 ug/ml) at 37°C and 5% CO2 in
75 ml culture flasks. SGH-PL4, (extravillous trophoblast cell line) cells were
maintained in F-IO Ham Nutrient Mixture with L-glutamine and the same
antibiotic and culture conditions as HepG2. The cells were subcultured once they
approached 80% confluence (usually after -3 days of growth). Cells in a single
75 cm2 flask were split equally into 3 new flasks as part of this process. The
passage number was limited to 8-10 times, over the experiment after which fresh
aliquots were taken from the liquid nitrogen to establish consistency in the
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growth pattern and cellular characteristics over the experiments. For transfection
2x 106 cells were plated in 60mm culture plates 24 hours before transfection.
Transfections were performed using 1ug plasmid DNA and TFx20 transfection
reagent (Promega) in 3:1 charge ratio. The DNA:TFx20mixture was incubated at
room temprature in 2 ml serum free medium for 15min then transferred to cells
and incubated for 1 hour at 37°C after which 3 ml of complete medium was
added. Because the assay applied in this experiment was a qualitative assessment
of splicing pattern using vector specific primers for RT·PCR to confirm that
transfection was successful, we did not opt to control for transfection efficiency.
However if different transcripts were noticed and comparison between the levels
of these transcripts was required controlling for transfection efficiency would be
important. Co-transfection by vector expressing fluorescent protein like green
fluorescent protein that can be visualized would be an option, or the use of
flowcytmetry sorting, an expensive option can be used to control for transfection
efficiency. The number of dead cells was trivial and comparable in all plates.
Twenty four hours later, cells were harvested and prepared for total RNA
extraction. All transfections were performed in three independent experiments.
3.4.2.4 RNA extraction and RT-PCR
Total RNA was isolated from HepG2 and SGH·PL4 cells using RNeasy kit
(QIAGEN) with application of the DNase treatment step to ensure the removal
of any genomic and plasmid DNA. Reverse transcription was performed in 20~L
reactions using 2J.lg of total RNA, 300 ng random primers (Promega), plus
RNase free water. This reaction was heated at 65°C for 5 min and then chilled on
ice. IX Supcrscript-RT buffer, 200mM DTT (Dithiothreitol), 80mM dNTPs, 1U
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RNase Block and 2U of Superscript-RT (Invitrogen) was then added to the
reaction and heated as follows: 25°C for 10 min, 42°C for 60 min, 70°C for 15
min and 10°C hold. As a control for contamination with plasmid DNA, duplicate
samples were used in which reverse transcriptase was not added to the mixture in
one sample. For the RT-PCR the following pair of vector specific primers was
used: sense primer RSV5U: 5'-CATTCACCACATTGGTGTGC-3' and the
antisense primer TNIE4: 5'-AGGTGCTGCCGCCGGGCGGTGGCTG-3'. The
amplification was carried out in 30llL reactions, containing 1ilL of eDNA,
1XTaq buffer with (NH4)2S04, 1.5 mM MgCh, 200 JiM dNTPs, 0.5 mM of each
primer, and 1 unit of Taq polymerase. The PCR conditions and analysis were
the same as described above.
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3.4.3 Results
3.4.3.1 Initial in silico sequence analysis
ESE-Finder showed that EGF exon 14 contains a putative SF2/ASF protein
binding site ESE sequence motif (GAGAGTA) within the rs2237051 G allele
with the potential to enhance splicing and inclusion of exon 14 in the mature
mRNA. The rs2237051 G>A SNP (AAGAGTA) disrupts this site, potentially
leading to loss of enhancer function with possible exon 14 skipping (Figure 3-4)
The output of RESCUE-ESE also showed that substitution of A for G
completely eliminates the hexamer ATGAGA (Table 3-6).
Exon 14 is a well defined exon considering the strength of both acceptor (score
0.87) and donor site (score 0.98) and the consensus 31and SI SS. Although the
polypyrimidine tract of the preceding intron has no more than 3 uridine stretches,
based on the analysis of the sequence -4/-25 (tttaacaaacttgaattgtttc) a high
pyrimidine:purine ratio (13:9) was found just upstream to the 31 SS, making that
PPyT potentially effective in splicing.
Further exploration of the G and A alleles of exon 14 sequence using
http://www.umd.be/SSF. showed that while rs22370S1 G>A destroyed the low
threshold SF2/ASF and SF2/ASF(IgM-BRCAl) ESE motif (GAGAGTA), it also
creates another 3 SR protein binding ESEs, 2 with higher thresholds for TRA2-8
and one for 9G8. It also disrupts a weak ESS hnRNP (heterogeneous nuclear
ribonucleoprotein protein) Al binding site, introduces a moderately powerful
one, and reduces the threshold for a third one (Table 3-6).
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In total 25 SR protein binding ESE motifs and 17 hexamer sequences that may
act as ESEs were identified using bioinformatic tools in exon 14. It is noteworthy
that 2 of the 25 ESE motifs have a very strong threshold, indicating that these 2
motives might be the functional ones in EGF exon 14 (Figure 3-4).
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Figure 3-4: ESE-Finder graphical output for exon 14
Upper panel: full length exon 14; middle panel: the G allele; lower panel: the A allele.
The arrow refers to the ESE-SF2/ASF protein binding motif in the upper and middle
panels; this motif is lost in the A allele shown in the lower panel. The highlighted text is
the protein binding motif and the SNP is underlined. The height of the bars indicates
higher threshold for binding proteins.
SRp40
SRp65
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3.4.3.2 In vivo splicing assay
To validate these findings, hybrid mini gene constructs from both major
(RCHGLO-EGF-G) and minor alleles (RCHGLO-EGF-A) of exon 14 were
prepared. The insert included both exon 14 and the flanking intronic sequence
which contains the core splicing signals (5' SS, BPS, PPyT and the 3' SS) so that
any splicing difference between G and A alleles is due to SNP rs2237051 G>A
(Figure 3-5, A). The in vivo splicing experiments were performed by transfection
of the minigene constructs into HepG2 (hepatoma) and SGH-PL4 (extravillous
trophoblast) cell lines to study the splicing reaction in two cellular contexts and
exclude any splicing variation due to tissue specific changes in the trans-acting
splicing proteins. The expected size of the spliced product was 248bp
representing 40bp from each mini gene exon with 168 bp of exon 14 included.
The expected size of the unspliced product was 80 bp due to exon 14 skipping.
Identical patterns of splicing were observed for G and A alleles in both cell lines,
,
generating 248 bp transcripts with inclusion of exon 14 (Figure 3-5, B).
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3.4.4 Discussion
Large numbers of human synonymous and non synonymous mutations have
been implicated in disruption of mRNA splicing, linking coding sequence
mutations to genetic diseases. Although initial sequence analysis predicted
disruption of a putative SF2/SAF binding motif in the A allele (variant allele) of
exon 14 of the EGF gene, the in vivo splicing assay in 2 different cell lines
showed that this alteration is not functionally significant and does not lead to
exon 14 skipping.
The lack of functional effects secondary to disruption of this ESE motif raised
several possibilities. The predicted G allele motif might be functionally neutral
or part of a Composite Regulatory Elements of Splicing (CRES) that functions
both as an enhancer and silencer according to their sequence context. The second
possibility is that the G allele motif might overlap other ESE motifs not tested
for by the programs ESE-Finder and RESCUE. Lastly, the SNP G>A might
create a new ESE sequence motif or, it might destroy an ESS sequence motif.
The fact that rs2237051 G>A does not affect splicing of exon 14might indicate
either that exon 14 splicing is not dependent on this motif, or that the tested
motif is present by chance, or that it is neutral in the context of EGF exon 14. In
agreement with this, it has been suggested that the vast number of ESEs in
human exons, and the short and degenerate nature of the ESE elements reduces
the possibility that all of them are binding targets of the SR proteins (Wu et al.,
2005). For example, the consensus ESE sequence for the splicing regulatory
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protein SF2/SAF is CRSMSGW, indicating that the sequence is not exclusively
specific as 5 out of 7 nucleotides can vary within this short sequence motif. It is
worth noting that the full length exon 14 has at least 24 other SR binding
sequences, many of which have higher scores than the tested ESE. It is possible
that one of those high score motifs might be a genuine ESE (Figure 3-4) ifany is
required. The strength of the splice sites, the position of the ESE along the exon,
and the length of the flanking intron playa significant role in ESE activity and
dependence (Dewey et al., 2006. Hertel, 2008, Cartegni et al., 2002). In this
respect, it is worth noting that EGF exon 14 is strongly defined by its splice site
and that the ESE element analyzed here is located 70 nuc1eotides from the 5'
splice site and flanked by long introns; all of those reduce the dependence of
EGF exon 14 splicing on ESE sequences.
There is a possibility that the tested ESE sequence is a part of a Composite
Regulatory Element of Splicing (CRES) with overlapping silencer and enhancer
functions that are context dependent rather than SR protein dependent (Pagani et
al., 2003) and altering the binding affinity to SR protein does not interfere with
its function. It has been suggested that the term enhancer or silencer is
appropriate only if the context is considered; an ESE element may well act as a
negative regulator of splicing in another context, e.g., when inserted into
flanking intron regions or other exons (Holste and Ohler, 2008).
Analysis of the G allele sequence using SSF shows nearly complete overlap
between ESE (SF21ASF; GAGAGT A) and 3 ESS sequences (Sironi silencer
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Motif2: TGAGAGTA (Sironi et al., 2004); hnRNP AI: TAATGA, and hnRNP
AI: GAGAGT). Substitution of A for G destroys the SF2/ASF binding ESE but
introduces 3 new ESE motifs, 2 for Tra2 B and one for 9G8. Substitution of A
for G also affects silencer motifs: one hnRNP Al ESS binding motif is destroyed,
but a new one is introduced (Table 3-6). Considering the competitive «Expert-
Bezancon et al., 2004) and spatial constraints, overlapping binding sites will have
positive or negative effects depending on which proteins bind to them, and this
plays an important role in the regulation of numerous splicing events. Although
this Minigene experiment has not determined which, if any, are functional in the
exon 14 environments, theoretical considerations suggest that rs223705l G>A
might increase the overall enhancer activity, as when ESS sequences operate in
conjunction with ESE sequences, the latter are dominant over the adjacent ESS
sequence (Disset et al., 2006).
There are limitations to the use of sequence analysis alone in identifying
functional ESE, as bioinformatic tools tend to over-estimate the ESE. Vast
numbers of SRE are currently defined all of which are 6-8 nucleotides in length
and highly degenerate in nature. In spite of the loss of sequence context in a
mini gene assay, this approach provides a better method of assessing loss and
gain of function for cis and trans-acting factors that affect splicing until the
precise interplay between the core splicing elements and cis and trans-acting
SREs in defining the "splicing code" is elucidated (Cooper, 2005).
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3.5 Functional Characterization of the EGF 5'UTR genetic
variation: translational versus transcriptional effects
3.5.1 Introduction
Translation of mRNA into protein is a necessary constitutive step in the gene
expression process. Translational control enables a cell to control its protein
requirements very rapidly which is of great importance, particularly in the
regulation of genes implicated in cell growth and differentiation (Cazzola and
Skoda, 2000).
Translational control can be exerted by global machinery that affects all cellular
mRNAs by alteration of the available initiation factors and ribosomal proteins
(Kozak, 2005). In addition, specific mechanisms that influence the function of
particular mRNAs through sequence motifs in the mRNA untranslated regions
(UTRs) are also recognized. Many features reside in the 5' UTR and are known
to impede the translation of the downstream gene. The presence of stem loops
will interfere with the formation of the initiation complex and ribosomal
scanning of message and consequently lower the efficiency of translation
particularly if the stem loops create structures which are targets for mRNA
binding proteins which regulate translation. These stem loops arise due to self-
complementary sequence, with formation of stable structured mRNA that
requires increased energy for unwinding. The second major feature which alters
the efficiency of translation is the presence of upstream open reading frames
(uORF) initiated by AUG codons. These uAUGs can cause premature initiation
and inhibit translation by preventing the ribosome from reaching the
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physiological start codon (Figure 3-6). The efficiency of translation is also
reduced in genes in which the S'UTR is simply longer than the average UTR
length of70-200 base pairs (Kozak, 2005).
Figure 3-6: Features by which S'UTRs may reduce the efficiency of
translation
(A) mRNA with no negative regulatory element, showing the 7 methyl guanine (7mG) for
initiation of translation, and the AUG start codon. (8) Self-complementary sequences
with stable stem-loop structures (C) stem loop with RNA-binding proteins (green). (0) A
5'-UTR which contains an upstream open reading frame (uORF).
7mG AUG
0 , I-A 5' 3'
0 Stem loop AUG0 , I-B 5' 3'
on
Stem loop-protein complex
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~
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Earlier in this chapter (Section 3.3) we showed that SNP rs4444903 (c.61A>G)
of the EGF S'UTR has a potential protective effect against the risk of
preeclampsia. Previous studies in our laboratory showed that the minor G allele
was associated with low birth weight and FGR (Dissanayake et ai., 2007). In the
field of cancer research, a number of investigators have demonstrated that the G
allele of c.61A>G is associated with different types of cancer, including
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melanoma, glioblastoma, and hepato-cellular carcinoma (Bhowmick et al., 2004,
Shahbazi et al., 2002, Tanabe et al., 2008). Others researchers attempting to
reproduce these findings failed to show an association with an increase in cancer
risk (Randerson-Moor et al., 2004, Vauleon et al., 2007).
To link a genetic variation to a disease entity it is important to show that the gene
has a feasible physiological function in the tissue of interest, and that the
polymorphism causes a relevant alteration in the level or the function of the gene
product. In this regard, EGF is a major regulator of the placentation process
(reviewed in Section 3.3.1) and the EGF 5'UTR contains features which may
affect the translation of the downstream gene that merit investigation.
The 5'UTR of the EGF is twice as long as an average 5'UTR (442 base pairs
compared to 70-200 base pairs average UTR length). It carries 2 upstream open
reading frames (uORF) 5' of the ATG which initiates translation ofpreproEGF.
It is predicted to form a structured mRNA. All of these features are reported to
lower the efficiency of gene translation in the context of other genes (Chatterjee
and Pal, 2009).
3.5.2 Hypothesis and aims
The rs4444903 polymorphism in the EGF-5'UTR is expected to alter the
efficiency of translation of the EGF gene and consequently contribute to either
increased or decreased gene expression or function. If this is true mRNA levels
transcribed from the A and G alleles would be the same whilst levels of the final
protein product would differ. This is in contrast to a transcriptional effect in
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which the allele-specific levels of both the mRNA and protein products would
differ. The hypothesis was tested using a luciferase reporter gene assay, and in
vitro transcription and translation (lVT).
3.5.2.1 Luciferase reporter gene assay
Reporter gene assays are based on the measurement of a reporter gene protein
expressed in mammalian cells following transfection with the DNA sequence of
interest in order to test its effect on the level of reporter gene expression. This
gives an understanding of how this DNA sequence may affect the expression of
the native gene in vivo. The reporter gene product should not be produced by the
mammalian cells, and it should be easy to measure, quantitative, reproducible
and sensitive to a wide range of concentrations.
Luciferase refers to a family of enzymes that catalyse the oxidation of various
substrates (e.g. luciferin and coelenterazine), resulting in light emission. Firefly
luciferase and Renilla luciferase are produced from two distinct organisms,
American firefly photinus pyralis and renilla reniformis respectively. They
catalyze two different reactions as shown in (Figure 3-7).
Figure 3·7: Firefly and Renilla luciferase mediated reactions
Firefly D-luciferin +ATP + 01 Oxyluclferin +AMP +PPI + Light
Firefly luciferase +MtI+
Renilla luciferase
Coelenterazine +02 Coeintermide + Light
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Inevitable experimental variations during the reporter gene assay such as cell
number, pipetting volume errors, transfection efficiency, cell lysis efficiency, and
assay efficiency can be minimized by using a dual reporter gene assay. This
makes use of two different reporters, one as the experimental reporter and the
other as a control to normalize the activity of the experimental reporter with
respect to experimental errors. The experimental reporter is expressed partially
under the control of the test DNA sequence introduced in the plasmid constructs
and partially under the control of elements integrated in the reporter gene vector.
The control reporter is constitutively expressed, and its activity correlates to the
amount of DNA transfected into the cells and the cell's ability to produce protein
under the transfection conditions applied. So normalizing the experimental
reporter activities to the control reporter activities adjusts for well to well
transfection variability and efficiency. Throughout these experiments the
maximum acceptable coefficient of variation (CV%) between each experimental
triplicate was limited to 20%, improving the statistical power of the study by
minimising the background noise from analytical imprecision.
The dualluciferase reaction (DLR) assay system from Promega benefits from the
fact that both firefly and renilla luciferase mediate reactions with the same
kinetics but different substrates, which renders the assay from a single sample
easy and rapid. Upon completing the measurement of firefly luciferase activity
by adding the luciferase assay reagent II (LARII) (the experimental reporter), the
firefly luminescence is rapidly quenched, with simultaneous activation of the
renilla luciferase luminescent reaction (the control reporter activity) using Stop
228
and Glo reagent. The reaction takes 2-3 seconds to start and the activity IS
measured over 10 seconds (Figure 3-8).
Figure 3-8: Dual luciferase assay
Left figure: a summary of the steps required to perform a luciferase reporter gene assay.
Right figure: measurement of firefly and Renilla luciferase activity in the Prom ega dual
luciferase assay.
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The different expression levels that can be obtained from different pGL3
vectors, pGL3control (pGL3C), pGL3 promoter (pGL3P) and pGL3basic
(pGL3B), were exploited in these experiments. pGL3C is a vector which
harbours the highly active Simian virus 40 promoter element (SV40P) and SV40
enhancer element (SV40E) upstream and downstream of the luciferase gene
(Figure 3-9). pGL3P harbours only SV40P upstream of the luciferase gene.
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pGL3B is a promoterless vector which harbours neither of these elements. Due
to the higher basal transcription levels from pGL3C and pGL3P vectors, any
variation in luciferase output after insertion of the 5'UTR region of EGF is
expected to be translational in origin, whilst variation in the luciferase output
from the pGL3B is expected to be transcriptional in origin.
Figure 3-9: pGL3 Control vector
The pGL3C vector differs from pGL3 Promoter and pGL3 Basic in that the pGL3P lacks
the SV40 enhancer and the pGL3B lacks both the SV40 enhancer and SV40 promoter.
The DNA fragment of interest was inserted at the Hindlll site (red box) (Promega)
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3.5.2.2 In vitro transcription and translation assay (IVT)
In vitro transcription and translation (IVT) methods were used to confirm the
effects of the rs4444903 polymorphism on translation in a cell free environment.
The principle is to generate a homogenous RNA population representing the
5'UTR of EGF and the luciferase gene after insertion into a pcDNA3.1
expression vector. The construct was inserted downstream of the T7 promoter
and the vector linearized just downstream to the insert. T7-RNA polymerase, a
bacterial derived enzyme, was used to initiate transcription from its specific
promoter sequence (Figure 3-10).
After generating the homogenous RNA from allele-specific constructs, equal
amounts were subjected to in vitro translation in rabbit reticulocytes. These are
prepared from red blood cells after losing their nuclei, but still containing all the
molecular components (80S ribosomes, transfer RNAs (tRNAs), aminoacyl-
tRNA synthetases, initiation, elongation and termination factors) required for
translation of exogenous RNA. For efficient translation, AA, ATP, creatine
phosphate, creatine phosphokinase and other co-factors (Mi+, K+)were added
to the reaction. Any variation in protein output from equal amounts of RNA
from each allele will be due to variation in translation efficiency.
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Figure 3-10: pcDNA3.1 (+) vector
This vector is used for in vitro transcription. DNA fragments were cloned downstream to
T7 promoter (green box) after restriction digestion by Kpn1 and Xba1 (blue boxes).
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3.5.2.3 Electrophoretic Mobility Shift Assay (EMSA)
The Electrophoretic Mobility Shift Assay (EMSA) is a technique used to
characterize protein:DNA interactions. It is based on the fact that complexes of
protein and double-stranded DNA migrate through a nondenaturing
polyacrylamide gel more slowly than DNA alone. The assay is performed by
incubating the protein, or a mixture of proteins, with biotinylated DNA
fragments containing the putative protein binding site and nonspecific DNA
competitors such as poly (dI-dC). The poly (dJ-dC) polymers provide an excess
of nonspecific sites to adsorb proteins in a crude nuclear lysate that will bind to
any DNA sequence. The complex is then analyzed on polyacrylamide gel. The
ability to determine protein:DNA complexes depends largely upon the stability
of the complex during its migration into the ge1. A low ionic strength
electrophoresis buffer is used to increase the stability of the DNA:protein
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complex. The specificity of an observed DNA binding reaction can be evaluated
using competition assays in which an excess of specific and non specific
unlabeled probe are added together with the labelled probe. Specific DNA
binding will be eliminated by lOO-foldmolar excess of unlabeled specific probe,
and maintained on addition of unlabeled non specific probe. In addition, specific
antibodies can be added to the gel shift reaction. If the protein that forms the
complex is recognized by the antibody, the antibody can either block complex
formation, or it can form an antibody-protein-DNA complex, resulting in a
further reduction in the mobility of the protein-DNA complex (supershift).
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3.5.3 Methods
3.5.3.1 Cloning of the S'UTR ofthe EGF-Iuciferase reporter constructs
442 bp of the 5' UTR region of the EGF gene starting from the transcription
start site (+ 1) and extending to the last base before the translation start site was
amplified by PCR from genomic DNA previously genotyped for the rs4444903
A>G SNP. 2 DNA samples which were homozygous for A and G alleles
respectively were used as template. Amplification was carried out using EGF-
UTR-S as forward primer and EGF-UTR-AS as reverse primer (Table 3-7).
These primers were flanked on both sides by HindIII restriction sites for use in
the cloning procedure.
The PCR reaction was performed in 30~1volumes containing 200ng of gDNA,
lxTaq buffer containing 1.5mM MgCh, 200 ~M dNTPs, 0.5~M of each primer,
and 1 unit ofTaq polymerase. The conditions were 94°C for 40 s, and 35 cycles
of denaturing at 94°C for 30 s, primer annealing at 61°C for 1min, and extension
at 72°C for 1 min, with a final extension of 10min at 72°C. peR products were
visualized by electrophoresis on 1% agarose gels stained with ethidium bromide.
Fresh PCR products were TA cloned into TOPO.2.1 vector according to the
manufacturer's protocol (Invitrogen).
After DNA mini-preparation (Qiagen), inserts were sequenced. The reactions
were carried out in 10J.lIvolumes using 5 pmol M13 reverse primer and lx Big-
dye 3.1 reaction mix, lx Big Dye terminator buffer (Applied Biosystems) and
400 ng DNA. These underwent 25 cycles on a thermo-cycler as follows:
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denaturation at 96°C for 30 s, primer annealing at 50°C for 15 sec and extension
at 60°C for 4 min. The reaction products were purified using DTR gel filtration
cartridges (Edge Biosystems), then heated to dryness at 90°C. Sequencing was
performed using an ABI-automated sequencer. Sequencing alignment was
performed using EBI-tools ClustalW web-based software (http://www.ebLac.uk
lTools/c1ustalw2/index.html)to confirm that the inserts were identical apart from
the base at rs4444903.
Restriction digestion of the TA constructs and destination vectors pGL3C,
pGL3P and pGL3B was carried out in IOIlIvolumes with 1III fast digest HindIII
(Fermentas), IIlI fast digestion buffer, and 1 ug DNA for 10 min at 37°C. The
reaction was heat inactivated at 80°C for 10 min. De-phosphorylation of the
linearized vector was carried out in the same reaction by addition of 1 U of
Shrimp alkaline phosphatase in order to minimize vector recircularization. The
fragments were gel purified using gel extraction kits (Qiagen). 100 ng of the
linearized de-phosphorylated vector and 30ng of the insert (1:3 molar ratio) were
subjected to a ligation reaction using 1 U T4 DNA ligase and l x Ligation buffer
in 10111at room temperature for 1 hour. Transformation of Xl-blue super-
competent cells was carried out according to the manufacturer's protocol
(Stratagene). The colonies containing the recombinant vector were selected by
restriction enzyme treatment using Hindlll, and were sequenced as above using
GL2 primer to confirm the exact sequence and orientation. Endotoxin free
minipreps (Promega) of the constructs containing the correct sequence were
prepared (PGL3CAlCG, pGL3PAlPG, and pGL3BAlBG) (Figure 3-11).
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Figure 3-11: Plasmid constructs used in the dual luciferase assay and in
vitro transcription
a) 442 bp of the 5'UTR region of the EGF gene from A and G alleles were cloned into
pGL3Basic (promoterless) vector to create BA and BG constructs. b) 390 bp
representing the EGF promoter region was cloned into pGL3Basic vector to create
EGFP construct. c) 832 bp representing 5'UTR region and EGF promoter was cloned in
pGL3Basic vector to create BAL and BGL constructs. d) 442 bp of 5'UTR region was
cloned in pGL3Promoter vector downstream to Simian virus promoter and upstream to
luciferase gene to create PA and PG constructs. e) 442 bp of 5'UTR region was cloned
in pGL3controi vector downstream to Simian virus 40 promoter (SV40P) and upstream
to luciferase gene and SV40enhancer (SV40E) to create CA and CG constructs. f)
5'UTR region of the EGF gene and luciferase gene were cloned from BA and BG
constructs into pcDNA3.1 vector downstream to T7 promoter to create A-Luc and G-Luc
respectively, to be linearized with Xba-1 before in vitro transcription. The Luc construct
was created by cloning the luciferase gene only from pGL3Basic vector into pcDNA3.1
vector in the same way.
5'UTR Luciferase a) BAI BG
EGFP Luciferase b) EGFP
EGFP 5'UTR Luciferase c) BAL/BGL
SV40P 5'UTR Luciferase d) PAlPG
SV40P 5'UTR Luciferase SV40E
e) CAlCG
o A-Luc/G-Luc
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Table 3-7: Primers used for experiments in 3.5.1
Hindlll site is underlined; AttB recombination sites are shown in bold.
Primer Sequence
EGF-UTR-S 5' -TCAAAAAAGCTTACTGTTGGGAGAGGAA TCGTA-3'
EGF-UTR-AS 5' -AGTGAGAAGCTT AATCTTGATGAGTTTGAACTTTCA-3'
EGF-PRO-S 5'GGGGACCACTTTGTACAAGAAAGCTGGGTGAACTAT
CTTT ACT ArrGCTCATGT -3'
EGF-PRO-AS 5'GGGGACCACTTTGTACAAGAAAGCTGGGTTTCTCTT
TITGAAAAGTGGAA T-3'
EGF-PUTR-AS 5'GGGGACCACTTTGTACAAGAAAGCTGGGTAATCTTG
ATGAGTTTGAACTTTC-3
MI3 Fprimer 5'-TGTAAAACGACGGCCAGT-3'
M13Rprimer 5' -CAGGAAACAGCTATGAC-3'
GL2 5' -CTTTATGTTTTTGGCGTCTTCCA-3'
RV3 5' -CTAGCAAAA TAGGCTGTCCC-3'
T7 5' -TAA TACGACTCACTATAGG- 3'
BGH_rev 5' -TAGAAGGCACAGTCGAGG- 3'
3.5.3.2 Cloning of the EGF promoter and EGF promoter/5'UTR fragments
The Gateway cloning system takes advantage of the site-specific recombination
reactions enabling the bacteriophage lambda to integrate and excise itself in and
out of a bacterial chromosome. Gateway protocols rely essentially on the BP and
LR clonase reactions described below (Karimi et al., 2007, Hartley et al., 2000).
390 bp representing the EGF promoter (-390>+ I) were amplified from genomic
DNA using the EGF-PRO-S and EGF-PRO-AS primer pair. 832 bp representing
EGF promoter/ 5'UTR (-390>+442) were amplified using gDNA homozygous
for the rs4444903 A and G alleles with the primer pair EGF-PRO-S and EGF-
PUTR-AS. These primers are tagged at the 5'end by the AttB recombination
sites (Table 3-7).
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The PCR reaction was performed in 30J.LIvolumes containing 200ng of gDNA,
1xTaq buffer containing 1.5 mM MgCh, 200 J.LMdNTPs, 0.5 J.LMof each primer,
and 1 unit ofTaq polymerase. The conditions were 94°C for 40 s, and 35 cycles
of denaturing at 94°C for 30 s, primer annealing at 58°C for 1 min, and extension
at 72°C for 1 min, with a final extension of 10 min at 72°C. PCR products were
visualized by electrophoresis on 1% agarose gels stained with ethidium bromide.
1. BP reaction
The principle of the BP reaction is illustrated in
Figure 3-12. peR products flagged by the AttBl and AttB2 sites were cloned
into the vector pDONR221 with AttPl and AttP2 sites to create an entry clone.
This recombination reaction was carried out using 150 fmol of the pDONR22l
vector, 3J.LIPCR product, 2J.LIBP Clonase II enzyme mix containing the phage
integrase and the integration host factor, made up to 8 J.Llwith TE buffer pH8.
The reaction was incubated at 25°C for 1 hour after which 1J.Llof proteinase K
was added and incubated again for 10 min at 37°C.
DH5a cells were transformed using 3J.LIof this BP reaction and plated on LB
plates with kanamycin antibiotic added (50J.1g/ml), and incubated overnight at
37°C.This creates entry clones carrying the gene of interest flanked by AttLI and
AttL2 recombination sites. The clones were tested by restriction digestion and
sequencing using Ml3 forward and reverse primers (Table 3-7).
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Figure 3-12: BP reaction
In the presence of clonase enzyme mix recombining AttB and AttP sites will produce
AttL and AttR sites with the formation of entry clones. The ccdB gene is toxic for the
bacteria so that nearly 90 % of the colonies created will be the correct colony, which
minimizes colony screening.
AttB
I
AIIB
2
AUP
I
AttP
2
+
pDONR221
Kanamycin resistance
peR Product
AttL
I
AttL
2 AttR
I
AttR
2
By product
2. LR reaction
A second recombination reaction was carried out to create the final expression
clones, using the pGL3B vector with AttRl and AttR2 recombination sites as a
destination vector and the entry clone from the BP reaction. The principle of the
LR reaction is illustrated in Figure 3-13. 150 ng of each vector, 2~1 of LR
Clonase II enzyme mix containing integrase, integration host factor, and the
phage excisionase, were mixed and made up to 8~1 with TE buffer pH8. The
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reaction was incubated at 25°C for 1 hour after which 1111of proteinase K was
added and incubated for 10 min at 37°C. This creates expression clones carrying
the genes of interest flanked by AttB 1 and AttB2 recombination sites. DHSu
cells were transformed using 3111of this LR reaction and plated on LB plates
with Ampicillin antibiotic added (SOllglml). Clones were tested by sequencing
using GL2 and RV3 primers (Table 3-7). Endotoxin free minipreps for the
constructs BAL, BGL and EGFP (Figure 3-11, B and C) were performed.
Figure 3-13: LR reaction
The recombination between AttL sites flanking the gene on the kanamycin resistant
entry clones and AttR sites flanking the ccdB gene on the ampicillin resistant destination
vector which carries the reporter gene creates an ampicillin resistant expression clone
carrying both the gene of interest and the reporter gene.
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3.5.3.3 Cell culture and transfection
1: Optimization for Jeg-3 cells transfection
Jeg-3 is a chorio-carcinoma cell line, which is highly proliferative and able to
secrete hPL and hCG in culture media. These cells have many of the features of
syncytiotrophoblast. Jeg-3 cells were maintained in Eagle's minimal essential
medium (EMEM) with 10% FCS, 10 mM L-glutarnine, penicillin (IOOU/ml),
streptomycin (100 pg/ml), Amphotericin B 2.5 pg/ml and 1% sodium pyruvate
at 37°C in 5% C02 in 75 cm2 culture flasks. 2x IDS Jeg-3 cells were plated in 12
well plates and cultured for 24 hours to attain 50-70% confluence before
transfection. The cells were subcultured once they approached 80% confluence
(usually after -3 days of growth). Cells in a single 75 cm2 flask were split
equally into 3 new flasks as part of this process. As it was evident that
expression of the reporter gene decreased as the cells were cultured for longer
times, the passage number of the cells was limited to 5-6 passages, after which
fresh aliquots were taken from the liquid nitrogen to establish consistency in the
growth pattern and cellular characteristics over the experiments.
Two different transfection reagents, TFx20 and TFx50 (Promega), and various
reagent to DNA ratios were tested to optimise the reaction. Serum free medium
was used as recommended in a number of publications (Buckland et al., 2005,
Hoogendoom et al., 2003).
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The transfection reagents were re-suspended in nuclease free water as specified
in the manufacturer's protocol at least 24 hours prior to transfection. The
reconstituted TFx reagents were stored in aliquots at -20°C. 3, 4.5, and 6 ul of the
reagent were used with 1 ug DNA to achieve 2:1, 3:1, and 4:1 charge ratios
respectively.
Co-transfection was performed using 200ng of pGL3C and pGL3P vectors
mixed with 20ng of pRL-SV40 (renilla expression vector) in 400J.1lserum free
medium. TFx20 and TFx50 reagents were added according to the defined charge
ratios. The reaction was vortexed briefly and incubated at room temperature for
15 min to allow the DNA to be incorporated into a complex with the lipid
particles in the reagent so it can pass through the cell membrane. During this
time the culture medium was removed from the cells and the cells were washed
in IX PBS. The TFxlDNA complex was then transferred to cells and incubated
for 1 hour at 37°C after which 800J.11of complete medium was added. All
transfections were performed in triplicate in two independent experiments.
2: Transfection of HepG2 and Jeg-J cells
Hep02 (hepatoma cell line) cells were maintained in culture as previously
described (Section 3.4.2). Ix 106 HepG2 cells and 2x lOS Jeg-3 cells were plated
in 12 well plates 24 hours before transfection to attain 50-70% confluence.
Co-transfection using 200ng of pOL3 experimental vectors (Figure 3-11, a-e)
and 20ng of pRL-SV40 (renilla expression vector) was performed using TFx20
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transfection reagent (Promega). Plasmid DNA and TFx20 transfection reagent in
3: 1 charge ratio were incubated at room temptature in 400J,11serum free medium
for 15 min then transferred to cells and incubated for I hour at 37°C after which
800J,11of complete medium was added. All transfections were performed in
triplicate in 4-6 independent experiments.
Transfection with the pGL3C, pGL3P, and pGL3B empty vector was included in
every experiment; a consistent fold increase from pGL3C to pGL3P vector over
all over experiments was required as evidence of successful transfection.
3: Dualluciferase assay (DLA)
The Dual-Luciferase" Reporter Assay System (Promega) was used for reporter
gene assays. All reagents were equilibrated to room temperature before use and
prepared according to the manufacturer's protocol.
24 hours after transfection culture media were removed and the cells were
washed 3 times with IX PBS followed by addition of 200J,1Iof IX passive lysis
buffer (PLB) and incubated on a shaker for 20 min at room temperature. 20J,11of
the cellular lysate was added to S0J,11luciferase assay reagent II (LARII) in
specific assay cuvettes suitable for the Turner Design Model TD-20/20
Luminometer. Firefly luciferase activity was measured then SOIlIof I X Stop and
Glo reagent was added to the reaction for the measurement ofrenilla luciferase.
The results are expressed as relative luminescence units (RLU); the ratio of
firefly luciferase/renilla luciferase is the normalized luciferase activity. The mean
normalized luciferase activity of triplicate wells was used for statistical analysis.
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3.5.3.4 In vitro transcription and translation
1: Cloning of constructs for in vitro transcription
BA, BG, pGL3B and pcDNA3.1 were subjected to restriction digestion using
fast digestion Kpn I and Xba I enzymes following standard techniques. The
DNA constructs representing the A and G alleles of the S'UTR region of EGF
with the luciferase gene, or the luciferase alone, were cloned into the pcDNA3.1
vector downstream to the T7 promoter using T4 DNA ligase as previously
described (Section 3.4.3) to generate A-Luc, G-Luc and Luc constructs (Figure
3-11, t).
After confirmation of the constructs by restriction digestion using Kpn-I and Xba
I and sequencing using T7 and BGH-rev primers (Table 3-7), midipreps
(Qiagen) were carried out to generate large amounts of DNA. 10 Ilg of DNA
were linearized using S U of fast digest Xba I and 1x fast digestion buffer in SOIlI
reaction volumes. Linearization was confirmed by running 2111of the restriction
digestion reaction on 1% agarose gel alongside the corresponding uncut
construct. Purification of the linearized DNA was carried out by extraction with
TE-saturated (pH 8.0) phenol:chloroform: isoamyl alcohol (25:24:1) and ethanol
precipitation according to the manufacture's protocol provided with the in vitro
transcription kit. The samples were re-suspended in 50111Rnase-Free water and
stored at -20°C.
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2: In vitro transcription (IVT)
RiboMAXTM Large Scale RNA Production System T7 Cat # P1300 (Promega)
was used for in vitro transcription. The IVT reaction was prepared at room
temperature by adding 10111of 5x transcription buffer, 15 ul of25 mM rNTPs, 4
ug linearized constructs, 1Dill T7 enzyme, and made up to 50111with Rnase free
water in a 0.5 ml microcentrifuge tube. The reaction was gently mixed and
incubated at 37°C for 3 hours. A positive control reaction using the commercially
supplied linear DNA was included in the experiment.
RQI-RNase free DNase at a concentration of IU/).1g of template DNA was used
for removal of the unused DNA template following transcription. The reaction
was incubated for 15 min at 37°C.
To confirm a single homogenous RNA product of the desired size, 2).11of IVT
reaction (RNA) were added to 18111of RNA sample buffer (10.0 ml deionized
fonnamide, 3.5 ml 37% formaldehyde and 2.0 ml 5x MOPS buffer). Sill of RNA
loading buffer (50% glycerol, ImM EDTA, and 0.4% bromophenol blue) were
added and the sample was heated for 5-10 min at 70°C. The sample was then
loaded onto a 1% agarose gel to which 0.5 pg/ml ethidium bromide was added.
Electrophoresis was carried out at 80 V for 30 min. The control reaction that
produces a transcript of approximately 1,800 bp, the same size as the Luc
control, was used for size comparison.
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3: RNA purification after in vitro transcription:
RNA was extracted from 30J.lI of the IVT reaction with 1 volume of citrate-
saturated phenol (PH 4.7): chloroform: isoamyl alcohol (125:24:1) and ethanol
precipitation according to the manufacturer's protocol. RNA was then suspended
in 30J.lIRNase free water. RNA was purified from the remaining 20J.lIof the IVT
reaction using RNA clean spin columns (RNeasy Mini Kit- Qiagen, Cat# 74104)
according to a standard protocol. These two methods of RNA purification were
compared for efficiency of removal of contaminants that can interfere with the
subsequent translation experiment. RNA concentration was measured on the
Nanodrop spectrophotometer.
4: In vitro translation
The template mRNA was denatured by heating at 6S0C for 3 min and immediate
cooling in an ice-water bath. The reaction was then assembled in a 0.5 ml
polypropylene microcentrifuge tube by adding 35111Rabbit Reticulocyte Lysate,
0.S111of ImM Amino Acid Mixture Minus Leucine, O.S111of ImM Amino Acid
Mixture Minus Methionine, 1111of RNasin® Ribonuclease Inhibitor (40U/l1l),
and 211g of the RNA constructs (A-Luc,G-Luc, and Luc), and made up to SOli}
with RNase free water. The reaction was then incubated at 30°C for 90 min. One
reaction using Luciferase Control RNA (l11g/111)supplied with the kit was
included as a positive control. A reaction without any added RNA was included
as a negative control to detect any luminescence from the reaction components.
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Luciferase output was measured using a luminometer by adding 2.5J.11of the 50J.11
translation reaction to the 50J.11of LARII. Each sample was measured in
triplicate. The luciferase output from the Luc construct was above the upper limit
of detection of the luminometer, so 1/5, 1110, and 1120 dilutions were prepared
from 2J.11of the translation reaction with the appropriate amount of nuclease free
water prior to determination of luciferase activity.
3.5.3.5 Electrophoretic mobility shift assay, EMSA
HepG2 nuclear extract was prepared using NucBuster TM Protein Extraction Kit
(Novagen) according to the instructions provided by the manufacturer. Double
stranded DNA oligonucleotides were prepared by mixing 1J.11of 100 pmol /ul of
the forward and reverse probes (1:1 molar ratio) with 98J.11of annealing buffer
(10 mM Tris, 1 mM EDTA, 50 mM NaCI , pH 8.0) to give a final concentration
of 1 pmol/ul of double stranded oligonucleotides. Annealing of oligonucleotides
was carried out by incubating at 95°C for 5 min then gradually reducing the
temperature to room temperature. A working concentration of 10frnoVJ.11was
prepared immediately before performing the electrophoretic mobility shift assay.
The oligonucleotide probes used were:
5'UTRA: 5' -AATCCAAGGGTTGTAGCTGGAACTTTCCAT -3 t
5'UTRG: 5' -CAA TCCAAGGGTTGTGGCTGGAACTTTCCAT -3'
Sp1: 5' -GTCCAAGCTCCCCGCCCCTCCCCAGC-3 t.
The probes were biotiny1ated at the 5' end. Unbiotinylated specific probes and a
non specific scrambled probe were also used in these experiments. Specificity
protein 1 (Spl) antibody was supplied by Milipore (Anti-Spl, Cat # 07-645).
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EMSAs were set up according to the protocol provided by the manufacturer
(Thermo Scientific, LightShift™ Chemiluminescent EMSA Kit, Product No.
20148), shown in Table 3-8. Briefly, HepG2 nuclear extract was incubated with
20 finol biotin-labelled double stranded DNA probe on ice for 20 min in a 20J,l1
reaction volume, with or without inclusion of competing specific or non-specific
oligonucleotides. 10J,l1of the reaction was then loaded onto a 6% polyacrylamide
gel and subjected to electrophoresis in 0.5% THE (Tris-borate EDTA) buffer.
For super-shift assays, 1ug of Sp1 antibody was incubated for 10 min on ice with
reactions containing nuclear extract before adding the double stranded DNA
probe followed by 20 min incubation on ice prior to electrophoresis. The binding
reactions were transferred to a nylon membrane using a semi-dry blotting system
and cross-linked by exposure to UV light for 15 min. Detection of the biotin-
labelled DNA was carried out using a chemiluminescent method. The membrane
was incubated with Streptavidin-Horseradish peroxidise solution, followed by
addition of stable peroxide solution according the manufacturer's protocol. The
bands then were viewed on X-ray film.
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Table 3-8: Electrophoretic mobility shift assay for 5'UTRA, 5'UTRG of the
EGF gene and Sp1 probes
Reactions are labelled 1-6 as follows: 1=1Ofmol/~L biotin end-labelled test probe;
2=1Ofmol/~L biotin end-labelled test probe and HepG2 nuclear extract; 3=1Ofmol!~L
biotin end-labelled test probe, HepG2 nuclear extract and 100 molar excess unlabeled
non specific probe; 4=10fmo1/1..lLbiotin end-labelled test probe, HepG2 nuclear extract
and 100 molar excess unlabeled specific probe; 5=10fmo1/1..lLbiotin end-labelled test
probe, HepG2 nuclear extract and Sp1 antibody; 6= HepG 2 nuclear extract alone.
Final Reaction"Component
concentration I 2 3 4 5 6
Ultrapure Water 15 13 11 11 12 15(!L (!L (!L l!L l!L l!L
lOX Binding Buffer IX 2JIL 2J.1L 2JU. 2J.1L 2J.1L 2J.1L!20148Al
IJ.1g1JIL Poly (dI·de) 50 ng/pl, IJIL IJIL lJU. lJU. IJIL IJ.1L!20148El
HepG2 cells nuclear Optimized 2JIL 2JU. 2JU. 2J.1L 2J.1Lextract
1pmol/ul, unlabeled non 2pmol 2JU.
seecific Tar~et DNA
lpmol/ul, unlabeled 2JU.
seecific Tarset DNA
Sp Iantibody 1J.1g11JIL IJIL
l Ofmol/ul, biotin end- 20 fmol 2JIL 2JIL 2JU. 2JU. 2JILlabelled test DNA
Total Volume 20J.1L
3.5.3.6 Bioinformatics
Mfold program was used for prediction of the EGF 5'UTR secondary structure
(http://mfold.bioinfo.rpLedulcgi-binima-form1.cgi) (Zuker, 2003) to determine
which allele is expected to translate more efficiently. The prediction was
performed for the full length and first 120 bases only of the 5'UTR region.
Prediction of transcription factor binding using the TF search program
(http://www.cbrc.jp/researchldbffFSEARCH.html) was also carried out. The
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input was 30 bp of the EGF 5' UTR with the c.61 A>G SNP in the middle. The
default parameter of the program was applied, where the lower limit of the score
was set to 70 points, implying the degree of correlation between the input
sequence and the consensus sequence for the transcription factor binding
included in the program.
3.5.3.7 Data analysis
In the dual luciferase assay, the mean of the relative luciferase activity
(firefly/renilla) for each construct was used. Data were rejected whenever the
coefficient of variation (CV) between the triplicates exceeded 20%. An average
fold change the range of 95 and 14 for pGL3C/pGL3P was required all the
experiments for Jeg-3 and HepG2 cells respectively. Each construct was then
corrected to its corresponding empty vector to obtain the activity related to the
construct itself. The empty pGL3B vector showed very low activity in Jeg-3
cells, so pGL3B constructs were corrected to the empty pGL3P vector. The
luciferase outputs for each allele were compared. To test whether 5'UTR
constructs in pGL3B conferred any promoter activity, both were compared with
the activity of the EGF promoter in the EGFP construct (Hoogendoom et al.,
2003). Comparisons between construct activities were carried out using
Student's t test for data with a normal distribution, or Mann Whitney U test for
data with a non-normal distribution.
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3.5.4 Results
3.5.4.1 Optimization of Jeg-3 cells transfection conditions
Use of TFx20 gave higher relative luciferase activity compared to TFx50 at all
charge ratios with both pGL3C and pGL3P vectors (Figure 3-14). So TFx20 was
used for Jeg-J transfection experiments. The fold change in pGL3C/PGL3P
activity was examined to determine the optimum charge ratio. TFx20 at a charge
ratio of 3:1 showed the highest fold change averaged over the two experiments.
Taking into account that the higher the fold change the better the experimental
conditions to discriminate between different constructs, a charge ratio of 3: 1 was
adopted for the subsequent experiments (Figure 3-14).
According to the Promega notes a pGL3CIPGL3P fold change of between 6 and
136 is acceptable and depends on the cell line under investigation. Based on the
results of optimisation experiments, a pGL3C/PGL3P fold change near to 95 was
considered acceptable for subsequent experiments. The coefficient of variation
(CV%) of relative luciferase activity under these experimental conditions was
11% for pGL3C and 17% for pGL3P. This is comparable to previous studies
(Hoogendoom et al., 2003, Buckland et al., 2005).
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Figure 3-14: Optimization of the Jeg-3 cells transfection
Transfection of 2x105 cells with 200ng of pGL3C (A), and pGL3P (8) along with 20ng of
pRL renilla at different charge ratio using TFx20 and TFx50 reagents. Transfection was
run in triplicate, data represent mean ± SEM for 2 experiments. pGL3C/pGL3P fold
change (C).
A) Relative luciferase activity of the PGL3C vector at different
charge ratios
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The transfection conditions for HepG2 cells had been optimized previously in
our laboratory. TFx20 at ratio 3:1 was used. The average fold change of
pGL3CIPGL3P was 14. A 20% coefficient of variation was accepted as
maximum variations between the replicates in subsequent experiments.
3.5.4.2 Effect of EGF 5'UTR on reporter gene expression
The pGL3C and pGL3P vectors have high basal transcription, so that any
variation in reporter gene expression is expected to be due to differences in the
effects of inserts on translation rather than transcription. Interestingly, the
relative luciferase activity of both A and G alleles of the S' VTR of the EGF
gene constructs was between 20 to 40% of the pGL3C and pGL3P empty vectors
in both cell lines, implying that the S'UTR down-regulates gene translation.
Constructs containing the 442 bp S'UTR of the EGF gene upstream to the
luciferase gene in pGL3C (CA to CG) and pGL3P (PA to PG) showed that
although the G allele tended to be more active than the A allele in HepG2 cells
and less active in Jeg-3 cells, the differences were not statistically significant
(Figure 3-15. and Table 3-9), with no evidence that this variant affects the
efficiency of translation.
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Figure 3-15: Relative luciferase activity for the EGF 5'UTR A and G alleles
in pGL3C and pGL3P
Data are presented as mean ± SEM of 5 independent experiments from the 2 cell lines
under investigation. CA and CG, PA and PG: 442 bp EGF 5'UTR from the A and G
alleles inserted into pGL3C and pGL3P vector respectively. V: empty pGL3C or pGL3P
vector.
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In pGL3B constructs, in which the 442 bp 5'UTR of the EGF gene was inserted
upstream to the luciferase gene in the promoter-less pGL3B vector, there was
higher expression from the G allele compared to the A allele in HepG2 (P=
0.004) but not in Jeg-3 cells (P= 0.08), (Figure 3-16). Inclusion of 390bp of the
EGF promoter together with the 442 bp 5'UTR in the BAL and BGL constructs,
inserted into the pGL3B vector, showed a non-significant difference in the
activity of the G allele compared to A allele in HepG2 cells (P=O.I) and Jeg-3
cells (P=O.09) ( Figure 3-16 and Table 3-9).
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Figure 3-16: Relative luciferase activity from EGF 5'UTR A and G alleles in
pGL3B constructs
Data are presented as mean ± SEM of 5 independent experiments from the 2 cell lines
under investigation. BA and BG: 442 bp EGF 5'UTR from the A and G alleles inserted
into pGL3B vector. BAL and BGL: 442 bp EGF 5'UTR from the A and G alleles and the
390 bp of the EGF promoter inserted in pGL3B. EGFP: 390 bp of the EGF promoter
inserted in pGL3B vector and V= empty vector.* BA compared to BG in HepG2 cells (P
= 0.004).
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In HepG2 cells, the mean CG/CA, PG/PA, BG/BA, and BGLI BAL fold change
in the luciferase activities were 1.10, 1.55, 2.59 and 1.38, respectively. CG/CA,
PG/PA, BG/BA and BALlBGL fold change in the luciferase activities in Jeg-3
cells were 0.80, 0.88, 1.85 and 1.65 respectively, (Table 3-9 and Figure 3-17) .
The increment in the G/A fold change in the pGL3B compared with the pGL3C
and pGL3P constructs indicates that the variation between A and G alleles is
mostly transcriptional, and is masked when basal transcription is high.
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Figure 3·17: Fold change in the activity of G aliele/A allele of the 5'UTR of
the EGF gene in different pGL3 constructs
Data are presented as mean ± SEM of 5 independent experiments from the 2 cell lines
under investigation. CA and CG, PA and PG, BA and BG: 442 bp EGF 5'UTR from the
A and G alleles inserted in pGL3C, pGL3P and pGL3B vector respectively. BAL and
BGL: 442 bp EGF 5'UTR from the A and G alleles and the 390 bp of the EGF promoter
inserted in pGL3B.
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Table 3-9: Relative luciferase activity for A and G alleles of the EGF 5'UTR
in different pGL3 vectors in HepG2 and Jeg-3 cells.
The data are presented as mean (SEM) and Student's t test P value, followed by fold
change in the activity of G/A alleles, mean (SEM). CA and CG: 442 bp EGF 5'UTR from
the A and G alleles inserted in pGL3C vector; PA and PG: 442 bp EGF 5'UTR from the
A and G alleles inserted in pGL3P vector; BA and BG: 442 bp EGF 5'UTR from the A
and G alleles inserted in pGL3B vector; BAL and BGL: 442 bp EGF 5'UTR from the A
and G alleles and the 390 bp of the EGF promoter inserted in pGL3B.
Relative luciferase activity
J1epG2 Jeg-3
CA 0.33 (0.06) 0.24 (0.02)
CG 0.37 (0.07) 0.19 (0.02)
P value 0.69 0.11
Fold change CG/CA 1.1 (0.07) 0.80 (0.07)
PA 0.26 (0.05) 0.42 (0.06)
PG 0.36 (0.07) 0.38 (0.08)
P value 0.22 0.63
Fold change PGIP A 1.55 (0.33) 0.88 (0.13)
BA 0.06 (0.01) 0.18 (0.06)
BG 0.14 (0.05) 0.33 (0.07)
P value 0.004 0.08
Fold change BGIBA 2.59 (0.46) 1.85 (0.19)
BAL 1.44 (0.17) 0.61 (0.17)
BGL 1.90 (0.14) 0.98 (0.12)
P value 0.1 0.09
Fold change BGLIBAL 1.38 (0.20) 1.65 (0.23)
When comparing the transcriptional activity of BA and BG constructs (442 bp
5'UTR region) to EGFP (390 bp of the EGF promoter) inserted in pGL3B
(promoter-less vector), both the A and G alleles had extremely low activity
compared to the EGF promoter in HepG2 cells (P< 0.001 comparing either BA
or BG to the EGFP). Interestingly, in Jeg-3 cells the A allele of the 5'UTR was
considerably less active than the EGFP (P= 0.02), but the G allele had
comparable activity to the EGFP (P= 0.25), (Figure 3-16 and Table 3-10).
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Comparing BAL and BGL (constructs containing both 5'UTR and EGF
promoter) to the EGFP (construct containing the EGF promoter alone) showed
no difference in the activity of BAL and BGL compared to EGFP (P= 0.95, and
0.08 respectively) in HepG2 cells. In Jeg-3 cells, BAL showed no difference in
activity while BGL had significantly higher activity compared to the EGFP
construct (P= 0.22 and 0.02 respectively), (Figure 3-16 and Table 3-10)
In HepG2, the mean fold change in the luciferase activity of BA, BO, BAL, and
BOL over EOFP were 0.05, 0.1 0.99, and 1.34, indicating that the 5'UTR A
allele confers no transcriptional activation to this DNA fragment additional to the
EOFP, while the 0 allele activates transcription. In Jeg-3 cells the fold change
of BA, BO, BAL and BGL over the EGFP were 0.39, 0.74, 1.4 and 2.37
respectively, indicating that in Jeg-3 cell both A and 0 alleles have
transcriptional activity but the 0 allele is transcriptionally more active Figure
3-18 and Table 3-10) .
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Figure 3-18: Fold change in the activity of EGF 5'UTR A and G alleles with
and without the EGF promoter relative to the EGF promoter alone
Data are presented as mean ± SEM of 5 independent experiments from the 2 cell lines
under investigation. BA and BG: 442 bp EGF 5'UTR from the A and G alleles inserted
into pGL3B vector; BAL and BGL: 442 bp EGF 5'UTR from the A and G alleles and 390
bp of the EGF promoter inserted into pGL3B; EGFP: 390 bp of the EGF promoter
inserted into pGL3B vector.
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Table 3-10: The activity of EGF 5'UTR A and G alleles with and without the
EGF promoter relative to the EGF promoter alone
The data are presented as mean (SEM) and Student's t test P value, followed by mean
(SEM) fold change in the activity of A and G alleles in relation to the EGFP, BA and BG:
442 bp EGF 5'UTR from the A and G alleles inserted in pGL3B vector; BAL and BGL:
442 bp EGF 5'UTR from the A and G alleles and the 390 bp of the EGF promoter
inserted in pGL3B.; EGFP: 390 bp of the EGF promoter inserted in pGL3B vector.
Relative luciferase activity
lIepGl Jeg-3
EGFP 1.46 (0.16) 0.44 (0.07)
BA 0.06 (0.01) 0.18 (0.06)
P value [<0.001] [0.02)
Fold change BNEGFP 0.05 (0.01) 0.39 (0.02)
BG 0.14 (0.05) 0.33 (0.07)
P value [< 0.001) [0.2S)
Fold change BGIEGFP 0.10 (0.01) 0.74 (0.11)
BAL 1,44 (0.19) 0.62 (0.098)
P value [0.95) [0.22)
Fold change BALlEGFP 0.99 (0.09) 1,40 (0.12)
BGL 1.90 (0.14) 0.98 (0.173)
Pvalue (0.08) [0.02)
Fold change BGUEGFP 1.34 (0.13) 2.37 (0,45)
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3.5.4.3 In vitro transcription and translation
In vito transcription of the A-Luc and G-Luc constructs generated a transcript of
2242 bp, while transcription of Luc construct and the RNA control supplied by
the Kit genetrated a 1800 bp transcript (Figure 3-19).
Figure 3-19: In vitro transcription reaction on 1% agarose gel
A and B are RNA products of 2242 bp from A-Luc and G-Luc constructs. C and Dare
1800 bp RNA products from the Luc construct and the commercial RNA control. RNA
loaded directly from the transcription reaction prior to purification.
In vitro translation of equal amounts of luciferase RNA under the control of the
A and G alleles of the 5' UTR region of EGF gene showed that both alleles are
translated with the same efficiency independent of the cellular environment,
indicating that this sequence variation from A>G has no impact on translation of
the down stream gene (Figure 3-20). The RNA was purified after transcription
by phenol:chloroform:isoamyl alcohol (125:24:1) followed by ethanol
precipitation (PPT) and by RNA clean spin column (Spin). The luciferase output
was higher with the second method of purification, but there was no difference
between the translational activity of the A and G alleles (P=0.86) and (P=0.76)
for RNA purified by PPT or by Spin column methods respectively.
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Both the A and G alleles lowered luciferase output by nearly 70% when
introduced upstream of the luciferase gene compared to the output from the
luciferase gene alone (P= 0.l3 and 0.09 comparing A-Luc and G-Luc to Luc
constructs prepared by PPT and SPIN methods respectively) (Figure 3-21). This
experiment confirmed the findings of the reporter gene assay in pGL3C or
pGL3P vectors that the 5'UTR region reduces the translation efficiency of the
downstream gene.
Figure 3·20: Luciferase output from A and G alleles of the 5'UTR of the
EGF gene after in vitro transcription and translation
Data are presented as mean±SEM of the relative luminescence units (RLU) from 4
independent experiments. A-Luc and G-Luc are the mRNA comprise of 5' UTR from the
A allele and G alleles and the luciferase gene. PPT: RNA purified by precipitation, SPIN:
RNA purified by spin column,
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Figure 3-21: Luciferase output showing the effect of EGF 5'UTR A and G
alleles on the translation of the downstream gene
Data are presented as mean ±SEM of the relative luminescence units (RLU) of a 1/10
dilution of the in vitro translation reaction from 4 independent experiments. A-Luc and G-
Luc comprise the 5' UTR from the A or G alleles and the luciferase gene; Luc: luciferase
gene; PPT: RNA purified by precipitation; SPIN: RNA purified by spin column.
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Bioinfonnatic examination of the EaF-5'UTR A and a alleles found them to be
identical in their mRNA secondary structure, other than the loop carrying A is
somewhat less stable compared to a because of internal complementarity
(shown in Figure 2-22 with the a allele boxed in red). The 5'UTR region of the
EaF gene is highly structured with multiple stem loops that may interfere with
the efficiency of translation (Figure 3-23). It also has 3 uORF upstream of the
physiological start site.
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Figure 3-22: mRNA secondary structure of the first 120bp of the EGF
5'UTR.
A (upper panel) and G (lower panel) alleles with SNP boxed in red. This mRNA
secondary structure predicted using Mfold software.
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Figure 3-23: mRNA secondary structure of the full length EGF-5'UTR
The red arrow refer to the SNP, both A and G alleles were identical when the entire 442
bp 5'UTR was tested. This mRNA secondary structure predicted using Mfold software .
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3.5.4.4 Electrophoretic mobility shift assay
Transcription factor binding site prediction showed that AML-l a, Sp 1 and P300
transcription factors can bind exclusively to the G allele. Three other factors,
ThlE4, Elk-l and STATx, are predicted to bind to both A and G alleles (Figure
3-24).
Figure 3-24: Prediction of the transcription factors binding to 5'UTR of the
EGF.
Output from the TF search program. The input was 30 bp of the EGF 5' UTR with the
rs4444903 (A>G) SNP in the middle.
Transcription factor binding to G allele
G CAATCCAAGG GTTGTGGCTG GAACTTTCCA T entry score
MOO271 AML-1a 83.7
MOO222 Th1/E4 76.5
MOOOOe Sp1 75.3
MOOO25 Elk-1 73.0
MOOO33 p300 72.3
MOO223 STATx 72.1
----->
----------------->
---------->
-------------->
-------------->
<---------
Transcription factor binding to A allele
A CAATCCAAGG GTTGTAGCTG GAACTTTCCA T entry score
M00025 Elk-1 74.3
M00222 Th1/E4 74.1
M00223 STATx 71.2
-------------->
----------------->
<---------
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Binding to Sp 1 in HepG2 nuclear extract was investigated by EMSA assay. The
results are shown in Figures 3-27 and 3-28. Both the G and the A alleles showed
a band that is comparable to the band created when the Spl consensus sequence
was used. The binding was specific for both G and A alleles, such that the use
of 100 molar excess of unlabelled non specific sequence did not abolish the band
(Figure 3-25), while the use of 100 molar excess of unlabelled specific
competitor abrogates the binding (Figure 3-26). In the case of the A allele the
band was removed by adding Sp I antibody to the binding reactions, an effect
which was also observed with Spi consensus sequence, but not observed with
the G allele (Figure 3-26).
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Figure 3-25: Electrophoretic mobility shift assays for 5'UTR of the EGF
gene, and Sp1 site
The arrows indicate protein-DNA interactions. Band A was observed with the three
probes used. This band most probably corresponds to Sp1. Band B was observed with
both 5'UTRA and G, while band C was observed only with 5'UTRA. All of these bands
were specific as they persisted in the presence of 100 molar excess of the unlabeled
non specific probe. Non-specific bands are observed at the top of the gel due to
endogenous biotinylated materials in the nuclear extract, which are also observed when
nuclear extract only is loaded onto the gel (extreme right lane).
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Figure 3-26: Supershift assays using antibodies to Sp1 with the 5'UTR of
the EGF gene
The binding pattern is as described in Figure 3-27, again the bands are specific as they
disappeared after addition of 100 molar excess of specific unlabeled probe. The arrow A
indicates protein-DNA interactions observed using the three probes in the absence of
the Sp1 antibody. This band significantly decreased when antibodies are included with
5'UTRA and Sp1 consensus site. In the case of 5'UTRG, the band is slightly diminished
in the presence of Sp1 antibody.
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3.5.5 Discussion
The results presented here showed the G allele of the SNP rs4444903
(c.61A>G) in the EGF-5'UTR region has greater transcriptional activity than the
A allele in the absence of the EGFP in HepG2 (Table 3-9) and greater activity
than the EGFP in JEG-3 cells (Table 3-10). When comparing the 5'UTR A and
G independent from the EGFP we found that the G/A fold change was 2.6 at a P
value of 0.004 in HepG2 cells over at least 5 experiments using different DNA
preparations of the same construct. In the presence of the EGF promoter the G
allele showed a 2.4 fold increase in the activity at P value of 0.02 in comparison
to the EGF promoter in Jeg-3 cells. Hoogendoom et al recommended three
criteria for defining promoter haplotypes using reporter gene assays: I)
statistically significant differences in expression at P<0.05; 2) replication with
independent construct preparations; 3) ~ 1.5-fold difference in expression
between haplotypes (Hoogendoom et al., 2003). They indicated the last criterion
to be the most important because it is the most consistently reproducible, did not
fall in the range of random errors intrinsic to the assay and change of this
magnitude when considered in vivo is equivalent to carrying an extra copy of the
gene, comparing homozygotes for the high activity allele to homozygotes for the
low activity allele (Hoogendoom et al., 2003). The data presented in the current
study indicated that this sequence variation in the 5'UTR region of the EGF gene
possibly confers a promoter activity. These findings are in agreement with
previous studies in other cell lines including peripheral white blood cells,
Chinese hamster ovary cells and glioma cell line (Shahbazi et al., 2002, Vauleon
et al., 2007, Costa et al., 2007) that showed greater transcriptional activity with
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the G allele. Previous studies have tested this variant only in the context of the
promoter region; this study has delineated the region responsible for the variation
in transcriptional activity by testing the 5'UTR region on its own.
Although this SNP at position +61 is 30 bp away from what is known as a
proximal promoter (up to bp +35), the G allele introduces promoter properties to
this region. Transcription factor binding prediction demonstrated that the A>G
transition introduces binding sites for 3 transcription factors (Sp l , P300, and
AML-la) all of which are known factors in regulation of expression of the
growth factors genes and genes related to cell cycle. TF search also identified
potential binding sites for another 3 TF which can bind to both the A and G
alleles (Elk-I, ThI, and STATx).
Multiple reports ascribe putative functionality to the 5'UTR region of genes in
transcriptional regulation more commonly than previously thought. S'UTR have
been implicated inmechanisms to repress transcription of the downstream genes
through binding to transcription factors. For example, pS3 suppresses the
expression of bc1-2through a p53 response element located in the 5'UTR of the
bc1-2gene (Miyashita et al., 1994). Similarly, the heat shock transcription factor
1 (HSF-I) like sequence in the murine TNF-a 5'UTR binds HSF-l and is
required for HSF-I-mediated transcriptional repression in the minimal mouse
TNF-A promoter (Singh et al., 2002). Also Berardi et al (2003) identified a
region in the cyc1inDI 5'UTR between +75 to +138 that selectively represses
cyclin DI gene expression in aging cells (Berardi et al., 2003). These
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investigations support the findings of this study that the 5'UTR region of the
EGF gene contributes to gene expression through repression of transcription
from the A allele.
Sp1 is the transcription factor potentially involved in this regulation. Numerous
Spl binding sites are present in the human genome. As a constitutive
transcription activator, Sp1 is associated with genes involved in almost all
cellular functions. However, a growing body of evidence indicates Spl as a
repressor of gene expression (Law et al., 2011, Bilsland et al., 2006, Mottet et
al., 2009). Consequently, Spl can be a transcription activator or repressor
depending on sequence specificity, and the spatial availability and the
recruitment of different protein complexes (Li and Davie, 2010). This may also
explain why the TF sites prediction was contrary to our findings in indentifying
the G allele as holding the potential binding sites for Spl rather than the A allele.
We have shown that Spl factor specifically bound the A allele of the 5'UTR
region. The G allele binding pattern was specific, but the addition of the Sp1
antibody only slightly diminished the band, indicating that binding of Sp1 to the
G allele may occur in a conformation that differs from the A allele. The
probability that Spl can bind different sequences in the same promoter and exert
activation and repression function is reported in mouse type 4 adenylyl cyclase.
The promoter of this gene carries more than one Spl site, the 5' one is an
activator and the middle is a repressor (Rui et al., 2008). The other explanation
for the DNA: protein binding pattern observed with the G allele is the binding to
a protein with similar size and structure to Sp1, possibly the long isoform of the
Sp3 although this was not tested. It has been demonstrated that Sp3 is a stronger
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transactivator of the p21 promoter than Sp 1 (Sowa et al., 1999). These findings
merit further investigation.
Sequence variation at rs4444903 did not show any effect on the efficacy of
translation in HepG2 or Jeg-3 cell lines, or in a cell free environment. We found
that the A>G transition does not add or remove any stem loops to the long highly
structured mRNA 5'UTR region. However, both alleles require around 128
kcallmol energy for the unwinding by the helicase eIF4A for translation of the
mRNA to continue. This amount of energy is large enough to inhibit the
translation process by the scanning ribosome. In addition, 3 uORF were
recognized in the 5'UTR region of the EGF gene, although none of them are
affected by this mutation. The presence of the uORF is known to interfere with
the efficiency of translation, as the production of short peptide (uORF) may
complex with the translation machinery and hinders the translation process. Also
the uORF may lead to targeting its own mRNA to a nonsense-mediated mRNA
decay. Interestingly it has been shown that the transcript carrying the G allele of
SNP rs4444903 has more mRNA stability compared to the transcript carrying the
A allele in the HepG2 cell line (Tanabe et al., 2008). These mechanisms for gene
regulation are frequently encountered with genes involved in cellular
development, cell cycle, and oncogenesis like TGF-fil and BReAI in breast
cancer. This study has shown that the 5'UTR of the EGF reduces the efficiency
of translation of downstream luciferase by about 70%.
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3.6 The effect of SNP rs4444903 on EGF and EGFR expression
in the placenta
3.6.1 Introduction
Epidermal growth factor receptor (EGFR) is a trans-membrane growth factor
receptor belonging to the c-erbB family of receptor tyrosine kinases. EGFR is a
ubiquitously expressed 170-kDa glycoprotein that consists of an extracellular
receptor domain, a trans-membrane region, and an intracellular domain. The
extracellular domain is formed of 622 AA with 12 N-tenninal glycosylation
sites, and a cysteine rich domain forming a groove for EGF binding. The trans-
membrane domain, the hydrophobic part of the receptor, consists of 23 AA. The
intracellular domain is formed of 542 AA that carries the tyrosine kinase activity,
a domain for internalization and multiple sites for phosphorylation at tyrosine,
serine and threonine residues (Boonstra et al., 1985).
Multiple ligands bind to and activate the EGFR, including EGF, transforming
growth factor-a (TGF-a), amphiregulin, and heparin-binding EGF. Ligand
binding of EGFR stimulates the proliferation of a wide variety of cell types.
EGFR is a transducer protein implicated in many types of cancer, and has been
used as a prognostic marker for many types of tumours.
3.6.2 Signal transduction by EGFR
Ligand binding with EGFR results in dimerization of the receptor at the cell
surface, followed by autophosphorylation of the intracytoplasmic domain,
activation of the receptor tyrosine kinase domains as well as internalization of
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the dimerized receptor. Phosphorylated tyrosine residues, located at the protein's
carboxy terminus, serve as binding sites for the recruitment of signal transducers
and activators of intracellular substrates, which then stimulate an intracellular
signal transduction cascade (Sibley et aI., 1987), (Figure 3-27).
Mitogen-activated protein kinase (MAP kinase) pathway is one of the
downstream signalling pathways associated with EGFR. Upon ligand binding
SOS (son of sevenless) guanine nucleotide exchange factor is recruited to the
plasma membrane via the Grb2 adaptor protein. SOS stimulates the
phosphorylation of the small G-protein Ras that subsequently stimulates the
MAP kinase pathway to promote cell proliferation. A second pathway for EGFR
signalling, the phospholipase C-y (PLC-y) transduction pathway, is involved
mainly in stimulation of cell motility. phospholipase C-y cleaves phospho-
inositol biphosphate (PIP), with the production of diacylglycerol (DAG) and
inositol l,4,S-triphosphate(PI3) followed by activation of protein kinase C (PKC)
and an increase in intracellular calcium. Activated protein kinase C
phosphorylates T654 in the juxtamembrane part of the EGFR, which leads to
disruption of the Ras-MAP kinase pathway and further biases the response to
EGFR activation towards cell motility. In the mean time PI3-kinase blocks the
activity of the inhibitory tyrosine protein phosphatase that is capable of
terminating EGFR activation, implying a regulatory feedback loop between
different signalling pathways for EGFR (Bogdan and Klambt, 2001).
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Figure 3-27: The EGFR-signalling pathway
A simplified schematic showing the downstream signalling pathways involved in signal
transduction. EGF: Epidermal Growth Factor, MAPK: mitogen activated protein kinases,
MAPKK: MAP kinase kinase, PLC-V: phospholipase C- y, DAG: Diacylglycerol, IP3:
InositoI1,4,5-triphosphate, PKC: Protein Kinase C, SOS: son of sevenless, Grb2:
Growth factor receptor-bound protein 2 (Bogdan and Klambt, 2001), with permission.
COOH coo- Qb2 SOS
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3.6.3 Internalization and down regulation of the EGFR
Activation of the EGFR by its ligand leads to rapid internalization of the receptor
through clathrin-coated pits. After internalization, EGF-receptor complexes
appear consecutively in early endosomes and multivesicular bodies. During
passage through the endosomal compartments, these complexes are either
recycled back to the cell surface or sorted to late endosomes and lysosomes,
where both ligand and EGFR are proteolytically degraded. The accelerated
internalization and efficient lysosomal targeting of ligand-occupied receptors
results in a down-regulation of the EGFR and the related responses. This is
because rapid sequestration of the receptor into endosomes removes it from its
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downstream target, Ras, the majority of which is constitutively associated with
the plasma membrane (Wells et aI., 1990, Wells, 1999), (Figure 3-28).
TGF-a, a highly potent EGFR agonist has an identical affinity constant for
binding to the EGFR and similar internalization kinetics, but dissociates at a
higher pH (half-maximal dissociation at pH 6.9). Targeting of the receptor for
degradation in lysosomes (down regulation) is achieved more effectively by EGF
than by TGF -a in murine B82L cells expressing the human EGFR or in human
keratinocytes with endogenous EGFR. Also the refractory period after which the
receptor can bind new ligands was 2.5 hours for TGF-a and 5 hours for EGF.
The recovery was more sensitive to protein synthesis inhibitor in the case ofEGF
indicating that new EGFR synthesis was required. The greater biological potency
ofTGF-a may be due to the repeated presentation of recycled receptors for TGF-
a and EGF at the cell surface, resulting in several rounds of signalling (Ebner
and Derynck, 1991), (Figure 3-28).
Exogenous EGF was shown to have growth inhibitory effects on selected cell
types that constitutively secrete TGF-a. For example, treatment of A-431 cells,
which over expresses EGFR, with growth-inhibitory concentrations (10_9 M) of
EGF leads to induction of the cell cycle inhibitor cyclin-interacting protein 1
(CIP1) with subsequent growth arrest. EGF at concentrations of (10.12 M) was
found to be growth-stimulatory (Chajry et aI., 1994).
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Figure 3-28: Ligand-regulated internalization and degradation of EGFR
Upon ligand binding EGFR is activated and the receptor is internalized via clathrin-
coated pits. This initial action is consistent between EGF and TGF-a. In the acidified
endosomal compartment, EGF remains bound and directs the receptor and its bound
EGF to degradation; TGF-a dissociates and the receptor is recycled while the free TGF-
a is degraded (Wells, 1999), with permission.
degrade
3.6.4 EGF -EGFR in trophoblast (in normal and abnormal
pregnancy)
The role of EGF in the developmental and functional aspects of the trophoblast i
well defined. However reports of the spatial and temporal pattern of EGF and
EGFR distribution in different trophoblast lineages are variable among
researchers.
Maruo et al (1987) showed that EGFR is expressed more intensely in the ISI
trimester ST trophoblast compared to mid and late term ST trophoblast, which
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explained why EGF increases the secretion of hCG and hPL after a short period
of stimulation in early compared to late trophoblast (Maruo et al., 1987). In
contrast to this pattern of expression, EGFR is expressed more intensely in the
proliferating CT trophoblast of early pregnancy, compared to ST trophoblast,
regulating mainly the proliferative component of the trophoblast (Muhlhauser et
al., 1993).
It is probable that different patterns of immunolocalization of the EGFR are
related to the trafficking stage of the EGF-EGFR complexes, especially in early
pregnancy in which EGF is suggested to be of maternal origin. The study carried
by Arnholdt et al supported this view (Arnholdt et al., 1991). The investigators
showed a trans-syncytial, receptor-mediated transfer of EGF from the maternal
blood to the cytotrophoblast, the proliferating part of the trophoblast, in the first
trimester placenta while EGF is directed mainly to the syncytium in term
placenta. Also, Duello et al (1994) demonstrated that EGFR is localized to both
trophoblast layers in first- and third-trimester placental in a pattern consistent
with the activation and internalization of the EGFR. The investigators were also
able to show an element of variation in the staining of adjacent syncytium, a
variable which may explain conflicting reports regarding the pattern of EGFR in
the trophoblast layers (Duello et al., 1994). Moreover, timing of sampling in
each study can explain the variation in such a dynamic, rapidly growing and
differentiated tissue.
Many studies have suggested the presence of an EGF/EGFR autocrine and
paracrine mechanism in human trophoblast cells. Mauro et al (1992, 1995)
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demonstrated the functional effects of EGF on trophoblast at 2 different stages,
4-5 and 6-12 weeks gestation. EGF stimulated proliferation in the early stage
trophoblast as indicated by enhanced staining for Ki-67 antibody. In the late
stage trophoblast, EGF induced differentiation of the trophoblastic explants as
indicated by increased secretion of hCG and hPL on addition of EGF to culture
media. Immunostaining localized EGF to the Cl' trophoblast and EGFR to the
syncytiotrophoblast. The authors also demonstrated the secretion of EGF by the
trophoblast tissue itself referring to the autocrine nature of this ligand receptor
system (Maruo et al., 1992, Maruo et aI., 1995).Amemiya et al (1994) showed
the same findings in 6-9 weeks gestation trophoblast and confirmed the presence
ofEGF and EGFR by immunostaining and RT-PCR (Amemiya et al., 1994).
Many reports have shown disturbances of EGF/EGFR in abnormal pregnancy.
Fujita et al (1991) showed reduced binding sites for EGF in the plasma
membrane of term placental tissues in FGR compared to normal pregnancy.
They were also able to show reduced mRNA levels of the EGFR, indicating
down regulation of the receptors (Fujita et aI., 1991). Another study showed
reduced EGFR autophosphorylation and reduced tyrosine kinase activity in the
plasma membrane fraction of the chorionic villi derived from placenta of FGR
cases. The alteration of EGF-dependent tyrosine kinase activity appeared to be
specific, as autophosphorylation of insulin receptors was preserved. Reduced
EGF binding in the FGR placenta might explain the reduced receptor
phosphorylation in this group of cases all of which presented with a maternal
history of smoking and preeclampsia (Fondacci et al., 1994). Higher EGFR
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concentrations in the placenta and fetal membrane in hypertensive pregnancy
have also been reported (Ferrandina et al., 1995).
EGF and EGFR are expressed in the trophoblast throughout gestation to regulate
its proliferation and differentiation. Intrauterine growth restriction and
preeclampsia are both associated with various alterations of the placental
EGFIEGFR system.
3.6.5 Aim of the study
This is an exploratory study to investigate the effects of genotype at rs4444903
in the 5'UTR of EGF on the expression of EGF in term placenta from healthy
and preeclampsia-FGR complicated pregnancies.
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3.6.6 Methods
3.6.6.1 Sample collection
Placental tissues were available from 9 healthy pregnancies and 16 complicated
pregnancies (8 preeclampsia and 8 preeclampsia-FOR placentas). Preeclampsia
was diagnosed according to ISSHP guidelines: systolic blood pressure of 140
mmHg or more and diastolic pressure of 90 mmHg or more on 2 occasions after
20 weeks gestation in a previously normotensive woman, and proteinuria
exceeding 300 mg/L, or 2+ on dipstick analysis of midstream urine if 24-h
collection result was not available (Brown et al., 2001). FOR was defined as
corrected birth weight centile <10th centile. These tissues were kindly provided
by Dr Hiten Mistry; details about sample collection have been previously
published (Mistry et al., 2010). In summary, these samples were taken from
midway between the placental border and cord insertion site within 10min after
delivery. After membrane removal, the tissues were washed in ice cold IX PBS
to remove maternal blood contamination. Parts of the tissues were snap frozen
in liquid nitrogen and kept at -80°C, while parts were paraffin embedded for
immunohistochemistry. Informed consent was taken at the time of sample
collection and the studywas approved by the local ethics committee.
3.6.6.2 Immunohistochemical staining for EGFR and EGF
Serial sections of 5 um thick formalin- fixed paraffin - embedded tissue were cut
and mounted onto glass slides. After incubation at 60°C for 10 min, sections
were deparaffinized by immersing in xylene (twice), and rehydrated through
descending graded alcohol (100,90, and 70%) 3 min each. Antigen retrieval was
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carried out by Proteinase K (DAKO - Proteinase K ready to use - S3020) at
37°C for 10 min for EGFR, and by heat induced retrieval where sections were
boiled in citrate buffer (O.IM concentration at PH 6.0) using a microwave for 20
min for EGF. The slides were loaded on Sequenza plates and placed in Sequenza
trays then rinsed with TBS pH7.6. Endogenous hydrogen peroxidase activity
was blocked by applying Dako Peroxidase block (DAKO REAL Peroxidase-
Blocking solution-S2023) for 5 min. For blocking of nonspecific binding,
sections were treated for 5 min with 200J,l1 of UV block (Ultra V Block-
ThermoScientific-TA-125-UB). Sections were incubated for 60 min at room
temperature with optimized diluted primary antibody, made up in Dako antibody
diluent (DAKO Antibody Diluent - 50809) (Table 3-11). A negative control
was included by omitting incubation with the primary antibody. A positive
control for each antibody was used to ensure specificity (Table 3-11).
Table 3-11: Details of antibodies and positive control tissues used In this
study
The optimal dilution for each antibody was selected as the lowest dilution that gives
maximal specific reactivity and minimal background staining
Antibody Clone Dilution Control Antibodytissue Supplier
Mouse anti-EGFr 31G7 1160 Placenta Zymed
antibody - 28-0005.
Rabbit polyclonal anti- 11300 Tonsil MilliporeEGF - 07-1432
After washing unbound primary antibody, immunostaining was performed using
DAKO REAL EnVision Detection System, PeroxidaselDAB RabbitIMouse -
code K5007, in which bound antibody was developed by using 3,3'-
Diaminobenzidine tetrahydrochloride for 6 min at room temperature. Sections
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were then counterstained with Mayer's haematoxylin, dehydrated with ascending
graded alcohol, cleared in xylene, and mounted with DPX.
3.6.6.3 Analysis of the EGF and EGFR immunostaining of the placenta
A visual examination was performed to ensure specificity and distribution of
immunolabelling. All slides were analysed by the same observer (Dr. Paula
Williams) who was blinded to which slides were from cases and which were
from controls. Five randomly selected fields were captured on NIS-Elements
F2.20 (Nikon UK Ltd, Surrey, UK) at 200X magnification. The total percentage
of positive labelled areas per 200X magnification field was determined using the
positive pixel count function of the ImageScope (Aperio Technologies Ltd,
Bristol, UK). Results are expressed as 'positivity' which takes into account both
the number of positive pixels and the intensity of staining (Williams et al., 20 10).
3.6.6.4 Genotyping of the placental samples
25 mg of frozen tissue was washed in ice cold PBS to eliminate any maternal
blood which may interfere with the genotyping. The tissue was then subjected to
homogenization in 80J.11of PBS using 2 ml Lysing Matrix A tubes with granite
matrix and ~ ceramic spheres (www.qbiogene.com) for 40 sec in Fastprep®24
homogenizer (www.mpbio.com). DNA was extracted from the cell homogenate
using QIAamp DNA Mini Kit (www.qiagen.com) according to the
manufacturer's protocol. DNA was quantified and stored at -20oe for
genotyping. For genotyping ofSNP rs4444903, 100 ng DNA was peR amplified
using primer pair EGF-PRO-S and EGF-PUTR-AS (Table 3-7) and the peR
conditions described previously (Section 3.5.3.1). peR clean up was carried out
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followed by DNA sequencing usmg Spmol of EGF-PRO-S primer. DNA
sequence was viewed by Chromas Lite, and aligned with ClustalW against the
reference sequence.
3.6.6.5 Statistical analysis
Statistical analysis was performed using SPSS for Windows version 16.0.
Summary data are presented as means (SEM) or number (frequency) as
appropriate. Between-group comparisons were made using oneway ANOVA or
Student's t test. The null hypothesis was rejected where P < 0.05.
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3.6.7 Results
Mothers from healthy and preeclamptic-IUGR pregnancies were similar in age,
parity, BMI, and placental weight distribution. By definition systolic and
diastolic blood pressure were significantly higher in the preeclampsia group
compared to healthy controls. Fetal weight and gestational age at delivery were
lower in the preeclampsia group compared to healthy controls (Table 3-12).
Table 3·12: Demographic and pregnancy characteristics of subject
groups
Data are presented as mean (SEM) except for parity and Caesarean section data
presentedas number (percentage).
Healthy pregnancy Preeclampsia & FGR P
(n=9) (n=16) value
Maternal age (years) 26.44 (2.11) 31.50 (1.55) 0.07
Nulliparous 5.0 (55.6) 10 (62.5) 0.73
BMI(kglml) 28.64 (1.88) 26.42 (1.24) 0.32
Mean systolic blood
117.17 (1.21) 157.81 (1.61) <0.001
eressure ~mmHg~
Mean diastolic blood
76.61(0.79) 97.81 (1.07) <0.001
eressure !mmHg}
Gestational age at 39.46 (0.27) 36.58 (0.95) 0.01delive!l. ~weeks~
Caesarean section 1.0(11) 6 (37) 0.20
Fetal Weight (kg) 3.52 (0.10) 2.68 (0.25) 0.02
Birth weight centile 48.83 (8.16) 33.55 (10.10) 0.21
Placental wt (g) 660 (50.55) 602 (37.07) 0.36
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Visual checks showed that EGFR staining was of moderate to high intensity and
none of the slides showed < 75% staining. Staining for EGF was shown to be
mild to moderate and none of the slides showed < 10% staining. EGFR staining
was mainly localized to the trophoblast tissues, and was more intense in the ST
trophoblast apical membrane. Although the Cf trophoblast was relatively
thinned out as expected in these term placental samples, EGFR immunoreactivity
was apparent in the cytotrophoblast. Both membranous (inner membrane of the
villous trophoblast) and cytoplasmic staining was evident (Figure 3-29). Some of
the slides showed no EGFR staining of the fetal side of the cytotrophoblast.
EGF immunoreactivity was mainly cytoplasmic in nature. However some patchy
staining of the maternal surface of the syncytium and some nuclear staining were
observed. Also some positivity was detected in the cellular component of the
villous stroma, around the fetal blood vessels, fibroblasts, and Hofbauer cells
(villous macrophages), (Figure 3-30). We did not observe any variation in the
EGFR or EGF staining of placental tissues from healthy (9 subjects) compared to
preeclamptic-FGR (16 cases) pregnancies with P= 0.86 and 0.93 for EGF and
EGFR respectively (Figure 3-31). EGFR and EGF immunostaining was similar
in the placenta when the analysis was carried for healthy pregnancy compared to
preeclampsia (8 cases) and preeclampsia-FGR placentas (8 cases). EGFR
positivity was (0.42 ± 0.04, 0.43 ± 0.05, and 0.45 ± 0.02) in healthy,
preeclampsia and preeclampsia-FGR placentas respectively (P=0.89). EGF
positivity was (0.14 ± 0.03, 0.11 ± 0.03, and 0.13 ± 0.03) in healthy,
preeclampsia and preeclampsia-FGR placentas respectively (P= 0.63). There was
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no correlation between EGF and EGFR imrnunostaining of the placenta
(correlation coefficient r = 0.21, P = 0.30).
Because no variation was detected between healthy and diseased pregnancies in
immunostaining, placental staining for EGF and EGFR was analyzed as a
function of genotype for cases and controls pooled together. The AA genotype
showed the weakest staining for EGF compared to AG and GG genotype (Figure
3-34). In contrast the AA genotype was associated with stronger staining for
EGFR compared to AG and GG genotype. These variations did not reach
statistical significance when analysed by ANDYA across all genotypes (P= 0.18
and 0.60) for EGF and EGFR respectively ( Figure 3-32).
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Figure 3-31: EGF and EGFR immunostaining in placentas from normal and
preeclampsia-FGR pregnancies
Data shown as mean ± SEM of positivity/200x field.
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Figure 3-32: EGF and EGFR immunostaining in placentae according to
genotype at marker rs4444903 of the EGF gene
Data are shown as mean ± SEM of positivity/200x field. Genotype numbers were 5, 16,
4 for AA, AG and GG genotypes respectively.
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3.6.8 Discussion
In this study showed that EGFR expression in the placenta was mainly localized
to the ST trophoblast (maternal side) and less intensely to the inner surface of the
CT trophoblast (fetal side) towards the villous stroma. Some areas showed
positivity in the cytoplasm of both layers. This pattern was in agreement with
previous studies (Duello et al., 1994). Rao et al showed that the maternal
interface of the ST trophoblast holds 40% more available receptors for binding to
radiolabelled EGF compared to the basolateral interface (fetal) (Rao et al., 1995).
Some patchy staining of the inner membrane of the CT trophoblast was
observed, which is consistent with synthesis of EGF by CT trophoblast and its
transfer to the syncytium during the fusion process (Duello et al., 1994) or with
transsyncytial transfer of the EGF bound EGFR from the maternal side to the
fetal side (Arnholdt et al., 1991). This fits well with the hypothesis of receptor
internalization upon EGF binding.
The pattern and the low intensity of EGF staining of the term placenta are in
agreement with previous studies (Hofmann et al., 1991, Ladines-Llave et al.,
1991). The lower levels of expression of EGF in the placenta were also reported
by Bissonnette et al (1992) who reported lower EGF mRNA and protein in term
placenta (Bissonnette et al., 1992). Bass et al (1994) also reported very low to no
expression of EGF mRNA or EGF protein in the culture media of
cytotrophoblast (Bass et al., 1994). These findings support the hypothesis that
EGF at the fetomaternal interface is mainly of maternal origin.
This study included placentas from 9 healthy pregnancies and 16 preeclampsia-
FGR cases, and EGF and EGFR expression did not differ between the two
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groups, as determined by immunostaining. The data regarding the EGFR levels
in the pathological placenta are conflicting. In agreement with these data, Calvo
et al (2004) demonstrated no variation in the EGFR mRNA levels between
appropriate and small for gestational age placentas (Calvo et al., 2004. Reduced
EGFR activity and mRNA expression in the placenta from FGR cases were
reported {Fondacci, 1994 #156, Fujita et al., 1991), both studies were
comparable to this study in terms of sample size. Although EGF was
immunolocalized in the placenta no data are available to describe variation in the
pathological placenta. The small sample size in the present investigation and
previous studies, incomplete data on the mode of delivery, and variation in
methods of detection hamper efforts to define possible alterations in the
EGFIEGFR system in the placentas of abnormal pregnancies, and none of the
findings can be considered conclusive. The present study used placenta collected
during labour, which has been reported to result in up regulation of the EGFR
(Gargiulo et al., 1997). This may mask any variation between normal and
pathological placentas. Furthermore, immunohistochemical studies have shown
that staining intensity of EGF and EGFR diminishes with increasing gestational
age (Arnholdt et al., 1991, Duello et al., 1994). Moreover, it is well recognized
that the pathological changes related to preeclampsia originate in early placenta,
so it would be interesting to investigate early placenta tissue in that regard. It is
difficult to obtain early placental tissues from pregnancies which known to be
destined to develop preeclampsia after 20 weeks of gestation. Chorionic villus
samples obtained for the purpose of genetic counselling in pregnancies which are
subsequently affected by pre-eclampsia may provide limited amounts of suitable
tissues, but potential complications and ethical issues should be considered.
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Previous studies that measured EGF levels in relation to genotype at SNP
rs4444903 in glioblastoma (Bhowrnick et at, 2004), colorectal cancer (Spindler
et at, 2007) and hepatocellular carcinoma (Tanabe et at, 2008) showed that the
G allele at SNP rs4444903 was linked to higher EGF expression both at the
mRNA and protein levels. However, in the current study, the G allele in the
placenta was not associated with higher EGF expression compared to the A
allele, (Figure 3-32). Likewise the levels ofEGFR expression tended to be lower
in placentae with the GG or AG genotype compared to the AA genotype but the
variation was not significant (P 0.34). Bhowrnick et al (2004) also noted that the
GG genotype was associated with non-significant lower expression of EGFR in
glioblastoma tissue. In trophoblast cell culture, EGF at low concentrations (0.1 to
1 nM) stimulated receptor biosynthesis, an effect that diminished at higher EGF
concentrations. The effect of EGF on receptor degradation was apparent only at
saturating concentrations (> 10 nM), (DePalo and Das, 1988). The situation in
vivo seems different, as the GG genotype at this locus does not lead to higher
EGF production to the critical values that downregulate the EGFR. However the
sample size that has been used in this study is small and conclusive data about
EGF expression in the placenta as a function of genotype at rs4444903 require
further verification in a larger sample set, preferably in earlier gestational age
placentas
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3.7 Conclusion
When single nucleotide polymorphisms are found to be associated with a
complex disorder it is vital to identify whether and how this SNP affects gene
function, providing further evidence that this gene is implicated in the disease
and giving a better understanding of the disease process. This study has shown
no role for SNP rs4444903 of the 5'UTR region of the EGF gene in the risk of
preeclampsia or FGR. Functionality of this polymorphism has been investigated
in hepatocellular carcinoma and choriocarcinoma cell lines. The higher
transcriptional activity of the G allele is possibly related to a repressor effect
exerted by Spl transcription factor on the A allele. However an interaction of the
G allele with Sp1 transcription factor was specific and merits more investigation.
This study showed no functional impact for this SNP on EGF or EGFR
expression in a small study of term placental tissues. This study excluded an
effect of SNP rs4444903 on the translation efficiency of the downstream gene in
HepG2, Jeg-3 cells and in a cell-free environment. SNP rs22370S1 does not
disrupt a functioning exonic splicing enhancer in EGF exon 14 in SGH-PL4 and
HepG2 cells as shown by the minigene assay.
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4 Final discussion and future work
4.1 Summary
There are two main areas of work presented in this thesis. Firstly, as there is a
known relationship between diabetes and preeclampsiaIFGR, maternal genes
which are known to be reproducibly associated with T2D (TCF7L2, FTO,
PPAR-y, CDKN2B-ASI and KCNJ11) were tested for association with
preeclampsia and fetal growth restriction. We also sought to investigate whether
these genes contribute to the variation in birth weight. Secondly, the role of EGF
(a major regulator of the placentation process) in susceptibility to preeclampsia
and FOR, and regulation of birth weight was also investigated. In addition,
molecular genetic studies were carried out to investigate the functional effects of
the SNPs rs4444903 and rs2237051 on the expression of EGF in vitro and in
vivo.
This study showed for the first time that a maternal haplotype on the T2D and
CAD region of the CDKN2B-AS 1 gene on chromosome 9p21 was a risk variant
for growth restricted pregnancies. The level of significance for the association of
CDKN2B-AS 1 haplotype and the risk of fetal growth restriction on global
haplotype testing was P=0.005; comparing the C-G (risk haplotype) to the T-G
(common or the reference haplotype) the level of statistical significance was
P=0.0008. This was robust enough to withstand correction for multiple testing.
No previous studies in humans relate CDKN2B-ASI to FGR, but animal studies
have noted that deletion of the orthologous region on mouse chromosome 4 was
associated with higher offspring birth weight (Visel et al., 2010), suggesting a
role for CDKN2B-AS 1 in growth regulation.
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The other 9 investigated SNPs in TCF7L2, FTO, PPAR-'Y, and KCNJlI showed
no association with the risk of having growth restricted pregnancies, nor were
any of the loci investigated associated with birth weight.
None of the T2D genes was associated with preeclampsia risk. This study
confirmed the findings of two previous studies (Laasanen et al., 2002,
Wiedemann et al., 2010) that SNP rsl801282 of PPAR-'Y is not associated with
preeclampsia. In contrast to the findings in a Finnish population (Peterson et al
submitted for publication) that variants in the CDKN2B-AS 1 gene were
associated with an increased risk of preeclampsia, no association was found in
this study, possibly due to differences in the LD pattern of the chromosome 9p21
region in UK and Finnish populations. Other possibilities are that this study is
underpowered to detect the association, or the findings of the Finnish study were
spurious. None of the other variants of T2D genes was associated with
preeclampsia risk. Consequently, the case control study did not confirm a shared
genetic basis between T2D and preeclampsia.
The G allele of the SNP rs4444903 of the 5'UTR of the EGF gene showed no
effect on preeclampsia or FGR risk, likewise the A allele at the SNP rs2237051
showed no effect on either the risk of preeclampsia or FGR. So the study
reported no genetic evidence for the major role of maternally derived EGF on the
placentation process early in pregnancy (Maruo et al., 1992, Morrish et al.,
1997). The rare genotype GG at SNP rs4444903 was associated with the highest
systolic blood pressure measures in healthy pregnant mothers. The effect on
blood pressure is thought to be related to the systemic effect of maternal EGF on
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vascular tone (Lundstam et aI., 2007). In relation to birth weight, the rare
genotype at these 2 SNP of the EGF gene was associated with the lowest birth
weight in healthy babies though the variation in birth weight was not statistically
significant. In view of a previous study which showed that the haplotype
comprised of the rare alleles (G-A) at these loci was transmitted more frequently
to FGR babies from heterozygous parents (Dissanayake et al., 2007), it is
possible that it is the fetal not maternal genotypes at these loci that contributes to
the variation in birth weight.
The G allele of the SNP rs4444903 in the 5'UTR of the EGF gene showed higher
transcriptional activity in hepatocellularcarcinoma (HepG2) cell lines, but no
evidence that allelic variation affects translational efficiency. The higher
transcriptional activity of the G allele was also evident in glioma (Bhowmick et
al., 2004), and colon cancer (Spindler et al., 2007). The study showed that this
transcriptional activity resides in the 5'UTR and is independent of the EGF
promoter. DNA-protein interaction with the transcription factor Spl that appears
to impose transcriptional repression on the A allele is offered as an explanation
for the higher activity of the G allele, although these results are preliminary and
require further exploration. No significant effect has been demonstrated for the
variant rs4444903 on the EGF or EGFR expression of the term placental tissues.
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4.2 Strengths and limitations of the study
1. Case-control study
The case-control study included women who were self identified as white
western European women, minimizing population stratification that may
confound the results. In addition to the diagnostic criteria used to define
preeclampsia and FGR, there were some variations in phenotypic data between
cases and controls, which is unavoidable in retrospective studies. For the pre-
eclampsia study, differences between cases and controls were observed for BMI,
the incidence of multiple pregnancy and primiparity. For the FGR study,
differences between cases and controls were evident for BMI, smoking habits
and chronic renal disease. All of these factors were adjusted for in the course of
the statistical analysis, which imposed some reduction in the study power.
Importantly, and in contrast to previous studies, this study included women with
medical risk factors for preeclampsia, to avoid selecting against genetic factors
shared with preeclampsia.
2. Molecular Studies
Although reporter gene assays are widely used to identify the effect of a
polymorphism on gene expression, they have limitations as they may not reflect
the in vivo situation (Cirulli and Goldstein, 2007). These limitations are related
to gene context, the experimental technique used, and the use of cell lines.
Chromatin structure, and the presence of other regulatory elements that may be
located up to 1 Mb from the gene promoters are not considered in the reporter
gene system, so reporter gene assays may not mirror the in vivo transcription for
a given gene (Buckland et al., 2005). In relation to the experimental technique it
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has been shown that factors like the amount of DNA, the ratio between the test
and control DNA, the quality and conformation of DNA used for transfection,
the method of transfection, and the passage number of the host cells used in
transfections can affect SNP-specific regulation in reporter gene assays (Karimi
et al., 2009). Bearing this in mind, we used the minimal amount of DNA that
can give consistent results; fresh preparations of DNA were used over
experiments. The effect of the passage number of the cell on the absolute
luciferase output but not the relative luciferase activity was indeed observed with
Jeg-J, consequently after passage number 5, fresh frozen cells were brought to
culture and used for transfection. However, the use of transient transfection
methods in which multiple copies of the test DNA are expressed from
extrachromosomal plasmid, may exhaust the regulatory protein machinery of the
cells. Karimi et al (2009) suggested the use of stable transfection with the use of
a single site integration method in which a single copy of the test DNA and the
reporter gene are integrated at exactly the same genomic location and orientation
in all cells within a chromatin context that is very similar to the genome in vivo.
Obviously this method will be difficult to apply to the large number of constructs
that have been tested in the current study, because creating such constructs and
producing stable cell lines would require a considerable amount of time. It is for
this reason that transient transfection methods are still widely used for
experiments such as those described here.
Cell lines have been extensively used to investigate SNPs in regulatory regions
on gene expression. The results from cell lines should be interpreted cautiously
as the gene expression pattern may be altered in immortalised cell lines. Not only
cells with monoclonal gene expression, unrepresentative of the polyclonal cell
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populations, but also the growth rate and pattern, and the molecular repertoire of
the cells do not reflect the in vivo situation (Gimelbrant et al., 2007).
There is no doubt that the use of immunohistochemistry technique is easy, cheap,
reproducible, and can be applied to large number of samples at the same time.
The most important issue in its superiority to Western blotting in protein
detection is the localization of the protein of interest within the tissue under
investigation, which of course gives an idea about its functionality. In the
placental tissues used in this study, it was possible to locate the EGF and EGFR
in different components of the trophoblast villi. But the IHC technique also has
limitations as a quantitative technique: in this study this was addressed by the use
of a computer based scoring system that can score a wide range of variability and
is more objective than the manual scoring system. IHC also has limitations
regarding tissue processing and time lapse between slide preparation and staining
that may reduce the antigenicity of the protein and the staining outcome. It is
worth noting that the slides used in the current study were freshly cut from the
paraffin blocks just before the staining process. It is also important to recognise
that EGF of maternal origin may be detected in placental tissues following
internalization subsequent to binding to EGFR expressed on the
syncytiotrophoblast.
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4.3 Further work
Many studies have investigated the effect of EGF on the proliferative and
invasive functions of the trophoblast, but in view of the findings of this study it
would be interesting to test these roles under allelic effects on primary
trophoblast cells or placental explants. Other approaches which would
complement the findings of this study include an investigation of allelic
imbalance in gene expression from endogenous heterozygous tissues.
Quantitative peR of EGF mRNA would complement the immunohistochemical
results which suggest that EGF protein expression is associated with genotype.
There is compelling evidence that in genetic studies of complex disorders larger
sample sizes generate more robust signals, and increase the probability of
detecting variants with small effect sizes. A larger sample size can also enable
analysis of subgroups, such as early onset and late onset preeclampsia which are
thought to have different pathological mechanisms, and preeclampsia
complicated by FGR. It would be valuable to know the glycaemic status of the
mother to be able to delineate the genetic from environmental effects when
testing the maternal T2D susceptibility genes and the risk for FGR. In studies
like this which attempt to include mothers with known medical risk factors for
preeclampsia an optimal design would include matching for these factors in
cases and controls.
Such large and detailed genetic studies require collaboration between research
groups. There are now a number of research groups within the international
research community which encourage collaborative research. An example is the
Norwegian mother and baby collection, "MoBa" (Magnus et al., 2006). DNA
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samples from mother-father-baby triads are available from this collection of over
100,000 pregnancies for investigations of the causes of disease in mother and
child. Such a collection would be valuable for the investigation of the role of
fetal genotypes, and the interaction between fetal and maternal genotypes, as
well as gene- environment interactions. Meta-analysis of the results generated by
the current study and similar investigations which recruit participants regardless
of their medical background risk, will enable the identification of mothers at high
risk for preeclampsia, and related disorders, including eclampsia, FGR, and
intrauterine death. In complex genetic disorders like T2D, CAD, preeclampsia,
and FGR, genetic risk factors are interacting and modifiable by environmental
factors. Understanding these factors will help to inform strategies directing life
style modification, creating a public health orientation to lower the risk of the
disease, or its complications.
The results from the first GWAS in preeclampsia carried out in UK as a part of
WTCCC3 are expected shortly (https:llwww.wtccc.org.uk/ccc3/projects/ccc3
_eclampsia.shtml). The study involves 2000 white UK women with preeclampsia
who are otherwise healthy, with no known medical risk factors for preeclampsia.
6000 subjects from the UK 1958 birth cohort, with available GWAS data, will be
used as the reference group. Results from studies such as this will offer new
insights into the genetics and pathophysiology of preeclampsia. T2D provides a
clear example of the potential of GWAS in complex disorders. Before the era of
GWAS there were only 3 proven T2D susceptibility genes, PPAR-G, KCNJ11,
and TCF7L2. Currently at least 3510ci are implicated in the risk ofT2D, most of
which would not previously have been considered on a biological basis as risk
factors for T2D (Bonnefond et al., 2010). Recruiting adequate numbers of
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women for GWAS of preeclampsia and FGR in those with pre-existing health
problems would be challenging, though not impossible. A more practical
approach would be to regard signals which arise in the course of GWAS of low
risk pregnant women as priorities for studying as candidate genes in a high risk
group. The emergence of new generation sequencing, with the capability of
rapid, high throughput sequencing, makes whole genome sequencing available,
exemplified by the 1000 Genomes Project. Whole genome sequencing has the
advantage of revealing all genetic variation, SNP and non-SNP (eg. insertion
deletion, and copy number variations), common and rare variations. Genome
wide sequencing will augment the design of the variants used for GWAS by
including rare variants. This of course will refine the search for the causal
variants of disease. However the cost and the analytical difficulties may mean
that using signals generated from the current GWAS platforms followed by deep
sequencing is a more feasible strategy for future genetic studies.
The identification of susceptibility loci must be supplemented by functional
studies to elucidate how these loci modify disease risk. The studies reported in
this thesis include a wide range of strategies to determine functional effects of
genetic variants mapped to regulatory regions, ranging from the use of
bioinformatics to reporter gene assays, protein DNA interaction, and in vivo
studies using human tissues. Advances in understanding the molecular genetics
of complex disorders will help in understanding the pathological processes of the
diseases. This will identify novel targets for the prediction, diagnosis, treatment,
and importantly prevention of complex disorders, and raises the prospect of
"personalized medicine" based on genetic variation information.
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Currently genetic association studies of preeclampsia and FGR are mainly
limited to populations of European descent. Extending these studies to other
ethnic groups, for example populations of African origin who have shorter LO
blocks, can help identification of causal variants. The author of this thesis has a
personal interest in hoping that studies of the genetics of complex disorders of
pregnancy will include the Egyptian population, at a level that engages the
scientific community and leads to improvements in public health.
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